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ABSTRACT 
 Idiopathic Pulmonary Fibrosis (IPF) is a deadly disease of unknown origin, which causes 80,000 
deaths every year in the US and Europe combined. Unknown etiology and late diagnosis, combined with 
limited treatment options, contribute to a dismal survival rate of 3-5 years post diagnosis. Although 
molecular mechanisms underlying IPF pathogenesis and progression have been studied for over two 
decades, lack of in vivo models that recapitulate chronic, progressive, and irreversible nature of IPF have 
contributed to limited therapeutic success in clinical trials. Currently, only two drugs, Pirfenidone and 
Nintedanib, are approved for IPF treatment in the US, with their efficacy yet to be completely determined. 
Patients with IPF often observe lung infections, alveolar collapse, and respiratory failure, which are 
associated with focal edema and local hypoxia and contribute to development of hypoxemia associated with 
acute exacerbation of IPF (AE-IPF). In my thesis, I posit that hypoxic injury to the lung epithelium can 
initiate profibrotic signaling that can contribute to pathogenesis and progression of pulmonary fibrosis in 
vitro and in vivo. In my in silico studies, I analyzed human protein kinases to identify structural peculiarities 
that diversify their functions and highlight central hub kinases governing cell signaling. Using this 
approach, I identified Focal Adhesion Kinase 1 (FAK1) as a central hub kinase contributing to cytoskeletal 
remodeling. My proteomics and transcriptional studies defined in vitro effect of hypoxia in activation of 
lung epithelial cells. Using systems biology approaches, I identified interplay between transforming growth 
factor – β (TGF–β) signaling, hypoxia signaling, and FAK1 signaling. Further, my studies identified 
Galectin-1 as a novel mediator of hypoxia-induced pulmonary fibrosis. To mimic exacerbation of PF in 
patients, I developed a novel mouse model of exacerbated pulmonary fibrosis using subclinical bleomycin 
injury with chronic hypoxia. Further, to fill the existing requirement of an in vivo model of chronic PF, I 
characterized a triple transgenic mouse model that conditionally activates hypoxia signaling in the lung 
epithelial cells and causes progressive PF over a span of 12 weeks. Lastly, I performed RNA-Seq 
x 
 
experiments on primary AEC2s isolated from our transgenic mouse model to identify a hypoxia-mediated 
profibrotic role of microRNA-96 in down-regulation of PTEN, a tumor suppressor and anti-fibrotic protein. 
In conclusion, my studies established in vitro and in vivo roles of hypoxia in profibrotic activation of lung 
epithelium and identifies FAK1 and Gal-1 as key drivers of hypoxia-mediated fibrosis, which should be 
further evaluated in animal and human studies to determine their therapeutic potential. 
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CHAPTER ONE:  
INTRODUCTION 
 
1.1 Idiopathic Pulmonary Fibrosis 
1.1.1 History, Pathogenesis, and Epidemiology 
Interstitial lung disease (ILD) is a group of over 300 disorders [1]. It is characterized by 
pathological remodeling of the lung. Aberrant airway epithelial structure and function associated with 
abnormal accumulation of connective tissue in the lung compromises lung functions. ILDs are generally 
classified as diseases of known and unknown causes [1]. Idiopathic interstitial pneumonia (IIP) is a major 
subtype of ILDs of unknown causes, characterized by a varying degree of pulmonary fibrosis (PF) [2]. PF 
is a group of fibro-proliferative disorders of the lung characterized by aberrant proliferation of fibroblasts 
and their terminal differentiation into apoptosis-resistant myofibroblasts, which results in excessive 
extracellular matrix (ECM) deposition [2]. The increasing accumulation of myofibroblasts progressively 
affects the alveolar structure, increases lung stiffness and decreases gas-exchange, causing shortness of 
breath and death in patients. This process is primarily attributed to the normal wound healing process gone 
awry in the lung, following acute or chronic lung injury [3].  
IPF, which is found in over 55% of patients suffering from IIPs, has an unknown etiology. It is a 
chronic, progressive, irreversible, and lethal disease that causes over 80,000 deaths/year in the US and 
Europe combined, with a dismally low median survival rate of 3 years after diagnosis [4]. Although two 
drugs, pirfenidone and nintedanib, have been approved for treatment, their efficacy remains unknown due 
to their recent approval. Furthermore, a cure for IPF remains challenging since molecular mechanisms 
underlying its pathogenesis and progression remain unknown. 
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 Chronic inflammation associated with fibrosis has been considered a contributing factor in 
initiating fibrotic lesions in the lung [5]. However, treatments with corticosteroids and other anti-
inflammatory drugs such as azathioprine, cyclophosphamide, and prednisone have failed in slowing the 
progression of the disease  [6]. A primary reason for the failure of anti-inflammatory therapies could be the 
advanced stage of the disease at the time of diagnosis, limiting treatment options to palliative care. Further, 
observations of fibrosis indistinguishable from IPF in patients with immune disorders such as rheumatoid 
arthritis [7] suggest that inflammation may indeed play a role at some stage of the IPF pathogenesis. 
Therefore, molecular understanding of initiation and progression of IPF is imperative. Over the last decade, 
a number of seminal discoveries have provided new paradigms in molecular detail that provide glimpses 
into the genesis of IPF.  Here, I will review the current molecular understanding of initiation and progression 
of IPF achieved through numerous in vitro and animal studies and highlight the importance of studying 
hypoxic injury in lung epithelium in the context of IPF. 
 
1.1.2 A Brief Review of Molecular Mechanisms of IPF 
 Recently, a number of studies have brought various molecular mechanisms of IPF into focus. Lack 
of success of anti-inflammatory drugs such as prednisone and immunomodulatory agents such as 
azathioprine or cyclophosphamide, therapeutics targeting fibro-proliferative and fibrogenic processes have 
been in focus [6]. Current therapeutic approaches have been extensively reviewed elsewhere [6, 8]. A 
number of studies have attempted to decipher these fibrogenic processes and provided important insights 
into the various cell types and molecular mediators involved in pathogenesis and progression of IPF [3]. 
Here, I will describe the contribution of pathogenic molecular mechanisms in various cell types driving 
IPF. 
 
1.1.2.1 Pathways Central to IPF Pathogenesis: 
Numerous studies have described well characterized roles of TGF-β and Wnt signaling pathways 
in the pathogenesis of IPF [9, 10]. Recently, contribution of non-canonical signaling functions of TGF-β 
3 
 
and Wnt pathways have been suggested to play important roles in the pathogenesis of IPF. Here, I will 
describe the contribution of the non-canonical TGF-β and Wnt signaling pathways contributing to IPF. 
 
1.1.2.2 Non-canonical TGF-β signaling in IPF 
TGF-β is a profibrotic cytokine, which is defined as a growth factor that initiates fibrogenic cellular 
processes. Early studies suggested a direct role of TGF-β in IPF. Intratracheal instillation of adenoviral 
TGF-β was sufficient to cause lung fibrosis in rats [11]. TGF-β governs a number of profibrotic processes 
including proliferation of lung epithelial cells, fibroblasts, apoptosis-resistance acquired by the fibroblasts, 
differentiation of lung fibroblasts to myofibroblasts [9]. TGF-β also induces exuberant synthesis and 
secretion of ECM proteins by the myofibroblasts. TGF-β, through its canonical transcription factors 
SMAD2 and SMAD3 (Mothers Against Decapentaplegic homologues) signaling, transcriptionally 
increases collagen production via fibroblasts and myofibroblasts in the fibrotic lung, which leads to lung 
remodeling and stiffening of the matrix [9]. The stiffened matrix, in turn, activates TGF-β in the ECM, 
setting up a profibrotic feed-forward loop of hyper-activated TGF-β signaling. 
In addition, non-canonical TGF-β signaling has been implicated in pathogenesis of IPF. For example, 
the bone morphogenic protein (BMP) pathway appears to mediate antifibrotic effects in the lung. The BMP 
antagonists Gremlin and BMPER (BMP-binding endothelial regulator protein precursor) are overexpressed 
in the parenchyma of IPF lungs [12-14]. Gremlin promotes AEC2 activation, characterized by simultaneous 
increase in apoptosis and proliferation, while BMPER contributes to lung fibroblast migration and invasion. 
Consistent with these observations, components of TGF-β/BMP signaling pathway such as the ligands 
BMP2, BMP3, and NOG and transcription factors FOS and JUN are down-regulated in IPF lungs [15]. 
Similarly, increased expression of Activin-A and Activin-B, which are ligands of Activin signaling – a non-
canonical TGF-β superfamily pathway, has been reported in hyperplastic AEC2s lining fibroblastic foci, a 
region of apoptosis resistant and motile myofibroblasts [15]. However, Activin receptor inhibition in mice 
injured with asbestos or silica, which are used to induce injury-associated PF in mice, had little anti-fibrotic 
effect. The inefficacy of Activin inhibition in experimental models of PF warrants further determination of 
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molecular determinants of Activin signaling in the context of PF. Delineating these non-canonical TGF-β 
signaling pathways may prove vital in developing therapeutic targets for IPF. 
Recent reports have suggested regulation of TGF-β signaling via components of other profibrotic 
pathways. For example, TGF-β is activated by the epithelial integrin-αVβ6 at the site of injury causing 
fibrosis and its inhibition prevents development of PF [16]. Integrins are cell surface adhesion receptors 
that cause cytoskeletal remodeling in the cell via interacting with ECM proteins [17]. Therefore, aberrant 
ECM remodeling observed in IPF lungs often activates integrin signaling causing fibrogenic response [18]. 
Consequently, a humanized monoclonal antibody targeting αVβ6, STX-100, is under phase 2 clinical trial 
for IPF (trial identifier: NCT01371305). Consistent with the profibrotic functions of integrins, another 
integrin subunit β5 interacts with latent TGF-β complex activates TGF-β signaling [19]. In addition to 
pirfenidone, which attenuates TGF-β production and signaling, several other TGF-β-antagonists have been 
recently identified. For example, small C-terminal domain phosphatase-1/2 (SCP-1/2) and protein 
phosphatase 2A (PP2A) antagonize TGF-β signaling by dephosphorylating TGF-β effector SMADs and 
receptor TGF-βRI, respectively [20]. Thus, studies focusing on ways to activate these phosphatases may 
provide further insight into regulation of TGF-β and aid in developing novel therapies for IPF. 
 
1.1.2.3 Non-canonical Wnt Signaling in IPF 
WNT ligands and their receptors Frizzleds (FZDs) constitute three distinct Wnt pathways: the canonical 
Wnt pathway, the planar cell polarity (PCP) pathway and the Wnt/calcium pathway. These three pathways 
influence cell proliferation, migration, and differentiation during lung development and diseases [21, 22].  
While the role of canonical Wnt signaling in IPF is well known [10, 23], roles of non-canonical Wnt 
pathways are emerging. Canonical Wnts and its components (Wnt-1, Wnt-3a, Wnt-10b, β-catenin, GSK-
3β, and FZD2/3) and non-canonical Wnt-7b are increased in AEC2s of IPF lungs (Figure 2) [24]. FZD8, 
which is a receptor for Wnt5a in the non-canonical pathway, partially regulates TGF-β-induced profibrotic 
signaling and its deletion protects mice from bleomycin-induced lung fibrosis [25]. Consistent with these 
in vivo data, non-canonical Wnt5a/b is increased in fibrotic lung parenchyma of IPF patients. Likewise, 
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ICAT (inhibitor of β-Catenin and TCF4) is decreased in highly fibrotic areas of the lung, which can 
contribute to sustained activation of Wnt signaling [26]. During lung development, deletion of Wnt5a is 
associated with thickened mesenchyme and delayed lung alveologenesis [27], suggesting that 
overexpression of Wnt5a can contribute to hyperplastic AEC2s observed in the lungs of IPF patients. 
Recent emergence of the non-canonical Wnt signaling pathway in IPF warrants further studies to determine 
its role in pathogenesis of IPF. 
  
1.1.3 Need for Novel Molecular and Preclinical Approaches 
 The intricate molecular etiology of IPF is difficult to decipher as multiple resident lung cell types 
and circulating MSCs and fibrocytes contribute to the disease. Further, many of the cell types express high 
levels of similar profibrotic molecules such as TGF-β. Our molecular understanding of IPF is further 
complicated by the observations of these same molecules causing seemingly paradoxical effects on the 
cells, a phenomenon called as “Antagonistic pleiotropy”. For example, TGF-β can simultaneously activate 
pro-survival and pro-apoptotic pathways in the lung epithelium [28-30]. Therefore, context-dependent 
distinct roles of central regulators of IPF such as TGF-β have rendered the candidate approach for 
therapeutic targeting ineffective. “Signaling pathway redundancy”, which highlights a number of disparate 
signaling events converging on the same physiological phenomenon, is often observed in IPF [31, 32]. 
Perhaps due to this redundancy, inhibitors of single profibrotic effects such as imatinib, a platelet derived 
growth factor (PDGF) pathway inhibitor, have failed to ameliorate IPF in clinical setting [33]. Conversely, 
the only two approved drugs, Pirfenidone and Nintedanib, target multiple signaling pathways and are thus 
“process centric” inhibitors. For example, Pirfenidone targets multiple profibrotic processes including 
fibroblast proliferation and its differentiation into myofibroblasts, ECM protein deposition, and causing 
apoptosis of the fibroblasts [34]. Similarly, Nintedanib is a triple tyrosine kinase inhibitor, which targets 
profibrotic processes mediated by vascular endothelial growth factor receptor (VEGFR), PDGF receptor 
(PDGFR), and fibroblast growth factor receptor (FGFR) [35]. Therefore, the success of these “process-
centric inhibitors” in tackling a complicated molecular etiology of IPF highlights the need for research 
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approaches that delineate the dynamic networks of profibrotic signaling. Here, I will highlight the 
importance of combining unbiased bioinformatics and computational biology approaches coupled with 
molecular biology techniques to identify central players contributing to hypoxia-mediated fibrotic events 
in the lung. 
 
1.1.3.1 Integrated informatics and molecular biology 
Omics studies in the lung fibrosis field together with systems biology approaches are providing 
detailed insights into pathogenesis of IPF [36]. Integration of mRNA, non-coding RNAs (ncRNAs), and 
protein expression data from the lungs of patients suffering from various ILDs, including IPF, are providing 
valuable insights in the pathogenesis of IPF [37-40]. These studies have highlighted the need for 
understanding how distinct signaling pathways are integrated through a small number of hub proteins, 
which renders cells profibrotic. The unique ability of these hub proteins to coordinate several signaling 
cascades can be attributed to their structural versatility, emanating from their inherent structural flexibility, 
which is defined as “intrinsic disorder” [41]. The intrinsically disordered regions (IDRs) of these hub 
proteins allow them to physically interact with multiple proteins, which translates into regulation of multiple 
signaling pathways. Identifying hub proteins that can coordinate several profibrotic signaling pathway 
within hypoxic cells represents excellent opportunities for discovering novel therapeutic targets. I have 
taken an approach that has identified hub protein kinases as playing central roles in profibrotic signaling 
pathways. The role of these kinases have been validated using molecular biology techniques in cell culture 
and animal models of pulmonary fibrosis by me. 
 
1.1.3.2 Animal models of pulmonary fibrosis 
One major reason why clinical trials have had limited impact is because of the lack of preclinical animal 
models that appropriately recapitulate the progressive and irreversible nature of IPF [42]. Animal models 
of injury-induced PF (e.g., bleomycin, silica, irradiation, or fluorescein isothiocyanate (FITC)) have 
provided us with a great deal of understanding about profibrotic events. However, the indiscriminate injury 
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caused by these agents has confounded the identification of critical molecular events driving PF.  Further, 
these fibrotic agents are clinically and physiologically largely irrelevant as bleomycin, the most commonly 
used injury agent in animal models of PF, is rarely used in the clinic. Lack of physiological relevance 
coupled with the reversibility of fibrosis observed in these animal models has stymied the efficacy of 
preclinical studies of molecules identified through various in vitro and large-scale sequencing studies. I 
believe that application of omics and systems biology approaches in a temporal manner during disease 
progression in these and other models, which are described in Chapter 4, may pave the way to defining 
more targeted therapies 
 
1.2 Hypoxia Signaling Pathway 
Hypoxia, characterized by low levels of available oxygen, is known to cause a number of profibrotic events 
such as cellular proliferation, migration, mitochondrial stress, epithelial plasticity and apoptosis [43, 44]. 
When oxygen is readily available, defined as normoxia, transducers of hypoxia signaling, the α-subunits of 
hypoxia inducible factors (HIF-1α, 2α, and 3α) are hydroxylated at their proline residues by prolyl 
hydroxylases (PHDs), which utilize cellular oxygen as co-substrate [45]. The tumor suppressor von Hippel-
Lindau (VHL) requires proline hydroxylation of HIF-α subunits to recognize and cause their proteasomal 
degradation (Figure 1.1). In hypoxic conditions, the PHDs fail to hydroxylate HIF-α subunits, leading to 
their stabilization. Stabilized HIF-α subunits is then translocated to the nucleus, interact with the 
constitutively expressed HIF-1β subunit to relay their transcriptional activities. The hypoxia signaling 
pathway is depicted in Figure 1.1. The functions of HIF-1α and HIF-2α are well characterized, while HIF-
3α has been recently identified and its functions are yet to be completely determined [46].  
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 Figure 1.1: Hypoxia signaling pathway 
The diagram illustrates VHL-mediated proteasomal degradation of HIF-α subunits in the presence of 
oxygen (left panel). HIF-1β subunit is constitutively expressed and localized in the nucleus. Right panel: In 
hypoxic condition, VHL fails to recognize HIF-α subunits, leading to their stabilization and nuclear 
transport. HIF-α subunits interact with HIF-1β subunit to form HIF complex, which initiates transcription 
of hypoxia-regulated genes (HRG). 
 
 
 
Although HIF-1α and HIF-2α share a number of functions such as regulation of angiogenesis and 
requirement for normal development, they also participate in numerous disparate functions. Both, HIF-1α 
and HIF-2α proteins, are required during development. HIF-2α-null mice embryos are defective in lung 
maturation and sometimes may survive postnatally, suggestive of its role in development of the alveoli [47]. 
In the adult mice, HIF-1α reduces expression of anti-fibrotic IL-8 via Nrf2 inhibition, while HIF-2α 
increases IL-8 expression via upregulation of SP-1 in endothelial cells [48]. Likewise, HIF-2α is solely 
responsible for expression of another profibrotic molecule erythropoietin (EPO) in hepatocytes, leading to 
polycythemia [49]. Furthermore, they also differ in their expression patterns as HIF-1α is largely expressed 
in most of the tissues, while HIF-2α is expressed in a tissue-specific manner [50]. It is interesting to note 
that HIF-2α is specifically expressed in AEC2s [51], consistent with its requirement in late-stage lung 
maturation. Furthermore, mice homozygous for a mutation at codon 200 of Vhl (R200W, reflective of the 
patients suffering from Chuvash polycythemia) had increased Hif-2α activity, but not Hif-1α [52]. 
Furthermore, mice heterozygous for Hif-2α, but not Hif-1α, are protected from Vhl mutation-induced 
pulmonary edema and polycythemia. It should be noted that heterozygous loss of Hif-1α and Hif-2α 
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together protected mice against PF caused by Vhl mutation [52]. Despite this line of evidence, whether HIF-
2α specifically plays a role in regulating signaling pathways involved in PF remains to be tested. 
Apart from its signal transduction via HIF-1α and HIF-2α described earlier, hypoxia also elicits a 
number of other cellular responses such as generation of reactive oxygen species (ROS) [53], mitochondrial 
[54] and endoplasmic reticulum (ER) stress [55], and epithelial cell death [56], all of which play active 
roles in fibrogenesis in the lung [57-59]. Therefore, hypoxic environment can create a highly integrated 
network of profibrotic signaling pathways and processes, creating a fibrogenic milieu in the lung. 
 
1.3 Hypoxia in IPF 
 Hypoxia is closely linked with fibrotic disorders such as kidney, liver, and skin fibrosis [60, 61]; 
low oxygen levels in blood supply, called hypoxemia, are also associated with lung pathologies including 
IPF [62]. Chronic repetitive injury to the lung epithelium leads to aberrant epithelial repair, which results 
in initiation of pathogenic programs in lung, leading to IPF. Chronic hypoxia of the lung is one such injury 
and a significant clinical feature of patients with IPF [63]. This is particularly true in the aged with a history 
of lung infections and other ILDs. History of chronic ILDs can cause progressive decline in the lung elastic 
recoil, reduced chest wall compliance, and loss of intercostal muscle mass, leading to restrictive ventilatory 
defect, chronic pulmonary hypoxia, and deterioration of lung function [64-66]. Indeed, worsening levels of 
hypoxemia is a clinical feature of a number of ILDs, including lung infections, as well as of acute 
exacerbation of IPF (AE-IPF), which is a leading cause of death in IPF patients [66-68]. Cause of 
hypoxemia may be attributed to several processes. For example, loss of tissue aeration can cause focal 
hypoxia at the alveolar gas-exchange interface while alveolar collapse, which is frequently observed in IPF 
patients [69], can also lead to lack of oxygenation and, consequently, hypoxic milieu. Therefore, it is not 
surprising that patients with IPF often undergo oxygen therapy [62, 70, 71]. 
 In addition to the physiological association of hypoxia with IPF, several studies have linked 
hypoxia with IPF at the molecular level. For example, transcriptomic analysis of the lungs of IPF patients 
identified several signaling networks including p53/hypoxia signaling, which was also present in patients 
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with emphysema [72]. This study [72] also established presence of active hypoxia signaling by confirming 
elevated expression of HIF-1α in the lungs of IPF patients. Hypoxia pathway, in association with activated 
p53 signaling, may cause cellular apoptosis that is often seen in the epithelial cells of IPF lungs. Conversely, 
hypoxia also causes AEC2 proliferation in a doxycytidine kinase (DCK)-dependent manner [73]. However, 
central players driving pathogenic AEC activation in hypoxic milieu via multiple signaling pathways 
remain largely unknown. I have attempted to elucidate the central hub proteins that can relay hypoxia-
mediated profibrotic signaling in AECs Chapter 3. 
 
1.4 Contribution of Lung Epithelium to IPF 
The role of dysfunctional epithelium in fibrosis, including the lung, is emerging [74]. Lungs of IPF 
patients are characterized, in part, by aberrant epithelial activation in response to multiple injuries, typified 
by initial apoptosis and followed by abnormal hyperplasia. Since the lung epithelium is the first line of 
defense against various toxicants, infections, and injuries, abnormal epithelial activation is thought to be 
one of the major initiating events in the pathogenesis of IPF [58, 75]. Consistent with the emerging role of 
epithelium in initiation of IPF, several pathological hallmark of IPF are associated with the lung epithelial 
cells. For example, AEC2s of IPF patients are characterized by ER-stress and apoptosis, telomere 
shortening and its dysfunction, and mitochondrial dysfunction associated with oxidative stress [3, 57, 76-
80]. Here, I will describe three aspects of lung epithelium: (1) Known mutations associated with the 
epithelium in IPF, (2) the role of hypoxia in hyperplastic and apoptotic epithelium, and (3) observation of 
epithelial plasticity associated with aberrant cytoskeletal remodeling. 
 
1.4.1 Genes related to epithelial dysfunction 
Although IPF remains an enigmatic disease with an unknown etiology, early evidence of PF 
incidences in families suggested a genetic predisposition to IPF. Genome-wide association studies (GWAS) 
and proteomic studies using lungs of IPF patients have identified a number of genes and molecules that are 
associated with increased risks of IPF. For example, mutations in surfactant protein C (SPC) and surfactant 
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protein A2 (SPA2) cause ER-stress in the AEC2s in patients with familial pulmonary fibrosis (FPF), which 
can contribute to epithelial dysfunction [81, 82]. Similarly, mutations in human telomerase genes, 
telomerase reverse transcriptase (hTERT) and telomerase RNA component (hTR), have also been identified 
in the lungs of IPF patients [3]. Telomerase shortening or its dysfunction, which is often observed in AEC2s 
of IPF, can contribute to exhaustion of lung stem cells and increased rate of AEC2 cell death, leading to 
improper lung repair [3]. Further, a recent study identified desmoplakin (DSP), a component of epithelial 
desmosome, as one of the susceptible loci for pulmonary fibrosis [83]. Likewise, polymorphism of 
rs35705950 SNP in Mucin-5B (MUC5B) gene was associated with increased expression of MUC5B in the 
lungs of IPF patients [84]. Although, another study identified that MUC5B promoter polymorphism is 
associated with improved survival of IPF patients [85]. These contradicting reports highlight the complexity 
of the disease and are suggestive of the requirements of more detailed studies interrogating molecular 
underpinnings that contribute to IPF. 
 
1.4.2 Hyperplastic and Apoptotic Epithelium and Hypoxia 
Lungs of IPF patients exhibit AEC2 apoptosis as well as hyperplasia lining fibroblastic foci, 
indicative of improper re-epithelialization. Signaling pathways behind the observation of these paradoxical 
observations remain largely unknown. Importantly, notch signaling was recently described to contribute to 
the hyperplasic epithelium, which lead to honeycomb-like cyst formation of lung epithelial progenitor cells 
[86]. It is likely that Notch signaling and TGF-β superfamily signaling require physiological cues to activate 
paradoxical processes such as epithelial proliferation and apoptosis. Hypoxia is one such injury that has 
been described to cause cell death and cellular proliferation in a context-dependent manner in numerous 
diseases, including fibrosis [87]. Kirck and colleagues described the role of hypoxia in initiation of AEC2 
apoptosis via hypoxia-responsive BCL2/Adenovirus E1B 19kDa Interacting Protein 3-Like protein 
(Bnip3L), which is part of the pro-survival B-Cell CLL/Lymphoma 2 (BCL2) family [56]. Conversely, a 
recent study by Weng and colleagues identified that DCK caused hyperplasia of AEC2s in vitro and in vivo 
in hypoxia dependent manner [73]. Importantly, levels of DCK were also elevated in hyperplastic AEC2s 
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in the lungs of IPF patients and were positively correlated with increased severity of the diseases [73]. 
Although direct evidence of hypoxia-mediated AEC2 apoptosis and proliferation in IPF patients is lacking, 
these studies provide strong a rationale to delineate the pathways contributing to hypoxia-mediated AEC2 
dysfunction. 
 
1.4.3 Epithelial plasticity leading to aberrant cytoskeletal remodeling 
Normal adult lung epithelial cells are non-proliferative, non-migratory, highly polarized, and 
7anchored in the matrix. They form tight junctions to maintain epithelial integrity, which contributes to the 
homeostasis of the lung [88]. However, aberrantly activated AEC2s in the lungs of IPF patients lack 
epithelial features, including loss of epithelial markers such as E-Cadherin, and acquire increased motility 
associated with altered cytoskeleton  [58, 89]. Further, some of the known profibrotic events such as ER-
stress initiate epithelial-to-mesenchymal transition (EMT) of AEC2s [90], while oxidative-stress induced 
mitochondrial DNA causes apoptosis in AEC2s [91]. Despite the controversy surrounding complete EMT 
in the lungs of IPF patients, it is widely accepted that AECs (marked by either SP-B, TTF-1, or SP-C 
expression) at least transiently express some mesenchymal markers such as N-Cadherin and α-SMA [92, 
93]. 
Furthermore, since IPF is a disease of aberrant wound healing, cytoskeletal remodeling leading to 
epithelial plasticity is a major feature of AEC2s in the lungs of IPF patients. Therefore, defining 
physiologically relevant factors that contribute to deregulated cytoskeletal remodeling is imperative. 
Oxygen plays a central role in several wound repair-associated processes such as energy metabolism, 
angiogenesis, and formation of procollagens – an important ECM protein involved in wound healing [94]. 
Therefore, in the context of IPF, it is important to note that these processes may be sensitive to dysregulation 
in regions of local hypoxia, which in turn can exacerbate formation of fibrotic lesions as a result of 
deregulated wound healing. Indeed, hypoxia plays a central role in epithelial wound healing processes, 
including cytoskeletal remodeling [95]. Since activated hypoxia signaling is often observed in several ILDs, 
including IPF [72], it is important to understand its role in wound healing initiated by the epithelial cells.  
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Several of the hypoxia-regulated genes and proteins are characterized as profibrotic molecules that 
contribute to cytoskeletal remodeling-associated processes such as proliferation, migration, and EMT [44]. 
Therefore, it is important to identify molecules that are central to the profibrotic hypoxia signaling involved 
in cytoskeletal remodeling. Utilizing principles of network biology and bioinformatics in Chapter 2, I have 
identified central hub proteins involved in hypoxia-regulated cytoskeletal remodeling. 
 
 
1.5 Profibrotic Roles of Focal Adhesion Kinase-1 (FAK1) and Galectin-1 
 My studies have identified FAK1 and Galectin-1 as central mediators of profibrotic hypoxia 
response in the lung epithelial cells. Here, I will review known functions of FAK1 and Galectin-1 in the 
context of profibrotic cellular processes such as cytoskeletal remodeling and cell proliferation and survival. 
 
1.5.1 FAK1 
 FAK1 is a cytoplasmic tyrosine kinase, playing a central role in mediating cellular proliferation 
and cytoskeletal remodeling [96]. A number of studies have implicated FAK1 in pathogenesis of various 
cancers [97, 98]. Specifically, it has been implicated in metastasis and maintenance of cancer stem cells 
[99]. These processes are highly analogous to aberrant migration and transdifferentiation of fibroblasts to 
myofibroblasts and sustained proliferation of epithelial cells with regenerative potential in IPF. Further, 
FAK1 is activated via autophosphorylation in response to a number of growth factors such as TGF-β [100], 
VEGF in endothelial cells [101] and FGF and PDGF in fibroblasts [102]. These growth factor signaling 
pathways are targeted via Pirfenidone and Nintedanib, the only two drugs approved for IPF therapy. 
Therefore, it is possible that FAK1 plays critical roles in fibrogenic processes observed in the lungs of IPF 
patients. Indeed, FAK1 actively contributes to wound repair by promoting cell proliferation and migration 
[103], suggesting that sustained FAK1 signaling can lead to proliferative cells as observed in the lungs of 
IPF patients. Further, pharmacological inhibition of FAK1 [104] or overexpressing its negative regulator 
FAK-related non kinase (FRNK) [31] attenuated progression of bleomycin-induced PF. 
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Importantly, FAK1 plays an important role in modulating the cellular response to ECM remodeling 
in the lung epithelium by binding with the integrin β-subunit and relaying cytoskeletal remodeling [32]. 
Hypoxia, with its active role in promoting cytoskeletal remodeling [95], likely leverages the integrin/FAK1 
signaling pathway in the lung epithelium. However, direct evidence of hypoxia-mediated FAK1 activation 
in lung epithelium is lacking. Therefore, I have focused on hypoxia-mediated FAK1 activation and 
subsequent profibrotic response of lung epithelial cells in Chapter 3. 
 
1.5.2 Galectin-1 
 Galectin-1, 14-Kda β-galactosidase-binding lectin-1 protein, is a protein involved in cell 
proliferation and migration, anti-apoptotic, and pro-survival cellular processes [105] that are associated 
with IPF. Hypoxia transcriptionally regulates Galectin-1 expression [106]. Therefore, Galectin-1 
expression is often detected in hypoxic tumor microenvironment, indicative of its pro-survival and 
proliferative function [105]. Consistent with its oncogenic role, Galectin-1 induces migration and invasion 
capabilities of lung epithelial cells by coordinating integrin and notch signaling pathways as well as 
acquisition of mesenchymal phenotype [107]. These features are often observed in the lung epithelium of 
IPF patients [58], suggesting that Galectin-1 may play a role in profibrotic activation of epithelial cells in 
lungs of IPF patients. Indeed, Galectin-1 has been shown to regulate TGF-β/SMAD signaling pathway by 
interacting with SMAD2 and increasing SMAD transcriptional activity, promoting PF [108]. However, its 
specific role in hypoxia-mediated profibrotic activities of the lung epithelium remains unknown. I have 
determined a functional relationship between FAK1 and Galectin-1 in AEC2s that coordinates hypoxia 
signaling, contributing to PF. The in vitro and in vivo roles of Galectin-1 have been described in Chapter 3 
and Chapter 4, respectively. 
 
1.6 Central Hypothesis and Specific Aims 
 Reemergence of epithelial dysfunction and aberrant wound repair as central events contributing to 
IPF pathogenesis has created the need to determine various factors contributing to epithelial activation. 
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Here, I focus on a physiological condition, hypoxia, and hypothesize that hypoxic injury contributes to 
profibrotic activation of AEC2s via activation of central hub proteins FAK1 and Galectin-1. I will be testing 
this hypothesis in four specific aims: 
Aim 1: Identify hub kinases central to hypoxia-regulated profibrotic cellular processes such as 
cytoskeletal remodeling. 
Aim 2: Determine profibrotic role of FAK1 and Galectin-1 in hypoxic AEC2s 
Aim 3: Characterize and establish novel mouse models of PF 
Aim 4: Identify molecular signatures of hypoxic AEC2s via RNA-sequencing 
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CHAPTER TWO:  
IN SILICO IDENTIFICATION OF PROTEIN KINASE SIGNALING HUBS 
 
2.1 Brief Outline 
In this chapter, I will describe the unbiased approach taken to identify signaling hubs that can potentially 
contribute to profibrotic activation of lung epithelial cells. Since about 90% of proteins are phosphorylated 
at some point in their lifespan [1], it is likely that the protein kinases form a very elaborate network that is 
leveraged by the cell to respond to extrinsic or intrinsic stimuli. Indeed, protein kinases are often aberrantly 
activated or inactivated in pathological conditions, including cancer and fibrotic disorders [2, 3]. In the 
context of IPF, one of the two drugs approved by the US-FDA, nintedanib, is a triple receptor tyrosine 
kinase (RTK) inhibitor [4]. Further, a number of profibrotic growth factor signaling pathways utilize RTKs 
such as epidermal growth factor receptor (EGFR) and TGF-β receptors I and II and cytoplasmic kinases 
such as phosphoinositol-3 kinase (PI3K), AKT and proto-oncogene SRC [3, 5]. Overrepresentation of 
protein kinases in various pathologies can partly be explained by their ability to form extensive protein 
signaling networks via transient and functional protein-protein interactions (PPIs) [6]. Kinase signaling 
networks, like other protein signaling networks, function in a hierarchical manner where a few central 
kinases govern the adaptive response of the cell by relaying their functions through multiple other kinases 
and non-kinase proteins [6]. Therefore, it was of interest to me to identify the central kinases that govern 
PPI networks in order to further ascertain their functions at the mechanistic level, which can be exploited 
as therapeutic targets. 
Despite the importance of kinases in regulating cellular signaling in numerous pathologies, their 
therapeutic inhibition has remained challenging with some success. Indeed, nintedanib has shown some 
success for IPF and non-small cell lung cancer [4, 7], while imatinib, a PDGF inhibitor, is used to treat 
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patients with chronic myeloid leukemia (CML) [8]. These two are among the 28 small-molecule kinase 
inhibitor approved by the US-FDA [9]. However, despite the initial benefits of these kinase inhibitor 
therapies, many of the patients invariably experience disease relapse, which warrants a greater 
understanding of kinase regulation and their contributions to disease relapse. 
Therefore, my goal was to define ideal hub kinases and their functional features that can be 
leveraged for targeted therapies in future. To this end, I focused on unique structural features of protein 
kinases and evolutionary conservation of these structural features. I specifically analyzed the human protein 
kinome (518 kinases) to identify intrinsically disordered regions (IDRs) that are characterized as stretches 
of amino acids unable to form tertiary structure in their native environment [6]. IDRs participate in various 
disease pathogenesis and exist as highly dynamic conformational ensembles [10]. Some of these regions 
acquire stable structures by engaging in PPIs. IDRs can interact with multiple unrelated protein partners 
and fold differently while interacting with different binding partners [11]. This disorder-based binding 
promiscuity of IDRs, acquired via faster rate of evolution at the amino acid level, allow them to play central 
roles in multiple cellular processes [12]. I have used these unique properties of IDRs to uncover critical 
kinases that potentially play important roles in organ fibrosis. 
 
2.2 Development of a pipeline to identify hub kinases that participate in profibrotic signaling 
First, I developed a strategy to analyze the predicted intrinsic disorder in all the kinases within the 
human kinome and defined hybrid kinases as kinases with at least one IDR of 25 amino acid or longer. 
Obtaining this data allowed me to interrogate the range of intrinsic disorder present among different kinase 
groups (Figure 2.1A). Second, I ascertained evolutionary relationship across all kinases and compared 
evolution of full-length kinases with respect to their KD (kinase-domain) and the IDRs (Figure 2.1B). Third, 
I identified conserved IDRs flanking the KD as an important feature of kinases, uncovering 36 kinases with 
unusual presence of IDRs extending into their KDs (Figure 2.1C). Fourth, FAK1 emerged as the 
topologically most central kinase, which engages in multiple PPIs via its IDRs, contributing to activation 
of processes involved in cytoskeletal remodeling (Figure 2.1C-F). 
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Figure 2.1: Flow chart depicting the approach leading to identification of intrinsically disordered 
FAK1 and its interacting partners as modulators of cytoskeletal pathway. 
(A) Analysis of disorder prediction of 504 human kinases [13] identified 83% of the kinome has hybrid 
kinases with 65% of the kinases with an IDR adjacent to their KDs. (B) Calculation of evolutionary 
conservation of IDRs in kinases revealed that although IDRs evolve at a much faster rate than the full-
length protein kinase their KDs, the IDRs adjacent to KDs evolve at a significantly slower rate than other 
IDRs. (C) 36 kinases were identified to have IDRs within the kinase domains. Network analysis of the 
interactome of 36 kinases identified FAK1 as a topologically most central hub kinase. (D) FAK1 has three 
IDRs, which are divergent in their sequence, but conserved in their spatial arrangement, suggestive of their 
functional relevance. (E) 77% of the FAK1 primary interactome is comprised of hybrid proteins. (F) 
Functional network analysis highlighted cytoskeletal remodeling pathway to be regulated by intrinsically 
disordered regions present in FAK1 and its interacting partners. 
 
 
2.3 83% of the human protein kinases are hybrid kinases 
I analyzed 504 kinases and computationally predicted intrinsic disorder in their structure using 
PONDR-FIT [14]. My analyses revealed that 417 of the 504 kinases (83%) contain IDRs (Figure 2.2A; 
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Table B.1). The kinome dendrogram is overlaid with % disorderliness of the kinases, which is defined as 
the fraction of disordered amino acids in each kinase (Figure 2.2A). Further, I observed that IDRs are 
distributed amongst all kinase groups. At least 70% of kinases in each group have IDRs with the exception 
of the RGC group, which comprises of only five kinases, representing a low sample size (Figure 2.2B). 
 
 
 
 
Figure 2.2: 83% of the human kinases are hybrid kinases. 
(A) Long stretches of IDRs were identified in 83% of the human kinome (417 of 504 kinases). Percent 
disorder (calculated as the percentage of disordered residues present in each kinase) is depicted for each 
kinase as a red filled circle overlaid on the human kinome dendrogram. The kinome dendrogram illustration 
is reproduced by courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). (B) A stretch of 25 or 
more consecutive disordered amino acids is called an IDR for this analysis. Percent kinases with at least 
one IDR (hybrid kinases) in each of the ten kinase groups are depicted in the bar graph. 
 
 
2.4 IDRs are associated with kinase-kinase interactions and participate in distinct disease 
pathologies 
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Kinases participate in extensive signaling crosstalk via PPIs. Since IDRs are known to facilitate 
PPIs, I tested whether they contribute to kinase-kinase interactions (KKIs). Through literature mining of 
experimentally validated PPIs, I identified a total of 2103 KKIs (Figure 2.3A). Amongst these interactions, 
1900 were between hybrid kinases, suggesting an association of KKIs with the presence of IDRs in these 
kinases. Interestingly, tyrosine kinase (TK) group participate in the highest number of experimentally 
validated kinases, which suggests their functional diversity. 
Since my analysis revealed differential participation of kinase groups in KKI network (Figure 
2.3A), I tested whether these groups also differentially associated with disease pathogenesis. Utilizing 
disease enrichment feature of IPA (Ingenuity Pathway Analysis), disease enrichment for each group of 
kinases was performed. I determined that different kinase groups preferentially participate in pathogenesis 
of a subset of diseases (Figure 2.3B). For example, kinases of TK group (vertical arrow) are strongly 
associated with a large number of IPF-related disorders such as respiratory diseases, inflammatory response, 
and connective tissue disorder (horizontal arrows; red boxes) (Figure 2.3B). Likewise, the group of tyrosine 
kinase like (TKL) kinases also participated in pathogenesis of respiratory diseases and connective tissue 
disorder (orange boxes) while PKA/PKG/PKC (AGC) group kinases participated in inflammatory response 
(orange box) but are very weakly associated with respiratory disease (green box). This analysis highlighted 
current knowledge about participation of different kinase groups in pathogenesis of different diseases 
including fibro-proliferative lung diseases. 
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Figure 2.3: IDRs are associated with Kinase-Kinase interactions and differential disease pathogenesis 
(A) Kinome level PPI analysis enriches the TK group with the highest number of kinase-kinase interactions 
(KKIs). Further analysis of KKIs within and between kinase groups identified a total of 2108 interactions 
within 393 of 504 kinases, while the remaining 111 kinases did not participate in any KKIs. These data are 
used to create a Group–Group Interaction model. The size of the circle corresponds to the total number of 
interactions the kinases from a specific group participate in. Red color in the circle indicates the fraction of 
KKIs involving at least one hybrid kinase. Blue color indicates the fraction of KKIs involving two 
completely structured kinases. (B) Disease association analysis reveals cancer as the most significant 
disease driven by kinases. The heat map shows group-wise participation of kinases in various diseases, with 
TK group observing the highest enrichment (vertical black arrow). The analysis was done using Ingenuity 
Pathway Analysis (IPA). The analysis revealed a number of IPF-associated diseases such as respiratory 
diseases, inflammatory response, and connective tissue disorder (horizontal black arrows).  
 
 
2.5 Differential evolution of IDRs in the kinome defines an evolutionary relationship between 
KDs and adjacent IDRs  
Each kinase group is classified by its differential evolution that includes sequence and functional 
similarity as observed in the kinome dendrogram [15]. While the evolutionary rate of IDRs is faster than 
the ordered regions in various protein families [16], the relative evolutionary rates of IDRs in the kinome 
have not been determined. Therefore, I analyzed the evolutionary rates of IDRs, KDs, and the full-length 
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protein kinase. My analyses revealed that the IDRs evolve at a much higher rate, while the KDs evolve at 
a much slower rate in comparison to the full-length protein kinase (Figure 2.4A). Further, I defined the 
relationship between evolution of kinases, their KDs, and their IDRs. Our studies revealed that there is a 
significant correlation between (1) the evolutionary rate of an IDR and the KD, (2) the evolutionary rate of 
an IDR and full length kinase, and (3) the evolutionary rate of a KD and full length kinase. This observation 
suggests that KDs and IDRs in a given kinase evolve in a correlative manner, albeit at different individual 
rates (Figure 2.4B). 
Since our data suggested that IDRs and KDs had correlative evolutionary rates, I tested whether 
this evolutionary pressure had any preference for IDRs that are found adjacent to the KDs.  I analyzed the 
kinome for spatial arrangement of IDRs flanking the KD. I used a cutoff of 100 amino acid flanking the 
KD since the predicted optimal number of residues corresponding to the maximum free energy of unfolding 
is 100 amino acids [17]. I discovered that 65% of the kinases (325 of 504 kinases) have at least one IDR 
within 100 amino acids on either side of the KD (Table B.2). Functional importance of these IDRs can be 
explained, in part, by their evolution in relation to other IDRs and the KDs. To test the hypothesis that IDRs 
adjacent to KDs evolve in correlation to the KDs, I analyzed kinases that had at least two IDRs and 
compared the evolution of IDRs closest to KDs (IDR1) with the evolution of second closest IDRs (IDR2). 
I identified a total of 211 kinases with at least two IDRs. Interestingly, I found that although both IDR1 and 
IDR2 evolved at a significantly faster rate than the KD, IDR1 was under greater evolutionary selection 
pressure and evolved at approximately 6-fold slower rate than IDR2 (Figure 2.4C). Further, I also identified 
a correlation between the rates of evolution of KDs and IDR1 compared to the KDs and IDR2 (Figure 
2.4D). In summary, our analysis revealed that IDRs evolve at a significantly higher rate than the KD and 
the WP. Further, IDRs evolve at a differential rate based on their spatial arrangement with respect to the 
KDs. 
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Figure 2.4: Differential evolution of IDRs in the kinome highlights 36 kinases with IDRs in their KD 
(A) Distribution of the rate of evolution of IDRs, KDs, and WPs (full length kinases) indicates that IDRs 
evolve at a higher rate as compared to the KDs and WPs. (B) Scatter plot of the relationships between the 
rate of evolution of each full length kinase (WP) and its KD (KD-WP; blue), each kinase and average rate 
of all of its IDRs (IDR-WP; green), and KD and average rate of all the IDRs of that kinase (IDR-KD; red). 
Pearson’s coefficient (r) reveals that there is a significant positive relationship between rate of evolution of 
WPs and their KDs (blue circles), WPs and their IDRs (green circles), and KDs and corresponding IDRs 
(red circles) (p < 0.0001). Kinases with at least one IDR were analyzed (n = 414). (C) IDRs adjacent to 
KDs evolve at a slower rate than IDRs away from the KDs. IDR1 = Closest IDR to the KD; IDR2 = second 
closest IDR to the KD. (D) Comparative analysis of evolutionary rates of KD with IDR1 (Blue) and KD 
with IDR2 (green) reveal higher correlation between the KDs and IDR1 (r= 0.56) as compared to KDs and 
IDR2 (r = 0.33) within the same kinase. Kinases with at least two IDRs were analyzed, which reduced the 
number of kinases analyzed to 211. 
  
2.6 Functional network analysis reveals FAK1 as topologically most significant hub 
Since 325 kinases were identified to contain IDR1 adjacent to the KD (within 100 amino acids), I 
further analyzed the spatial arrangement of these IDR1s with respect to their KDs. Strikingly, a unique 
subset of 36 kinases emerged with IDR1 that were not only adjacent to their KD but also extended into their 
KD (Figure 2.1A; Table B.3).  I hypothesized that these 36 kinases, with unique arrangement of IDRs, may 
participate in distinct set of cellular functions. To test this hypothesis, first, I derived experimentally 
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validated PPIs for all 36 kinases, thereby defining the primary interactome of each of the 36 kinases. A total 
of 959 proteins were identified to be interacting with these 36 kinases. Considering that IDRs facilitate 
PPIs, these interactions may be influenced by either direct binding of IDRs or allosteric influence of IDRs 
facilitating these interactions (Figure 2.5A). FAK1 emerged as topologically the most significant protein in 
this network using degree centrality as a measure [18] (Figure 2.5A). Biological significance of FAK1 was 
interrogated via a functional network analysis approach using IPA. Functional enrichment of the 36 kinases 
against the entire kinome identified that FAK1 had the highest number of functional relationships with 
other proteins in the network (Figure. 2.5A, B, blue edges). In summary, using two independent approaches, 
statistical and functional, FAK1 was identified as a central network hub regulating 36 kinases.  
The above functional enrichment revealed that this network of 36 kinases is critical for cell 
signaling, cell growth and proliferation, and cytoskeletal remodeling, including cellular movement and 
morphology (Figure 2.5C). Thus, it is likely that cells may preferentially utilize these 36 kinases to drive 
the above set of functions. In summary, my topological and functional analyses highlight FAK1 as a 
functionally important hub kinase. 
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Figure 2.5: Functional network analysis of the interactome of 36 Kinases reveals FAK1 as 
topologically the most significant hub. 
(A) A primary interactome was derived from 959 experimentally validated PPIs of 36 kinases. The PPI 
network was visualized using Cytoscape [19]. Topologically significant hub proteins were determined by 
calculating degree centrality as a measure (yellow circles). FAK1 was determined to be topologically most 
significant kinase. (B) In order to identify whether the topologically most significant kinases are 
functionally important, top two functional networks enriched by 36 kinases were merged using IPA 
(Background dataset used: Human Kinome – 504 kinases). Red colored symbols represent proteins that are 
part of the 36 kinases. The four topologically significant kinases are highlighted with their functional 
relationships (depicted as blue lines). FAK1, the most central kinase had the highest number of relationships 
within the network. (C) Functional and disease enrichment of 36 kinases using IPA revealed their 
involvement in critical cellular and molecular functions (Background dataset: Human Kinome – 504 
kinases). Cellular processes related to cytoskeletal remodeling such as cellular morphology and movement 
were highly significant. Infectious diseases were enriched as the most significant group. Red dotted line 
represents the threshold for significance (p<0.05). 
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2.7 FAK1 IDRs are spatially conserved in evolution 
Since I identified FAK1 as a topological and functional hub kinase of the 36 kinases, I sought to 
determine how FAK1 IDRs can be regulated, which, in turn, can regulate function of FAK1. FAK1 protein 
structure consists of three structured domains: FERM domain, KD, and FAT domain. I predicted IDRs in 
FAK1 protein using eight different disorder predictors, which identified three IDRs flanking each of the 
three structured domains (Figure 2.6A). The middle IDR (IDR1) overlapped with the KD towards the C-
terminus of the protein (Figure 2.6A). Since IDRs adjacent to KDs evolve slowly, I wanted to know whether 
this was the case for FAK1. To determine the evolutionary sequence conservation of FAK1 IDRs, I 
performed multiple sequence alignment of FAK1 orthologs from 11 different species ranging from 
invertebrates to human.  Majority of the FAK1 protein is largely conserved across the nine species from H. 
sapiens to D. rerio, while C. elegans and L. variegates (invertebrate species) had poor alignment and 
conservation of the IDR sequences (Figure 2.6B). Evolutionary analysis of FAK1, its KDs, and its IDRs 
reveal that IDR1 is indeed more conserved than the other two IDRs (Figure 2.6C), suggesting differential 
sequence adaptation of IDRs depending on their spatial arrangement within FAK1 protein structure. 
Higher evolutionary rate, implied by low conservation, is often associated with lack of conserved 
function for a given region within the protein. The lack of evolutionary selection pressure allows such 
regions to evolve at a rapid rate [20]. However, to test the possibility that FAK1 IDRs are conserved at the 
spatial level and maintain intrinsic disorder, I hypothesized that despite the poor conservation at the amino 
acid level, IDRs are spatially conserved across evolution. To test this hypothesis, I predicted intrinsic 
disorder in all eleven orthologs using the same 8 disorder predictors. I find that IDRs in FAK1 are present 
in all of the eleven species, including invertebrate species that showed poor alignment of IDR sequences 
(Figure 2.6D). In addition, the positions of IDRs are also relatively conserved, reaffirming the requirement 
for spatial conservation of IDRs. This spatial conservation of IDRs may enhance structural pliability 
adjacent to the FAK1 ordered domains, including its KD. Taken together, I reveal that FAK1 IDRs, 
although less conserved at the sequence level, are spatially conserved. 
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 Figure 2.6: FAK1 IDRs are spatially conserved in evolution. 
(A) Eight distinct disorder predictors were used to calculate disorder regions with high confidence for the 
human FAK1 protein. The average disorder score of all predictors is plotted (red line) ±SE as error bars 
(orange lines). Blue bars represent structured regions of FAK1 and red bars represent the IDRs. Broken red 
bars represent low agreement of disorder between eight predictors. (B) Multiple sequence alignment (MSA) 
was performed between FAK1 protein sequences from 11 species (from humans to echinoderms). MSA 
scores were calculated via ClustalW, a sequence analysis program using MacVector, a sequence analysis 
application (Apex, North Carolina). Green represents highly conserved amino acid residues while red 
represents highly divergent amino acid residues. A high degree of sequence disagreement is observed in 
IDRs, while structured domains are highly conserved. (C) Relative evolution rates of FAK1 domains were 
calculated to reveal distinct rate of evolution amongst IDRs based on their spatial arrangement with respect 
to the KD. Whole protein (grey), KD (blue), and each of the three IDRs (red). (D) Disorder scores of FAK1 
protein from 11 species were calculated using the eight disorder predictors. Average disorder was calculated 
for FAK1 protein from each species and plotted as line graph. 
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2.8 IDR-interacting protein partners of FAK1 participate in distinct molecular functions 
The role of intrinsic disorder in scaffolding is well known [21] and FAK1 has kinase-independent 
scaffolding activity, which is critical to its oncogenic functions [22].  Therefore, I hypothesized that FAK1 
IDRs play an important role in mediating its scaffolding activity by mediating PPIs. Many of the proteins 
interacting with FAK1 themselves act as scaffolding proteins at focal adhesions and in cytoskeletal 
remodeling. Through literature mining, I identified a total of 111 FAK1 interacting proteins, 45 of which 
were mapped to different domains of FAK1 while the remaining 66 proteins had no information of mapped 
domains (Figure 2.7A; Table B.4). Consistent with my hypothesis, FAK1 utilizes its IDRs to interact with 
23 proteins, a 3-fold enrichment when normalized to the total number of disordered and ordered residues 
of FAK1 (Figure 2.7B(ii)).  
I hypothesized that IDR-interacting proteins may drive a distinct set of molecular functions when 
compared to the proteins interacting with the ordered regions. Therefore, I analyzed the gene-ontology 
(GO) terms associated with the proteins interacting with either ordered regions (Interactome A) or IDRs 
(Interactome B) to derive two functional networks (Figure 2.7B (iii)), Comparison of the two networks 
using Cytoscape [19] identified clusters of unique functions driven by each set of proteins (Figure 2.6C). 
Interestingly, IDR-interacting proteins participate in kinase activity, scaffolding, adaptor- and protein-
binding, and Rho-GTPase activity. In order to further validate this result, I compared the signaling pathways 
enriched by proteins involved in either Interactome A or Interactome B. My analysis revealed that canonical 
integrin- and FAK1-signaling pathways are primarily driven by proteins in Interactome B (Figure 2.7D). 
Further, when comparing the molecular and cellular functions, cytoskeletal remodeling-related functions 
such as cellular movement and morphology are preferentially enriched in the subset of proteins participating 
in IDR-driven interactions (Figure 2.7E). Taken together, my analyses implicate that FAK1 IDRs play 
critical roles in modulating interactions with proteins that participate in cytoskeletal remodeling. 
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Figure 2.7: IDR-interacting protein partners of FAK1 participate in distinct molecular functions and 
drive FAK1-mediated cytoskeletal remodeling. 
(A) FAK1 primary interactome was visualized using Cytoscape. 86 of 111 protein partners (77% of the 
interactome) were identified as hybrid proteins. (B) (i) Bar structure of FAK1 shows IDRs and three 
structured domains (figure not to scale). A total of 45 FAK1-interacting proteins were mapped to different 
regions of FAK1. (ii) Enrichment of PPIs in IDRs (3.12-fold) was observed. Number of PPIs were 
normalized to the length of ordered (RO) or disordered regions (RDO). (iii) Interactomes comprising of 
proteins interacting with ordered regions (Interactome A) or disordered regions (Interactome B) were 
identified. The color coding of the proteins corresponds to the region of FAK1 each protein interacts with, 
as depicted in the bar structure. (C) Gene ontology analyses on Interactome A and Interactome B was 
performed using BiNGO App in Cytoscape and unique molecular functions of Interactomes A and B were 
identified. Blue circles: molecular functions terms unique to Interactome A; Red circles: molecular 
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functions terms unique to Interactome B. Molecular functions highlighted by green dotted lines represent 
common functions between the two interactomes. (D) Canonical pathways enriched by Interactome A and 
Interactome B were used for comparison analysis in IPA. Heat map depicting the –log(p-value) reveals 
signaling pathways that are specifically enriched via proteins in Interactome A or B. Top 10 canonical 
pathways are depicted here. (E) Comtparison of the molecular and cellular functions enriched by the 
proteins in Interactome A or B was performed using IPA. Processes involved in cytoskeletal remodeling 
had the highest difference between Interactome A and B (denoted by black stars). Red dotted line represents 
the threshold for significance (p<0.05). 
 
 
2.9 Hypoxia enhances FAK1 signaling in lung epithelial cells 
Since my in silico approach suggested that FAK1 plays a central role via its IDR-mediated kinase 
signaling, I wanted to test whether hypoxia can enhance FAK1 signaling in lung epithelial cells. In order 
to test this hypothesis, I used H441 cells as a model of AECs since they maintain morphological features 
of AECs and club cells, which are present in the bronchoalveolar regions adjacent to the alveoli [23]. I 
exposed H441 cells to hypoxia (1% O2) for 72 hours, confirmed stabilization of HIF-1α protein via western 
blot, followed by mass spectrometry (MS/MS) analysis (Figure 2.8A). MS/MS analysis identified 83 
significantly deregulated proteins, of which 36 were upregulated in hypoxic H441 cells (fold change ≥ 1.5 
or ≤ 0.5; Fisher’s exact test p < 0.05) (Figure 2.8B; Table 2.1). Since I was interested in determining 
signaling pathways upregulated by hypoxic injury to the lung epithelium, I performed functional 
enrichment of 36 hypoxia upregulated proteins using IPA. Enrichment of these 36 proteins revealed their 
role in cytoskeletal remodeling such as cell morphology, cellular assembly and organization, and cellular 
movement (Figure 2.8B). Network analysis of the 36 hypoxia upregulated proteins identified ras homolog 
gene family member A (RhoA) and FAK1 (gene name PTK2) mediated network that can drive 
aforementioned cellular processes (Figure 2.8C). RhoA is a significant transducer of FAK1 signaling during 
cytoskeletal remodeling [24]. In summary, my in vitro analysis also identified that FAK1 may play a critical 
role in regulation of hypoxia response in H441 cells. 
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Figure 2.8: Hypoxia enhances FAK1 signaling in lung epithelial cells. 
(A) HIF1-α was stabilized at 72 hours of hypoxia treatment. Hypoxia deregulated 83 proteins, of which 36 
were upregulated. (B) Bioinformatics analysis of 36 hypoxia upregulated proteins identified significantly 
up-regulated molecules driving signaling pathways that participate in the regulation of cellular morphology 
and cellular movement (red stars). Dotted red line denotes significance (P < 0.05) (C) Network analysis of 
HUPs identified RHOA and FAK1 (gene name: PTK2) mediated network. Red color denotes the HUPs, 
indicating the entire network is up-regulated under hypoxia. 
 
2.10 Conclusions 
This chapter highlights a novel approach of utilizing the IDRs present in human kinome to identify 
hub kinases playing important roles in cellular signaling. The unbiased structural approach in combination 
with functional analysis based on existing literature represents a novel pipeline, which helped identify hub 
kinases that govern epithelial response to hypoxic injury.  
My structural analysis of the human kinome identified prevalence of IDRs across all kinase groups; 
these IDRs evolve at a differential rate based on their spatial arrangement with respect to the KD. Slower 
rate of evolution of IDRs adjacent to the KDs likely fine-tune the enzymatic function of protein kinases. I 
identified 36 kinases that have IDRs adjacent to the KDs. These 36 kinases preferentially participate in 
processes associated with cytoskeletal remodeling largely driven by the topological and functional hub 
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kinase FAK1. Analysis of FAK1 and its IDRs revealed that FAK1, via its IDRs, interacts with proteins that 
are involved in FAK1 scaffolding activity and integrin signaling, which is critical in maintenance of 
epithelial characteristics, such as cell polarity and membrane integrity [25, 26]. Lastly, I confirmed the 
functional centrality of FAK1 to hypoxia response in the lung epithelium by performing a proteomics 
experiment on hypoxic H441 cells, again implicating enhanced FAK1 signaling and cytoskeletal 
remodeling. These results prompted me to further inquire into the role of FAK1 in regulating epithelial 
response to hypoxic injury in the context of IPF. The in vitro results of this inquiry are presented in the 
following chapter. 
 
 
Table 2.1: List of hypoxia-regulated proteins in H441 cells identified through MS/MS 
Proteins with significantly different expression values in hypoxic H441 cells are listed here. P-value is 
calculated using Fisher’s exact test and p-value < 0.05 is considered to be significant. Values in last two 
columns refers to number of unique peptides that were sequenced and mapped to the corresponding proteins 
in each condition (N: normoxia; H: Hypoxia). 
 
Protein Name Uniprot ID P-Value N H 
Isoform 6 of Extended synaptotagmin-2 A0FGR8 0.008 0 7
Tubulin, alpha 1 (Testis specific), isoform CRA_a A8MUB1 0.0001 0 54
Mucin 1, cell surface associated B1AVQ5 0.032 0 5
Uncharacterized protein B4DDN4 0.016 0 6
Histone H2B B4DR52 0.0001 0 18
Enolase B7Z2X9 0.0001 0 154
Uncharacterized protein E7ENH9 0.001 0 10
Uncharacterized protein E7ENU2 0.032 0 5
Uncharacterized protein E7ERJ7 0.004 0 8
Uncharacterized protein E9PFM1 0.0001 0 28
Serine/threonine-protein phosphatase E9PMD7 0.032 0 5
Uncharacterized protein F5GWP8 0.0001 0 15
Uncharacterized protein F5H897 0.002 0 9
Uncharacterized protein F8W8Q1 0.0001 0 33
General vesicular transport factor p115 O60763 0.016 0 6
Keratin, type II cytoskeletal 6A P02538 0.0001 0 23
Isoform C of Prelamin-A/C P02545 0.0001 0 25
Isoform 3 of 4F2 cell-surface antigen heavy chain P08195 0.008 0 7
Histone H2A.Z P0C0S5 0.004 0 8
Integrin beta-4 P16144 0.032 0 5
Carbonyl reductase [NADPH] 1 P16152 0.032 0 5
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Table 2.1 (Continued) 
Protein Name Uniprot ID P-Value N H 
Splicing factor, proline- and glutamine-rich P23246 0.002 0 9
Protein PRRC2A P48634 0.032 0 5
Actin, cytoplasmic 1 P60709 0.0001 0 120
Transforming protein RhoA P61586 0.032 0 5
Tubulin beta-2A chain Q13885 0.0001 0 41
Isoform 2 of Eukaryotic initiation factor 4A-II Q14240 0.002 0 9
Isoform 4 of Plectin Q15149 0.0001 0 137
Beta-actin-like protein 2 Q562R1 0.0001 0 15
Putative heat shock protein HSP 90-beta 4 Q58FF6 0.00025 0 12
Galectin-1 P09382 0.036 1 7
Neuroblast differentiation-associated protein 
AHNAK Q09666 0.00017 5 24
Uncharacterized protein B5MCQ5 0.033 2 9
Uncharacterized protein E9PMT2 0.027 6 16
Heat shock 70 kDa protein 1A/1B P08107 0.0086 12 28
Endoplasmin P14625 0.00048 24 54
Puromycin-sensitive aminopeptidase P55786 0.017 12 26
Keratin, type I cytoskeletal 9 P35527 0.00017 62 110
Phosphoglycerate kinase 1 P00558 0.0015 51 87
Actin, cytoplasmic 2 P63261 0.00042 182 124
14-3-3 protein epsilon P62258 0.039 40 25
Uncharacterized protein F8VXY0 0.025 26 13
Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 0.031 24 12
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein K P61978 0.014 25 11
X-ray repair cross-complementing protein 5 P13010 0.025 19 8
ADP/ATP translocase 2 P05141 0.02 15 5
60S acidic ribosomal protein P0 P05388 0.024 13 4
Non-POU domain-containing octamer-binding 
protein Q15233 0.019 10 2
Isoform 2 of Extended synaptotagmin-2 A0FGR8 0.0038 8 0
Uncharacterized protein A8MQ02 0.031 5 0
Tubulin, beta 6, isoform CRA_a B3KS31 0.00024 12 0
Uncharacterized protein B4DDN4 0.0077 7 0
Uncharacterized protein B4E2Z3 0.0038 8 0
Uncharacterized protein E7EQV3 0.031 5 0
Uncharacterized protein E7EUU4 0.0001 33 0
Uncharacterized protein E9PAQ6 0.0077 7 0
tr|E9PDF3|E9PDF3_HUMAN-DECOY 
Uncharacterized protein E9PDF3 0.0077 7 0
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Table 2.1 (Continued) 
Protein Name Uniprot ID P-Value N H 
Uncharacterized protein E9PMS6 0.015 6 0
6-phosphogluconate dehydrogenase, 
decarboxylating F5H0L3 0.015 6 0
Uncharacterized protein F8VTL3 0.0001 14 0
Ribosomal protein L18 G3V203 0.031 5 0
ATP citrate lyase, isoform CRA_a G3XAI4 0.00047 11 0
Isoform 3 of C-Jun-amino-terminal kinase-
interacting protein 4 O60271 0.015 6 0
Isoform 7 of C-Jun-amino-terminal kinase-
interacting protein 4 O60271 0.031 5 0
Microsomal glutathione S-transferase 1 P10620 0.015 6 0
ADP/ATP translocase 3 P12236 0.015 6 0
Isoform 2 of Ras-related protein Rab-6A P20340 0.031 5 0
Isoform Short of Splicing factor, proline- and 
glutamine-rich P23246 0.0077 7 0
Enoyl-CoA hydratase, mitochondrial P30084 0.031 5 0
60S ribosomal protein L9 P32969 0.0038 8 0
Isoform 3 of Nuclear autoantigenic sperm protein P49321 0.0019 9 0
Histone H2B type 1-D P58876 0.0001 22 0
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit P62136 0.0077 7 0
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit P62140 0.015 6 0
Rho-related GTP-binding protein RhoB P62745 0.031 5 0
Histone H3.1 P68431 0.031 5 0
Heat shock protein 75 kDa, mitochondrial Q12931 0.0038 8 0
Isoform 2 of Acetyl-CoA carboxylase 1 Q13085 0.0077 7 0
Isoform 3 of Plectin Q15149 0.0001 123 0
Tubulin beta-8 chain Q3ZCM7 0.0001 18 0
HEAT repeat containing 1 Q5T3Q7 0.015 6 0
Epidermal growth factor receptor kinase substrate 8-
like protein 2 Q9H6S3 0.015 6 0
Isoform 2 of Microtubule-actin cross-linking factor 
1, isoforms 1/2/3/5 Q9UPN3 0.0001 21 0
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CHAPTER THREE:  
EPITHELIAL FAK1 AND GALECTIN-1 ARE KEY DRIVERS OF PRO-FIBROTIC HYPOXIA 
RESPONSE 
 
3.1 Brief Outline 
Severe morbidity in IPF patients include lung infections, alveolar collapse, and respiratory failure 
associated with focal edema and local hypoxia, which lead to hypoxemia and acute exacerbation of IPF 
(AE-IPF). In this chapter, I define the role of FAK1 and Galectin-1 in driving hypoxia signaling, which 
contributes to lung fibrosis. 
My proteomics and transcriptional studies in cell culture defined effects of hypoxia in profibrotic 
activation of AECs. Network analysis of hypoxic lung epithelial cell-proteome identified Wnt3a, TGF-β, 
and FAK1 pathways, which synergized to activate lung epithelial cells. Wnt3a, TGF-β, and hypoxia 
activated FAK1, which was critical in activation of profibrotic genes. Further, candidate-based analysis of 
the proteomics data identified a new profibrotic protein, Galectin-1 – a 14 kDa β-galactosidase lectin 
binding protein. My experiments revealed that Galectin-1 interacts with FAK1 and is regulated by hypoxia 
and TGF-β/SMAD signaling. 
 
3.2 Hypoxia reprogramed and increased epithelial cell plasticity, proliferation, and migration 
I first assessed the physiological effects of hypoxia on lung epithelial cells. I used H441 cells as a 
model of AECs since they maintain morphological features of AEC2s and club cells, as described in 
Chapter 2 [1]. I first exposed H441 cells to hypoxia and tested the levels of stabilized HIF-1α, which 
confirmed activated hypoxia signaling (Figure 3.1A). I assessed whether hypoxia can induce proliferation 
and migration of H441 cells, which could partially explain the presence of hyperplastic (proliferating) 
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AEC2s detected in the patients of IPF lungs. My experiments indicate that hypoxia increased proliferation 
and migration of H441 cells (Figure 3.1B, C). To determine the effect of hypoxia as a profibrotic injury to 
distinct lung epithelial cells, I exposed four different cell types derived from proximal and distal lung 
epithelium. NuLi-1 cells: primary bronchial cell line, H441 cells: club cells derived from acini of 
bronchioles, A549 cells: representing AEC2s, and primary murine AEC2s were exposed to hypoxia. I 
observed that, in each of the different cell types, hypoxia increased mRNA levels of a host of profibrotic 
genes, including platelet derived growth factor B, TGF-β, tumor necrosis factor α (TNF-α), endothelin-1 
(EDN1), and plasminogen activator inhibitor-1 (PAI-1) (Figure 3.1D-F). Further, hypoxia increased mRNA 
levels of ECM proteins (collagens, fibronectin, and matrix metalloproteases (MMPs)) and mesenchymal 
proteins (N-Cadherin) in murine AEC2s, suggesting initiation of epithelial plasticity (Figure 3.1G, H). 
These observations are consistent with the notion that IPF lungs feature profibrotic activation of AEC2s, 
which display acquisition of mesenchymal phenotype [2]. My findings indicated that epithelial hypoxia is 
a likely fibrogenic insult in the lung, which is capable of altering the lung matrix, causing lung remodeling. 
 
3.3 SILAC-based LC-MS/MS proteomics identified TGF-β and Wnt3a as regulators of hypoxic 
proteome 
To identify pathogenic protein signatures that may arise exclusively in the hypoxic lung epithelial 
cells (H441 cells), we performed a comparative proteomics analysis. Utilizing stable isotope labeling of 
amino acids in cell culture (SILAC)–based differential proteomics approach, light isotope labeled cells 
were exposed to normoxia and heavy isotope labeled cells were exposed to hypoxia for 72 hours, which 
stabilized HIF-1α (Figure 3.2A, B). LC-MS/MS analysis identified 1476 significantly deregulated proteins 
in hypoxic lung epithelial cells (Figure 3.2C). Functional analysis of these proteins identified that the targets 
of major fibrotic regulators such as TGF-β and Wnt3a were significantly enriched in hypoxic proteome 
(Figure 3.2D). Further, bioinformatics-based functional analysis of the hypoxic proteome identified 
important cellular processes such as cell death, cellular movement, cellular growth and proliferation, and 
cellular assembly and organization (Figure 3.2E). Cytoskeletal remodeling does, in part, regulate these 
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processes in aberrantly activated lung epithelial cells [3]. Since abnormal epithelial migration and invasion 
characterize IPF lungs, I sought to identify important mediators of cellular movement by performing 
functional network analysis on my proteomics data (Figure 3.2F). The functional network revealed that 
cytoskeletal proteins central to FAK1 functions such as RHOA, paxillin, ICAM1, and vinculin [4, 5] are 
increased in the hypoxic lung epithelial cells, confirming the increased signature of cytoskeletal remodeling 
in hypoxic lung epithelial cells (Figure 3.2G). 
 Figure 3.1: Hypoxia reprogramed and increased epithelial cell plasticity, proliferation, and migration 
(A) Exposure of H441 cells to hypoxia (1% O2) for 24 hours stabilized HIF-1α protein and increased (B) 
proliferation at 48 and 72 hours of hypoxia compared to normoxic control cells (0 hrs). First column (72 
hours normoxia; 0 hour hypoxia). Second column (24 hours of normoxia followed by 48 hours of hypoxia). 
Third column (0 hours normoxia; 72 hours hypoxia); (n=8 in each experimental group). (C) Hypoxia 
increased rate of wound closure in H441 cells (1% O2) as compared to normoxic control cells (solid bars: 
Hypoxia and open bars: Normoxia; calculations were performed on at least five scratches in each 
condition). (D-E) A549 cells, H441 cells, NuLi-1 cells, and primary murine Type-II AECs (AEC2s) had 
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increased expression of mRNAs of profibrotic genes. AEC2s were exposed to hypoxia (1% O2) for 48 
hours; rest of the cell lines were exposed to hypoxia for 24 hours. (H) E-cadherin/vimentin staining of 
primary AEC2s determined the purity of AEC2s to be at ~95%. 
 Figure 3.2: SILAC-based LC-MS/MS proteomics identified TGF-β and Wnt3a as regulators of 
hypoxic proteome 
(A) H441 cells labeled with either light lysine/arginine (blue) or heavy lysine lysine(U-13C6)/arginine(U-
13C6,15N6; red) isotope were grown for 8 doublings and were respectively exposed to normoxia (21% O2) or 
hypoxia (1% O2; 72 hrs). (B) Hypoxia stabilized HIF-1α expression. (C) Heat map of 1476 proteins with 
significantly altered expression levels in at least 2 samples (Mann Whitney test, p < 0.05) was generated 
using XLSTAT software developed by Addinsoft (Paris, France). List of top 50 upregulated 50 
downregulated proteins is provided in Table 3.1 (D) Upstream network analysis using IPA identified TGF-
β and Wnt3a as significantly upregulated upstream regulators of hypoxia-deregulated proteins. Hypoxia-
deregulated proteins, which are influenced by TGF-β and Wnt3a, are depicted. (E) Functional enrichment 
of the 1476 proteins was performed using IPA. Top five cellular and molecular processes that were altered 
are plotted. (F) Functional crosstalk between cellular migration-related proteins identified in our proteomics 
dataset revealed FAK1 as a regulator of cellular migration. Red color in the network depicts upregulated 
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proteins in hypoxic proteome. Pink color depicts down-regulated proteins. Proteins with significantly 
enriched functions involved in cellular migration network are labeled. FAK1-effector proteins are 
highlighted and listed in (G). 
 
3.4 Hypoxia induced phosphorylation and membrane localization of FAK1 
FAK1 was identified as one of the central molecules in my network analysis. Given that FAK1 
plays important roles in cell migration via assembly/disassembly of focal adhesions at the cell membrane 
[4], I examined whether hypoxia activates FAK1. Consistent with my hypothesis, hypoxia increased 
membrane localization of FAK1 as examined by a 2-fold increase in membrane FAK1 intensity in H441 
cells (Figure 3.3A, B). Further, hypoxia caused FAK1 autophosphorylation at Y397 (Figure 3.3C), resulting 
in FAK1 activation. 
 Figure 3.3: Hypoxia caused phosphorylation and activation of FAK1, enhancing its membrane 
localization 
(A, B) H441 cells exposed to hypoxia (1% O2; 6 hours) had 2-fold increase in membrane localization of 
FAK1. (C) Hypoxia mimic, CoCl2 (100 µM, 15 minutes) increased pFAK1 (Y397) levels in H441 cells. p-
values are calculated based on student’s t-test (n=3). p < 0.05 is assumed to be significant. 
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3.5 FAK1 regulated TGF-β signaling, which synergized with Wnt/β-catenin pathway in hypoxic 
lung epithelial cells 
The proteome derived from hypoxic epithelial cells (hypoxic proteome) revealed TGF-β and Wnt3a 
proteins as upstream regulators of hypoxic proteome (Figure 3.2). Therefore, I tested whether TGF-β and 
Wnt3a contributed to the phosphorylation and activation of FAK1 in hypoxia. TGF-β and Wnt3a, 
significantly increased pFAK1 (Y397) levels in H441 cells (Figure 3.4A), suggesting FAK1 activation. 
Since the crosstalk between TGF-β/SMAD and Wnt/β-catenin signaling pathways is well established [6], I 
sought to determine whether hypoxia facilitated functional synergy between these two pathways. I 
transfected lung epithelial cells with TOP-FLASH, an artificial β-catenin reporter [7], and treated cells with 
either TGF-β or hypoxia mimic CoCl2 or both. There was a synergistic increase in β-catenin transcriptional 
activity in the presence of TGF-β and hypoxia, even without the addition of Wnt ligands (Figure 3.4B). 
Hypoxia also increased endogenous SMAD activity as determined by increased activity of SBE4-Luc 
reporter [8], which was further induced by TGF-β, while FAK1-inhibition attenuated endogenous and TGF-
β-dependent SMAD activity (Figure 3.4C, D). Thus, my data suggest that FAK1 inhibition attenuated 
hypoxia-mediated SMAD3 phosphorylation in H441 cells (Figure 3.4E). Taken together, these data suggest 
that hypoxia enhances TGF-β and Wnt3a signaling, which in turn, increase pFAK1 levels, while FAK1 can 
partially mediate TGF-β/SMAD signaling in H441 cells. 
 
3.6 FAK1 contributed to proliferation and migration of lung epithelial cells 
Profibrotic AEC2s are highly proliferative, migratory, and secrete fibrogenic growth factors and 
cytokines [9].  My bioinformatics analysis of the hypoxic proteome suggested that FAK1 may participate 
in profibrotic activities of lung epithelial cells. To validate these findings, I generated FAK1-deficient H441 
cells (FAK-null; Figure 3.5A). First, I assessed proliferative and migratory potential of normal and FAK-
null H441 cells using Electric Cell-substrate Impedance Sensing (ECIS). The data suggests that FAK-null 
H441 cells have limited proliferative and wound healing capabilities compared to normal H441 cells 
(Figure 3.5B, C). 
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Figure 3.4: FAK1 regulated TGF-β signaling, which synergized with Wnt/β-catenin pathway in 
hypoxic lung epithelial cells 
(A) Treatment of H441 cells with TGF-β protein (5ng/mL; 15 minutes) and Wnt3a protein (20ng/mL; 15 
minutes) significantly increased pFAK1 (Y397) levels (n=3). (B) TGF-β and CoCl2 (hypoxia mimetic) 
treatment synergistically increased β-catenin reporter activity. TOP-Flash is the artificial β-catenin reporter 
and its mutant form FOP-Flash served a control reporter. H292 lung epithelial cells treated with either TGF-
β (5ng/mL) or CoCl2 (100 µM) or both. (C) We observed that both hypoxia and TGF-β were able to increase 
SMAD-mediated transcription in H441 cells. Cells were transfected with artificial SMAD reporter (SBE4-
Luc; 2 µg/well) and treated with either TGF-β (5ng/mL) or CoCl2 (100 µM) or both. (D) Inhibition of FAK1 
reduced TGF-β-independent and –dependent SMAD transcriptional activity. H441 cells were transfected 
with SBE4-Luc and treated with TGF-β (5ng/mL) or FAK-inhibitor (10 µM) or both. p-values are 
calculated based on student’s t-test (n=3). p < 0.05 is assumed to be significant. All transfection experiments 
were performed at least twice in triplicates. (E) H441 cells were treated with or without FAK1 inhibitor 
(PF-573,228; 10µM) for 1 hour before treating with hypoxia (1% O2; 12 hrs). FAK1 inhibition reduced 
hypoxia-induced pSMAD3 levels in H441 cells. 
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Figure 3.5: FAK1 contributed to proliferation and migration of lung epithelial cells. 
(A) H441 cells were transduced with 4 lentiviral constructs harboring shRNA targeting FAK1 and stable 
shRNA expressing lines were selected using puromycin (1µg/mL). Protein lysates obtained from these 
stable cell lines were screened for FAK1 expression by immunoblotting. Cell lines with the least expression 
of FAK1 (lane 1) were selected for further experiments and are referred to as “FAK-null cells” for brevity. 
(B) FAK-null cells have compromised proliferative and (C) migratory capabilities compared to normal 
H441 cells (n=4 independent experiments) as examined by ECIS. 
 
3.7 FAK1 knockdown dampened hypoxia-mediated TGF-β/SMAD signaling in lung epithelial 
cells 
My previous results suggested that FAK1 inhibition reduced hypoxia-mediated SMAD3 activation 
and stable knockdown of FAK1 reduced proliferative and migratory capabilities of H441 cells. Therefore, 
I tested whether stable knockdown of FAK1 affected hypoxia-mediated SMAD3 activation. Indeed, FAK1 
knockdown reduced hypoxia-induced SMAD3 phosphorylation to its basal levels (Figure 3.6A). I 
confirmed these results by determining hypoxia-induced pSMAD3 levels that were significantly reduced 
in FAK-null cells as compared to the normal H441 cells (Figure 3.6B). FAK1 knockdown also interfered 
with expression of some of the SMAD-dependent gene up-regulation in hypoxia (Figure 3.6C). Taken 
together, our findings demonstrate that FAK1 mediates profibrotic activities of lung epithelial cells. 
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Figure 3.6: FAK1 knockdown dampened hypoxia-mediated TGF-β/SMAD signaling in lung 
epithelial cells. 
FAK1 knockdown reduced hypoxia-induced pSMAD3 levels when compared to normal H441 cells. This 
effect was determined by: (A) western blots (n=3) and (B) ICC. Cells were serum starved for 24 hours at 
~60% confluency before hypoxia treatment (12hrs; 1% O2). Quantitation of pSMAD3 (ICC) intensity was 
performed on images of at least 3 fields at 10X magnification in each conditions (n=3 independent 
experiments). (C) Hypoxia failed to increase profibrotic mediators TGF-β, TNF-α, and PAI-1 in FAK-null 
cells compared to normal H441 cells (n=3 independent experiments). p-values are calculated based on 
student’s t-test. * indicates p < 0.05, which is assumed to be significant; n.s. refers to not significant. 
 
3.8 Hypoxia induced Galectin-1 expression, which interacted with FAK1 and regulated hypoxia-
mediated FAK1 activation 
Since my systems biology approach identified a central role of FAK1 in profibrotic activation of 
lung epithelial cells, using the candidate approach, I analyzed the hypoxia proteome of H441 cells to 
identify novel regulators of FAK1. I identified Galectin-1 as one of the hypoxia-responsive proteins (Figure 
3.7A) with previously known function in oncogenesis [10]. Galectin-1 as a hypoxia-responsive protein 
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participates in cancer cell invasion, increasing metastatic potential of cancer cells [10, 11]. Further, 
Galectin-1 has been shown to interact with SMAD2, increasing its nuclear localization in response to active 
TGF-β signaling, likely contributing to pathogenesis of fibrosis in a mouse model of experimental fibrosis 
induced by bleomycin [12]. Therefore, my interest was to determine the contribution of Galactin-1 to 
hypoxia-mediated profibrotic events in the lung epithelium. First, Galectin-1 increased pFAK1 levels by 
approximately 1.8-fold (Figure 3.7B). Second, inhibition of Galectin-1 by OTX008 [13] reduced hypoxia-
induced pFAK1 levels in H441 cells (Figure 3.7C). One of the mechanisms contributing to the requirement 
of Galectin-1 in FAK1 phosphorylation could be its direct interaction with FAK1 as observed by pull-down 
assays (Figure 3.7D) and proximity ligation assay (Figure 3.7E). 
 
 Figure 3.7: Hypoxia induced Galectin-1 expression, which interacted with FAK1 and regulated 
hypoxia-mediated FAK1 activation 
(A) Hypoxia increased Galectin-1 protein levels as determined by proteomics studied in three independent 
experiments. (B) Galectin-1 treatment (50ng/mL; 15 minutes) increased pFAK (Y397) levels in H441 cells, 
which were serum starved for 24 hours. (C) H441 cells were serum starved for 24 hours and pre-treated 
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with Galectin-1 inhibition with OTX-008 (10 µM) for 1 hour followed by exposure to hypoxia (1% O2; 12 
hours). Galectin-1 inhibition reduced hypoxia-mediated pFAK1 (Y397). (D) HEK-293T cells were co-
transfected with pCDNA/Galectin-1-V5 or pCDNA/FAK1-GFP or Galectin-1-V5/FAK1-GFP. 
Immunoprecipitation with V5 antibody and immunoblotting with GFP antibody revealed interaction 
between Galectin-1 and FAK1. (E) Proximity Ligation Assay (PLA) performed in H441 demonstrated 
direct physical and interaction between endogenous Galectin-1 and FAK1 proteins. Each red dot indicates 
interaction between the two proteins. 
 
3.9 Active SMAD signaling and FAK1 signaling are required for hypoxia-mediated Galectin-1 
induction 
TGF-β is an upstream regulator of hypoxic proteome (Figure 3.2D) and Galectin-1 was upregulated 
in the hypoxic proteome (Figure 3.7A). Therefore, I wanted to determine whether TGF-β/SMAD signaling 
induced Galectin-1 transcription. I utilized a SMAD3-specific inhibitor, SIS3, which reduces 
phosphorylation of SMAD3 and interferes with its DNA-binding ability [14]. I treated H441 cells with SIS3 
(3µM) in the presence of normoxia or hypoxia and determined Galectin-1 mRNA level by qRT-PCR. My 
data suggest that hypoxia required active SMAD3 to induce Galectin-1 mRNA expression (Figure 3.8A). 
Since FAK1 is required for hypoxia-mediated SMAD3 activation (Figure 3.6), FAK1 may also regulate 
hypoxia-mediated induction of Galectin-1 mRNA expression. Indeed, I discovered that FAK1 is required 
for hypoxia-mediated induction of Galectin-1 mRNA (Figure 3.8B). Thus, crosstalk between hypoxia and 
TGF-β/SMAD signaling is influenced by FAK1activity resulting in Galectin-1 induction. 
 
 Figure 3.8: Active SMAD3 is required for hypoxia-mediated Galectin-1 induction  
(A) H441 cells were pretreated with SMAD3 inhibitor SIS3 (3 µM; 2hrs) or vehicle followed by exposure 
to hypoxia (1% O2; 24 hours) and mRNA levels of Galectin-1 were determined by qRT-PCR (n=3, derived 
from independent experiments). (B) H441 cells or FAK-null (FAK-) cells were exposed to hypoxia for 24 
hours followed by determination of mRNA levels of Galectin-1 via qRT-PCR (n=3 independent 
experiments). p-values were calculated based on student’s t-test. * indicates p < 0.05, which is assumed to 
be significant. 
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3.10 Galectin-1 levels are marginally increased in IPF patient serum samples 
My previous experiments identified Galectin-1 as a novel hypoxia-responsive profibrotic protein. 
Increased serum levels of Galectin-1 has also been identified in several cancers and associated with 
increased malignancy [15-18]. Therefore, I tested whether levels of Galectin-1 were increased in serum 
samples of IPF patients. Analysis of the serum samples via ELISA determined that there was a trend towards 
increase in Galectin-1 levels in the serum of IPF samples (n=10) when compared to healthy controls (n=7) 
(Figure 3.9). Although my analysis failed to reach significance, perhaps due to heterogeneity of human 
population and a small sample size, these data provide impetus for further characterization of Galectin-1 
levels in IPF patient samples. 
 Figure 3.9: Galectin-1 levels are marginally increased in IPF patient serum samples 
Serum samples of IPF patients (n=10) and control subjects (n=7) were purchased from Proteogenex Inc 
(Culver City, CA). Levels of Galectin-1 were measured via ELISA kit purchased from R&D systems 
(Minneapolis, MN). 
 
3.11 Conclusions 
In summary, my studies suggest that hypoxia increased transcription of several profibrotic 
molecules including TGF-β, PDGF-B, EDN1, and PAI-1. The systems biology approach and the traditional 
candidate selection approach of analyzing the hypoxic proteome revealed that FAK1 and Galectin-1 
regulated profibrotic response in the lung epithelial cells. While little is known about Galectin-1 in the 
context of lung epithelium and PF, my results suggest a functional relationship between Galectin-1 and 
FAK1, which provides novel opportunities to target profibrotic epithelium in fibrotic lung diseases, 
including IPF. Further implications of these findings are discussed at length in Chapter 6. 
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Table 3.1: List of top 50 differentially expressed proteins in hypoxic lung epithelial cells identified 
through SILAC 
List of 50 proteins that are significantly upregulated in hypoxia down-regulated in hypoxia. Significance 
was calculated with altered expression levels in at least 2 samples (Mann Whitney test, p < 0.05). 
 
Upregulated Proteins Down-regulated Proteins 
Gene Name Uniprot Fold-Change   Gene Name Uniprot Fold-Change 
DNMBP Q6XZF7 18.2624   K1C10 P13645 -7.173601148
A6NJD9 Q16540 6.13675   GLNA P15104 -5.780346821
B4DN26 P00750 5.2116   B4DNW5 B4DNW5 -5.350454789
CH3L1 P36222 4.5406   DCD P81605 -4.340277778
P4HA1 P13674 3.8248   K1C9 P35527 -4.224757076
NDRG1 Q92597 3.6156   K2C1 P04264 -4.042037187
CHM2A O43633 3.5667   RBM3 P98179 -4.009623095
IREB2 P48200 3.3591   DUS2L Q9NX74 -3.988831272
PVRL4 Q96NY8 3.0492   K22E P35908 -3.789314134
B1AN15 Q8IZA0 2.9621   CIR1A Q969X6 -3.227888961
MSMO1 Q15800 2.9481   FAKD2 Q9NYY8 -2.98596596
FA83A Q86UY5 2.8684   2AAB P30154 -2.853067047
LEG1 P09382 2.7608   UBCP1 Q8WVY7 -2.715177844
ALDOC P09972 2.624   E9PBS6 E9PBS6 -2.653575693
CCDC9 Q9Y3X0 2.56175   VRK1 Q99986 -2.636435539
RRAS P10301 2.5587   SQSTM Q13501 -2.490660025
B4DUI1 B4DUI1 2.5196   CLPT1 O96005 -2.439619419
MUC21 Q5SSG8 2.4656   B3KP14 B3KP14 -2.438429651
E7ETU9 O00469 2.4512   NOB1 Q9ULX3 -2.428953121
RMD3 Q96TC7 2.38145   UBE2T Q9NPD8 -2.399808015
GTR1 P11166 2.2645   VAS1 Q15904 -2.369668246
ENOG P09104 2.2036   TOR3A Q9H497 -2.341372044
K2C6B P04259 2.1298   PHLP1 O60346 -2.258100937
H0YLA2 P37108 2.1135   DYR P00374 -2.229654404
PHAG1 Q9NWQ8 2.1044   ERAL1 O75616 -2.213368747
FA83D Q9H4H8 2.059   NADK O95544 -2.204099625
ERO1A Q96HE7 2.0364   GTPBA A4D1E9 -2.203613927
B4DLE8 Q68DQ2 2.0231   C9JJU7 Q9NSI2 -2.187226597
HERP1 Q15011 2.013   DOHH Q9BU89 -2.159827214
IF4A2 Q14240 2.0022   LARP4 Q71RC2 -2.150537634
VKORL Q8N0U8 1.9733   URB2 Q14146 -2.134471718
AHNK Q09666 1.9648   F5H702 Q96GC5 -2.102607233
PCAT1 Q8NF37 1.9639   B4DRD5 B4DRD5 -2.072109407
CNPY3 Q9BT09 1.9487   FAT1 Q14517 -2.057613169
HSP71 P08107 1.9375   BRAT1 Q6PJG6 -2.032107295
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Table 3.1 (Continued) 
Upregulated Proteins Down-regulated Proteins 
Gene Name Uniprot Fold-Change   Gene Name Uniprot Fold-Change 
AT2B4 P23634 1.9222   DPOA2 Q14181 -2.021427128
PTMS P20962 1.9098   F203A Q9BTY7 -2.015316405
PGK1 P00558 1.9057   TIM Q9UNS1 -2.007226014
E7ER77 Q7Z2K6 1.8924   KAP0 P10644 -1.996007984
ALKB5 Q6P6C2 1.8894   GPR56 Q9Y653 -1.984520738
PTRF Q6NZI2 1.8692   MBD4 O95243 -1.979022363
B4DIT7 B4DIT7 1.8608   TRM6 Q9UJA5 -1.966568338
B4DI61 B4DI61 1.8319   ACADV P49748 -1.95427008
D6RDX7 Q6PCB8 1.8159   NCDN Q9UBB6 -1.930501931
RFIP5 Q9BXF6 1.8134   NPT2B O95436 -1.929570671
K2C80 Q6KB66 1.802   ZNHI2 Q9UHR6 -1.902587519
AHNK2 Q8IVF2 1.7976   E9PDU5 Q9NNW5 -1.898974554
CYTM Q15828 1.78015   H0YMA4 Q15004 -1.898253607
B4DR87 Q02809 1.7763   B4DVK1 B4DVK1 -1.895734597
F134A Q8NC44 1.7581   DDX5 P17844 -1.889644747
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CHAPTER FOUR:  
NOVEL MOUSE MODELS OF PROGRESSIVE PF AND EXACERBATED PF 
 
4.1 Brief Outline 
 Current animal models of PF do not appropriately mimic the complex and progressive nature of 
IPF as seen patients [1]. Although the models have provided us with a greater understanding of fibrotic 
events in the lung, the types of fibrotic agents used in these models have limited their utility for preclinical 
studies. Therefore, there is a need to create animal models that utilize physiologically relevant insults 
associated wth lung injury. I have used hypoxia as a pathophysiological injury contributing to PF. 
 In this chapter, I will describe two mouse models of progressive PF and exacerbated PF utilizing 
hypoxia as an injury factor. First, I will describe a mouse model in which conditional deletion of tumor 
suppressor von-Hippel Lindau (Vhl) in a subtype of lung epithelial cells serves as a surrogate to activate 
hypoxia signaling in the lung epithelium. Second, I will describe an animal model that utilizes subclinical 
injury via bleomycin followed by exposure of mice to hypoxia, which exacerbates the injury, causing PF. 
 
4.2 Conditional deletion of epithelial Vhl caused progressive fibrosis over a span of 12 weeks 
 Conditional deletion of Vhl is achieved by the use of rat Clara Cell Specific Protein (CCSP) 
promoter, which is expressed in majority of bronchiolar epithelial cells and a subset of AEC2s in mouse 
lungs [2]. The CCSP promoter drives expression of reverse tetracycline-dependent transcactivator (rtTA). 
In the presence of doxycycline (Dox), rtTA is activated and binds to tetO operator sequences in the promoter 
driving expression of Cre recombinase, which deletes loxP-flanked exon I of Vhl, causing genetic loss of 
Vhl [3]. In order to achieve deletion of Vhl, mice were given Dox for 4 weeks via chow. The mouse model 
had been generated and preliminary phenotype was characterized in the lab before beginning of this project, 
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which is described briefly in Figure 4.1. The preliminary data suggested that the conditional deletion of Vhl 
caused progressive fibrosis over a span of 12 weeks with increasing collagen deposition at 4, 8, and 12 
weeks as assessed by Masson’s trichrome staining (Figure 4.1), which stains collagen fibers blue. 
 
 Figure 4.1: Conditional deletion of epithelial Vhl caused progressive fibrosis over a span of 12 weeks 
(A) Three single transgenic mice were crossed together to generate a triple transgenic CCSP-rtTAtg/tg, TetO-
Cretg/tg, Vhlflox/flox mouse, which would cause deletion of exon 1 of Vhl after doxycline (Dox) treatment. (B) 
Experimental design showing dox treatment for four weeks followed by VhlΔ/Δ lung harvest at 4, 8, and 12 
weeks. (C) Masson’s trichrome staining at 4 weeks, 8 weeks, and 12 weeks post initial dox treatment shows 
increased peribronchiolar and subpleural collagen deposition. 
 
 
4.3 Epithelial Vhl deletion caused increased HIF-1α and HIF-2α expression associated with 
increased profibrotic gene signature 
Since Vhl deletion showed substatial fibrosis at 12 weeks, I performed hematoxylin and eosin 
staining (H&E staining) of mouse lungs at 12 weeks post Vhl deletion, which indicated subpleural fibrotic 
lesions in the lung (Figure 4.2A). In addition, VhlΔ/Δ lungs also displayed increased HIF-1α and HIF-2α 
expression in the fibrotic lesions, suggesting active hypoxia signaling in the fibrotic lungs (Figure 4.2B). 
Further, I also confirmed the presence of α-SMA, pFAK1, and Galectin-1 in the fibrotic lungs of VhlΔ/Δ 
mice (Figure 4.2C). Interestingly, consistent with my previous experiments that established the role of 
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hypoxia in increasing Galectin-1 expression (See Chapter 3), Galectin-1 was predominantly present in the 
bronchiolar epithelial cells in the lungs of VhlΔ/Δ mice – the major site of Vhl deletion and consequent 
hypoxia signaling (Figure 4.2C). To ascertain molecular signature of IPF in this model, I tested mRNA 
levels of a number of profibrotic genes that are known to be elevated in the lungs of IPF patients. I observed 
that mRNA levels of Wnt3a, Collagen-1, α-SMA, PAI-1, and MMP-2 are increased in the lungs of VhlΔ/Δ 
mice as compared to the littermate controls (Vhlfoxl/flox mice) that did not receive doxycycline (Figure 4.2C). 
 In summary, this mouse model shows features of IPF for up to 12 weeks. Previous studies have 
established that inhibition of FAK1 ameliorates bleomycin-induced fibrosis [4] and Vhl loss induces 
expression of profibrotic Galectin-1. Therefore, it will be of interest to determine the role of FAK-1 and 
Galactin-1 in this model during the initiation (0-8 weeks) or progression (8-12 weeks) of PF. Likewise, 
numerous other profibrotic molecules can be tested to characterize hypoxia-driven fibrosis in this model. 
 
4.4 Hypoxia caused exacerbation of fibrosis via Galectin-1 in mice injured with low levels of 
bleomycin 
Although overall prognosis of IPF remains poor, the clinical course of IPF for each patient is highly 
variable [5]. Patients who suffer from stable IPF have slow lung function decline over several years but 
may suffer from sudden episodes of extreme exacerbation of the disease, which is characterized by acute 
decline in lung function associated with hypoxemia. This condition is defined as “Acute Exacerbation of 
IPF” (AE-IPF), which is the most common cause of deaths in IPF patients [6, 7]. Although gastroesophageal 
reflux disease (GERD) and pulmonary hypertension (PH) are associated with increased chances of the 
exacerbation events [8], the causes of AE-IPF remain largely unknown. Since patients undergoing AE-IPF 
also display signs of hypoxemia, I hypothesized that hypoxic environment in already compromised lungs 
may accelerate fibrogenic events, leading to exacerbation of fibrosis. Therefore, in order to develop a model 
to test this clinically relevant hypothesis, I caused mild injury to the mouse lungs with two doses of 
bleomycin (0.05U) on day 0 and day 7 (Figure 4.3A). On day 8, I exposed mice to hypoxia (13% O2) until 
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day 28, following which, I performed lung function tests and harvested lung tissue for histochemical 
analysis. 
  
Figure 4.2: Epithelial Vhl deletion caused increased HIF-1α and HIF-2α expression associated with 
increased profibrotic gene signature 
(A) Hematoxylin and eosin (H&E) staining showed increased fibrosis at 12 weeks post Vhl deletion. Of 
note, I also observed presence of subpleural fibrosis, which is a feature of IPF. (B) HIF-1α and HIF-2α 
protein expression was elevated in the fibrotic lungs of VhlΔ/Δ mice. (C) Lungs of VhlΔ/Δ mice displayed 
increased α-SMA (a marker of myofibroblasts), pFAK1(Y397), and Galectin-1 when compared to the lungs 
of control Vhlflox/flox mice. (D) RNA was isolated from the lungs of VhlΔ/Δ and control Vhlflox/flox mice followed 
by qRT-PCR for profibrotic genes (n=3). Error bars represent standard deviation. p-value was determined 
for all the genes by student’s t-test (p < 0.05 is considered significant). 
 
My data suggests that two bleomycin insults cause minor injuries to the lung, characterized by 
minimal lung remodeling (H&E staining; Figure 4.3B(e)) and no significant increase in collagen content of 
the lung (Figure 4.3B(f); Figure 4.3C, column 3). However, it is possible that some of the profibrotic 
pathways are already activated as evident by increased Galectin-1 expression (Figure 4.3B(h)). Likewise, I 
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also observed that exposing mice to hypoxia alone caused minimal lung remodeling (Figure 4.3B(m)), no 
increase in collagen content (Figure 4.3B(n); Figure 4.3C, column 2), and elevated Galectin-1 expression 
(Figure 4.3B(p)). Activation of Galectin-1 may prime the lungs to become fibrotic in the event of a 
physiological challenge like hypoxia that impairs normal injury repair in the lung. Consistent with this 
notion, I observed that bleomycin-injured mice developed fibrosis in hypoxic condition much more readily 
compared to the saline-treated mice exposed to hypoxia (Figure 4.3B). Mice challenged with both 
bleomycin and hypoxia had significantly increased collagen (Figure 4.3B(r); Figure 4.3C, column 4) 
compared to mice treated with bleomycin (Figure 3B(f)) or hypoxia alone (Figure 4.3B(n)). The increased 
fibrotic phenotype was associated with increased expression of α-SMA, a marker of myofibroblasts in the 
parenchyma (Figure 4.3B(s) arrows).  
I also observed increased expression of Galectin-1 in fibrotic lesions (Figure 4.3B(t)). Notably, 
Galectin-1 expression was increased in distal (Figure 4.3B(t) left inset) and proximal parenchyma (Figure 
4.3B(t) arrow, right inset). Therefore, it is possible that Galectin-1 may be a fibrogenic factor contributing 
to hypoxia-mediated exacerbation of PF. These results indicate that hypoxia signaling promotes aberrant 
injury repair in the lung. Therefore, it is possible that sustained hypoxia signaling and its effectors contrivute 
to episodes of acute exacerbations in IPF patients, who already have poor lung function and compromised 
injury repair potential. 
 
4.5 Galectin-1 inhibition reduced collagen deposition and fibrotic phenotype observed in the 
exacerbated PF model 
Since the fibrotic lungs of mice displayed increased expression of profibrotic molecule Galectin-1, 
which is known to be induced in hypoxia [9], I hypothesized that Galectin-1 inhibition can attenuate the 
fibrotic phenotype observed in my mouse model. I utilized a Galectin-1 specific small-molecule inhibitor, 
OTX008 [10], which is currently in Phase I clinical trial for patients with advanced solid tumors (trial 
identifier: NCT01724320). I treated mice with 2mg/kg OTX008 in 25% EtOH/75% Saline (50 µl) via 
intraperitoneal (i.p.) injections once a day starting on Day 5. Control mice were given 50 µl vehicle.  
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Histopathological analysis revealed no detectable effect of Galectin-1 inhibition in mice treated 
with bleomycin alone in terms of lung remodeling (Figure 4.3B(i)) and collagen deposition (Figure 4.3B(j); 
Figure 4.3C, column 5). Consistent with my hypothesis, I observed that Galectin-1 inhibition reduced lung 
remodeling (H&E staining, Figure 4.3B(u)) and collagen deposition (Figure 4.3B(v); Figure 4.3C, column 
6)) in the lungs of fibrotic mice that were treated with bleomycin and hypoxia. In addition, I also observed 
that there was a decrease in α-SMA expression in the fibrotic lungs (Figure 4.3B(w)), which suggested 
attenuation of fibrotic lesions. These results demonstrate that Galectin-1 is a potent fibrogenic molecule in 
hypoxic environment, which contributes to exacerbation of fibrotic conditions in the lung. 
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 Figure 4.3: Hypoxia caused exacerbation of fibrosis via Galectin-1 in mice injured with low levels of 
bleomycin. (A) Experimental design depicting two bleomycin insults on Day 0 (D0) and Day 7 (D7) 
followed by hypoxia treatment for 3 weeks (Day 8 to Day 28). (B) Histochemical analysis of mouse lungs. 
Mice were treated with either hypoxia (m-p) or bleomycin alone (e-h) or hypoxia and bleomycin together 
(q-t). Mice were also treated with Galectin-1 inhibitor (i-l, u-x) or saline (e-h, q-t). Galectin-1 inhibitor 
OTX008 was used at 2mg/kg in 25% EtOH/75% saline via intraperitoneal injections once a day starting on 
Day 5. H&E staining (a, e, i, m, q, u), Masson’s trichrome staining for visualization of collagen deposition 
(b, f, j, n, r, v), α-SMA staining (c, g, k, o, s, w), and Galectin-1 staining (d, h, l, p, t, x) was performed. 
Black scale bars = 100 µm; Blue scale bars = 20 µm. α-SMA expression is increased in the proximal 
parenchyma (s; arrows) and distal parenchyma (s, inset) of mouse lungs treated with hypoxia and 
bleomycin. Likewise, Galectin-1 expression is increased in proximal parenchyma (t; arrow and right bottom 
inset) and distal parenchyma (left bottom inset). Galectin-1 inhibition reversed lung remodeling (u), 
collagen deposition (v), and reduced α-SMA (w) and Galectin-1 expression (x). (C) Semi-quantitation of 
total collagen was performed using sircol assay. One-way ANOVA was performed with post hoc one-tailed 
t-test (n=4 in each group). * p < 0.05. n.s. = not significant. 
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Figure 4.4: Galectin-1 inhibition rescued hypoxia-induced lung function decline in bleomycin-injured 
mouse lungs. Hypoxia treatment of mice injured with bleomycin elevated (A) Total lung resistance and 
(B) total lung compliance of mouse lungs. Galectin-1 inhibitor treatment significantly decreased lung 
resistance and increased lung compliance. (C) Airspace closure, reflective of airway collapse, increased in 
mice treated with hypoxia and bleomycin. The airway collapse was reduced by Galectin-1 inhibitor 
treatment. Resistance of (D) small airways (terminal bronchioles and alveoli) and (E) conducting airways 
(airways larger than 2 mm in diameter) increased due to hypoxia and bleomycin treatment. Galectin-1 
inhibition significantly reduced the increase airway resistance. I used the flexiVent system (SCIREQ 
technologies, Montreal, Canada) to measure lung function. Total lung measurements (A and B) were 
measured using Snapshot-150 perturbation maneuver. Airspace closure (C) was measured using Pressure-
Volume loop (PVs-P) perturbation while small airways and conducting airways resistance (D and E) were 
measured using QuickPrime-3 perturbation maneuver. One-way ANOVA was performed with post hoc 
one-tailed t-test (n=4 in each group). * p < 0.05.  
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4.6 Galectin-1 inhibition rescued hypoxia-induced lung function decline in bleomycin-injured 
mouse lungs 
IPF patients suffer from gradual decline in lung function, which worsens during phases of acute 
exacerbation associated with hypoxemia.  I hypothesized that hypoxia could be a major contributor in lung 
function decline in my bleomycin-injured mouse model and that this decline can be slowed down by 
Galectin-1 inhibition. To test this hypothesis, I performed lung function tests on all groups of mice on Day 
28 after initial bleomycin or saline insult followed by hypoxia (Figure 4.3A). My data suggests that total 
lung resistance was increased in the lungs of mice challenged with bleomycin and exposed to hypoxia, 
which was reduced by Galectin-1 inhibition (Figure 4.4A; columns 4 and 6). Likewise, total lung 
compliance was decreased due to bleomycin and hypoxia challenge, while Galectin-1 inhibition 
significantly increased total lung compliance (Figure 4.4B; columns 4 and 6). Increased resistance and 
decreased compliance of the lung reflects stiffened matrix and reduced elasticity of the lung. 
 Since IPF is characterized by lung remodeling and alveolar collapse [11], I measured the area 
covered by airspace closure, which is indicative of collapsed airways in my mouse model. My data suggests 
that the airspace closure was significantly increased (7-fold) in mice challenged with bleomycin and 
hypoxia together (Figure 4.4C, column 4) , while mice treated with Galectin-1 inhibitor had significantly 
reduced (6-fold) airspace closure (Figure 4.4C, column 6). This result suggest that Galectin-1 inhibition is 
able to reduce lung function decline likely by inhibiting lung remodeling associated with alveolar collapse. 
The peribronchiolar fibrosis observed in bleomycin model affects the conducting airways and small 
airways. Conducting airways are larger than 2 mm in diameter in humans and 500 µm in diameter in mice. 
The conducting airways do not participate in gas exchange. Conversely, majority of the gas exchange occurs 
in small airways consisting of terminal bronchioles and alveoli, which are smaller than 2 mm in diameter 
in humans and 200 µm in diameter in mice [12-14]. In my mouse model, hypoxic injury to the mice 
challenged with bleomycin significantly increased resistance of both small airways and conducting airways, 
as assessed by tissue damping and airway resistance, respectively (Figure 4.4D, E). I observed that Galectin-
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1 inhibition rescued hypoxia and bleomycin-induced resistance in both conducting and small airways 
(Figure 4.4D, E). In summary, my data highlights the profibrotic role of Galectin-1. 
 
4.7 Conclusions 
Taken together, these results suggest that despite the obvious limitations of bleomycin, it can be 
combined with physiologically relevant injuries such as hypoxia to study progression of PF, as seen in IPF 
patients. This model is ideal to study changes in various profibrotic molecular events that contribute to 
worsened prognosis during the clinical course of the disease. Further, I have also demonstrated that 
Galectin-1 is one of the major driver molecules contributing to the profibrotic events in the in vivo model 
of exacerbated PF. By successfully targeting Galectin-1 activity using a specific inhibitor, which reduces 
the severity of PF, my data provides a strong preclinical platform. My in vivo studies also provide an ideal 
entrée to build a clinical rationale for the development of combinatorial drug therapy regimen, which can 
include Galectin-1 inhibitor to treat IPF patients. I believe that further characterization of Galectin-1 in 
other animal models and in our progressive mouse model can establish Galectin-1 as a novel therapeutic 
target for the treatmemt of fibrotic lung remodeling diseases including IPF. 
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CHAPTER FIVE: 
RNA-SEQUENCING OF HYPOXIC AEC2s IDENTIFY HYPOXIA/mir-96/PTEN CLUSTER 
5.1 Brief Outline 
Deletion of Vhl in CCSP+ cells in the lung epithelium generated epithelial hypoxia response and 
caused progressive fibrosis over span of 12 weeks. Although my analysis revealed that pFAK1 (Y397) and 
Galectin-1, the two profibrotic molecules involved in the hypoxic response, are upregulated in VhlΔ/Δ lungs, 
the molecular determinants of progressive PF remains unknown. It is likely that along with hypoxia 
signaling, pFAK1 (activated FAK1) and Galactin-1 orchestrate a molecular program driving PF. To get a 
comprehensive understanding of the molecules and mechanisms driving PF due to hypoxia signaling, in 
this chapter, I will describe the approach and results of RNA-sequencing of primary VhlΔ/Δ or hypoxic 
AEC2s. I have determined the mRNA, miRNA, and lncRNA signatures that are differentially regulated due 
to either Vhl deletion or hypoxia in the AEC2s. 
I deleted Vhl from the Vhlflox/flox primary AEC2s ex vivo by treating with Ad-Cre:GFP, an adenovirus 
carrying a Cre and GFP (green fluorescent protein) fusion protein, which generated VhlΔ/Δ AEC2s. Vhlflox/flox 
primary AEC2s treated with adenovirus carrying GFP alone were exposed to either normoxia or hypoxia 
for 48 hours. Normoxic Vhlflox/flox primary AEC2s treated with adenovirus carrying GFP alone were used as 
control cells. 
The two sets of transcriptomics signature supports several hypotheses that I tested in previous 
chapters validating a central role of FAK1 signaling in hypoxic AEC2s. The experiments conducted herein 
also allowed me to compare the effects of systemic hypoxia signaling with epithelium-specific Vhl deletion 
in vivo, which causes PF in our mouse model. 
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Since my previous in vitro experiments suggested a profibrotic role of hypoxia, with increased 
hypoxia signaling in in vivo studies, I focused on hypoxic transcriptome signature. First, I have identified 
that hypoxia stimulated Activin signaling, which in turn contributed to FAK1 activation. Second, I 
identified that PTEN was transcriptionally down-regulated while FAK1 signaling was up-regulated in 
hypoxic AEC2s. Since PTEN is a known suppressor of FAK1 signaling, my attempt to determine the link 
between hypoxia and suppression of PTEN transcription via microRNAs has defined miRNA, miR-96, 
which targets PTEN 3’-UTR (untranslated region). Hypoxia up-regulates miR-96 in AEC2s, suggesting a 
mechanism of hypoxia-dependent PTEN down-regulation. 
 
5.2 Generation of primary VhlΔ/Δ or hypoxic AEC2s 
 I isolated primary AEC2s from Vhlflox/flox mice and grew on fibronectin-coated plates, followed by 
either Ad-Cre:GFP or Ad-GFP treatment, to delete Vhl gene. I confirmed expression of GFP alone or 
Cre:GFP fusion protein using fluorescence microscopy. GFP expression was detected throughout the cell, 
while Cre:GFP had localized to the nucleus as Cre, a DNA recombinase, is targeted to the nucleus (Figure 
5.1A). Subsequently, I tested Vhl deletion by performing PCR (polymerase chain reaction). The forward 
and reverse PCR primers are designed complimentary to the DNA sequence outside of the loxP sites that 
flank exon 1 (Figure 5.1B). Therefore, when Cre-mediated deletion of loxP-flanked exon I occurs, the 
primers are expected to bind DNA sequences that are 274 bases apart. Therefore, a band representing 
amplified DNA appears at 274bp confirmed Vhl deletion in primary AEC2s treated with Ad-Cre-GFP 
(Figure 5.1C). Three sets of samples (control, hypoxia, and VhlΔ/Δ) were selected as described (Table 5.1 
and Figure 5.1). I isolated total RNA from all 3 sets and visualized them on an agarose gel to determine 
RNA integrity (Figure 5.1D). Quality and other parameters of the total RNA described in Table 5.1, 
confirmed that RNA of high quality was used for transcriptomics analysis. RNA-sequencing (RNA-Seq) 
analysis identified 3511 significantly altered mRNA transcripts in hypoxic AEC2s and 4792 transcripts in 
VhlΔ/Δ AEC2s. There were 1436 mRNAs that were common between hypoxia signaling and Vhl loss (Figure 
5.1E). Future studies focusing on the common and unique mediators in hypoxic AEC2s and VhlΔ/Δ AEC2s 
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can provide a detailed understanding of the role of Vhl protein in modulating profibrotic signature through 
hypoxia-dependent and hypoxia-independent mechanisms.  
 
 Figure 5.1: Generation of primary VhlΔ/Δ or hypoxic AEC2s 
(A) Primary AEC2s were transduced with either Ad-GFP or Ad-Cre:GFP for 12 hours followed by 24 hours 
of recovery period. Cells were then exposed to normoxia (i, iii) or hypoxia (ii) for 48 hours followed by 
RNA isolation. Images were taken before RNA isolation. (B) Design of primers (Fwd: Forward; Rev: 
Reverse) spanning loxP sites that flank exon 1 of Vhl. Administration of Cre via Ad-Cre:GFP causes 
deletion of exon 1, which reduces the distance between primer pairs to 274 base pairs. (C) Deletion of exon 
1 generated a 274bp PCR product in cells transduced with Ad-Cre:GFP (7-10) compared to cells treated 
with control Ad-GFP (1-6). (D) Total RNA isolated from primary cells had high quality as visualized via 
agarose gel electrophoresis. Top band (near 4000 bps) is 28S rRNA, intermediate band (near 2000 bps) 
is18S rRNA and the bottom band (below 200bps) is the 5-5.8S rRNA. (E) Significantly deregulated 
mRNAs unique to hypoxia (2075, red) or unique to Vhl (3356, blue) or common to both (1436, purple) 
were identified through RNA-sequencing experiment. 
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5.3 Distinct gene expression patterns revealed by high variability between treatments 
Statistical analysis of RNA-Seq data was performed using Box plot analysis, unsupervised 
hierarchical clustering, and principal component analysis to determine the variability within treatment 
groups (treatment replicates) and between treatment groups. First, the box plot analysis allowed me to 
visualize and determine the distribution of expression values in each samples. A high variability between 
the replicates or between treatment groups can lead to a biased interpretation of the change in gene 
expression. Analysis of the normalized expression values identified that there was low variability between 
each of the nine samples (Figure 5.2A). Similarly, unsupervised hierarchical clustering arranges each 
sample in a group with other samples based on the similarities in gene expression changes [1]. The 
clustering analysis revealed that replicates of each of the three treatment groups (Control, hypoxia, and 
VhlΔ/Δ) clustered together (Figure 5.2B). Further analysis identified a higher degree of similarities between 
the control and hypoxia group as compared to the VhlΔ/Δ and hypoxia group (Figure 5.2B). The higher 
degree of gene expression changes between hypoxia and VhlΔ/Δ transcriptomic signature was confirmed by 
principal component analysis (PCA) (Figure 5.2C). PCA is a statistical analysis performed to determine 
and visualize overall effect of experimental variability and technical variability, which arises from handling 
of the samples and variability between the replicates [2]. Similar to the unsupervised hierarchical clustering, 
PCA clusters samples by the groups of most significantly altered genes followed by progressively less 
significantly altered genes. Therefore, samples where a large number of genes are altered at a similar rate 
will be clustered together, indicating a low variability between these samples. Thus, the analyses of my 
transcriptomics data reveal that there was very little difference between replicates of a treatment while the 
different treatments (either Vhl deletion or hypoxia) had significant difference in gene expression patterns, 
indicative of distinct gene expression profile for each set of cellular response. 
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 Figure 5.2: Distinct gene expression patterns revealed by high variability between treatments 
(A) Box plot analysis of the three treatments (n=3 each) was conducted using quantile-normalized and log2-
transformed expression values. The median in each of the sample shows minimal variability, suggesting 
similar distribution of the values across each of the three samples after normalization. The line in each box 
represents median. (B) Unsupervised hierarchical clustering was performed using quantile normalized and 
log2-transformed RPKM (Reads Per Kilobase of transcripts per Million mapped reads) values. The analysis 
identifies low variability within each replicate of the treatments and clusters each of the three treatments 
separately. Transcripts were sorted from high expression (red color) to low expression (green color). (C) 
PCA (Principal Component Analysis) was performed on quantile-normalized and log2-transformed RPKM 
values. The samples are displayed in the first and second principle components. Replicates of the same 
treatment sample, reflected by a particular color, are clustered together, suggesting a higher degree of 
similarities between replicates of the same sample. 
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5.4 Hypoxia induces Activin signaling 
In order to determine the role of hypoxia in profibrotic activation of AEC2s, I focused on the 
differentially regulated mRNA identified through my RNA-Seq. I identified a total of 3511 mRNAs that 
were significantly altered due to hypoxia (Figure 5.3A). Consistent with my earlier experiments, RNA-Seq 
also identified increased transcription of known profibrotic genes such as Pai-1, Edn1, Collagens-1 and -5 
(Col1a1, Col5a1), and Fibronectin (FN) (Figure 5.3B, C) (Figure is adapted from Figure 3.3). These results 
confirm the reproducibility and consistency of my experiments that identified a similar profibrotic gene 
signature through different experimental approach in Chapter 3. Analysis of differentially regulated mRNA 
also identified increased transcription of Activin A, Activin Receptor 1, and Activin Receptor 2B (Figure 
5.3B). Activin pathway is associated with profibrotic phenotype of hyperplastic AEC2s surrounding 
fibroblastic foci (Figure 5.3D) [3]. Despite the observation of components of Activin pathway in 
hyperplastic AEC2s, mechanisms that underlie activation of the Activin pathway and its molecular 
determinants, i.e., proteins that relay Activin signaling, remain unknown. I confirmed hypoxia-induced 
transcription of Activin pathway components, including Activin A, Activin B and their receptors ACVR1, 
ACVR1B, ACVR2A, ACVR2B in A549 cells, a human cancer cell line derived from AEC2s (Figure 5.3E). 
Since I had confirmed FAK1 as a central protein coordinating profibrotic effects of hypoxia in AEC2s 
(Chapter 3), I tested whether Activins can also induce FAK1 activation. Consistent with my hypothesis, 
both Activin A and Activin B treatments induced pFAK (Y397) levels in A549 cells (Figure 5.3F), 
suggesting a novel possible mechanism of Activin signaling in hypoxic AEC2s. In summary, analysis of 
differentially regulated mRNAs confirmed some of the previously known profibrotic genes. I identified a 
novel crosstalk between stimulated Activin signaling and FAK1 signaling in hypoxic AEC2s, which opens 
up possibilities of determining novel molecular pathway downstream of Activins in hypoxic AEC2s.  
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 Figure 5.3: Hypoxia induced Activin Signaling. 
(A) Heat map of 3511 significantly altered mRNAs in hypoxia (1.5-fold, student’s t-test, p < 0.05) was 
generated using XLSTAT software (Addinsoft, Paris, France). (B) List of profibrotic genes that were earlier 
tested in Chapter 3 are also identified through RNA-Seq. Components of Activin signaling pathway that 
are upregulated are highlighted in blue. (C) mRNA of profibrotic genes responsive to hypoxia in primary 
AEC2s (figure adapted from Figure 3.3G). (D) Conceptual diagram of upregulated Activin signaling in 
hyperplastic AEC2s surrounding fibroblastic foci. Activin-A, Activin-B and Follistatin (a negative 
regulator of Activin signaling), are upregulated in hyperplastic AEC2s [3]. (E) Components of Activin 
pathway, including Activin receptors, are up-regulated in hypoxic A549 cells, a model of human AEC2s. 
(F) Activin A treatment (20 ng/ml) and Activin B treatment (10 ng/ml) increased pFAK1 (Y397) levels in 
A549 cells, suggesting the function of FAK1 as a mediator of hypoxia-induced Activin signaling pathway. 
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5.5 RNA-Seq of hypoxic AEC2s identified activated FAK1 signaling 
In order to determine the cellular processes regulated by hypoxia in AEC2s, I performed functional 
enrichment of the differentially regulated mRNAs via IPA. I identified cellular processes such as cell 
assembly and organization, cell morphology, and cellular movement (Figure 5.4A, red stars). These 
signatures are similar to the processes identified in my earlier proteomics studies (see Chapter 3). Therefore, 
I tested whether FAK1 signaling is also upregulated at the transcript level in hypoxic AEC2s. Indeed, 
analysis of the several signaling pathways upregulated by hypoxia revealed that FAK1 signaling is enriched 
by differentially regulated mRNAs (Figure 5.4B). Proteins associated with cytoskeletal remodeling such as 
Integrins, Vinculin, α-Actinin, F-actin, and p130Cas are transcriptionally upregulated by hypoxia (Figure 
5.4B). These proteins may directly contribute to increased FAK1 signaling, resulting in cytoskeletal 
remodeling-associated processes highlighted in Figure 4A. 
Interestingly, further analysis of elevated FAK1 signaling also revealed transcriptional suppression 
of phosphatase and tensin homolog (PTEN) in hypoxic AEC2s (Figure 5.4B, red star). PTEN, a dual 
lipid/protein phosphatase, is a tumor suppressor; PTEN dephosphorylates phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) to phosphotidylinositol 4,5-bisphosphate (PIP2), thereby suppressing the downstream 
AKT/mTOR (mechanistic target of rapamycin) signaling pathway [4]. The AKT/mTOR pathway 
contributes to cellular proliferation [5]. PTEN as a protein phosphatase also contributes to 
dephosphorylation and subsequent inactivation of FAK1, suppressing its profibrotic activities [6]. Further, 
epithelial Pten deletion also exacerbated fibrosis following lung injury [7]. Therefore, hypoxia-mediated 
suppression of PTEN transcript represents a novel mechanism of sustained FAK1 activation in hypoxic 
AEC2s. Further studies delineating this mechanism will likely provide detailed understanding of profibrotic 
activation of AEC2s in a sustained hypoxic environment. 
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 Figure 5.4: RNA-Seq of hypoxic AEC2s identified activated FAK1 signaling. 
(A) Significantly increased mRNAs (≥ 1.5-fold) in hypoxia were subjected to functional enrichment 
analysis using ingenuity pathway analysis (IPA). Significantly enriched molecular and cellular processes 
are depicted here. Cytoskeletal remodeling-associated processes are marked with a red star. Dotted red line 
represents p-value of 0.05. (B) FAK1 signaling is significantly upregulated (p < 0.05) in hypoxia-induced 
mRNAs. Canonical FAK1 signaling is depicted here with fold-change values of differentially regulated 
mRNAs overlaid (red: up-regulation; green: down-regulation). 
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5.6 Hypoxia down-regulated Pten transcription via up-regulation of miR-96 
Hypoxia-mediated downregulation of PTEN activity has been described in various lung 
adenocarcinoma cell lines [8]. However, hypoxia-mediated downregulation of PTEN transcript via 
microRNAs (miRNAs) remains unknown in the lung epithelium. Therefore, I focused on determining the 
role of miRNAs in downregulation of PTEN in lung epithelial cells. miRNAs, usually 22 nucleotides long, 
sequester mRNAs by targeting their 3’UTR [9]. Recently, miRNAs have been associated with pathogenesis 
of IPF [10]. I predicted 9 miRNAs that target PTEN 3-’UTR (Table 5.2). I selected miR-96 since it had the 
highest increase (2.1-fold) in hypoxic AEC2s. I confirmed increased levels of miR-96, in MLE-12 cells, an 
immortalized primary AEC2 cell line (Figure 5.5A) [11]. Likewise, I also confirmed that Pten protein levels 
were significantly reduced in hypoxic AEC2s in MLE-12 cells (Figure 5.5B). Consistent with my 
hypothesis that Pten 3’UTR can be targeted via a miRNA in hypoxia, my data demonstrate that hypoxia 
reduced luciferase activity of Pten 3’UTR, which harbors a miR-96 binding site (Figure 5.5C, D). These 
results suggest that hypoxia may be able to reduce Pten mRNA levels via a 3’-UTR-dependent mechanism 
in lung epithelial cells. 
Although my studies do not confirm a direct role of miR-96, it opens up possibilities for future 
studies of the in vitro and in vivo roles of miR-96 in regulation of Pten in hypoxic environment. miR-96 is 
observed to be upregulated in fibroblastic foci of IPF patients [12] while PTEN is down-regulated in 
hyperplastic AEC2s surrounding these foci [7], which suggests an epithelial-mesenchymal crosstalk. 
Therefore, the role of miR-96 in causing loss of epithelial integrity by down-regulating Pten represents an 
important venue for future research. 
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Figure 5.5: Hypoxia down-regulated Pten transcription and increased miR-96 transcript 
(A) Hypoxia induced expression of miR-96 in MLE-12 cells. (B) Hypoxia reduced Pten protein levels in 
immortalized AEC2s (see Appendix A for more details). (C) Consistent with my hypothesis, 3’UTR of 
Pten mRNA has complementary sequence for miR-96-5p. (D) Pten 3’UTR luciferase construct was 
transfected in primary AEC2s followed by normoxia or hypoxia treatment for 24 hours. There was 35% 
reduction in luciferase activity of Pten 3’UTR. 
 
 
 
5.7 Conclusions 
 In this chapter, using RNA-Seq technique, I have presented transcriptomic signature of primary 
VhlΔ/Δ or hypoxic AEC2s. My analysis of the hypoxia-responsive transcriptome of primary AEC2s have 
identified a profibrotic effect of hypoxia on cytoskeletal remodeling of AEC2s. Further, the data also 
suggest activation of FAK1 signaling at the transcript level, complementing my proteomics studies that 
identified a similar signature at the protein level. The RNA-Seq experiment has also identified hypoxia-
dependent and independent signatures of Vhl, which can be analyzed to gain insights into various novel 
molecules involved in the pathogenesis of PF. Likewise, Vhl-independent signatures of hypoxia can also 
be interrogated to gain further insights into a global role of hypoxia at the level of gene transcription.  
Further implications of these study will be discussed in Chapter 6. 
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Table 5.1: Overview of RNA quality 
Total RNA were isolated from primary AEC2s after the indicated treatments. ID: Sample ID. Treatment: 
Viral treatment of cells (either Ad-GFP or Ad-Cre:GFP to delete exon 1 of Vhl. RNA Integrity Number: 
Integrity of RNA calculated using Agilent Bioanalyzer. 28S/18S: ratio of 28S rRNA to 18S rRNA, reflects 
integrity of RNA. 260/280: Ratio of absorption of nucleic acid at 260 nm to absorption of nucleic acid at 
280 nm. The ratio reflects purity of RNA; low ratio (< 1.8) reflects possible contamination from proteins 
or phenol, which absorb UV at 280nm. 260/230: ratio of nucleic acid absorption at 260 nm to absorption at 
230 nm. Concentration: Concentration of each sample. 
 
ID Viral Treatment 
RNA Integrity 
Number 28S/18S 260/280 260/230 
Concentration 
(ng/µl) 
Ctrl 1 Ad-GFP 8.6 1.5 1.93 2.08 98 
Ctrl 2 Ad-GFP 8.6 1.4 1.92 1.97 96 
Ctrl 3 Ad-GFP 8.8 1.4 1.94 1.82 82 
Hypoxia 1 Ad-GFP 8.2 1.3 1.83 2.02 89 
Hypoxia 2 Ad-GFP 8.7 1.4 1.9 2.06 95 
Hypoxia 3 Ad-GFP 8.8 1.5 1.82 2.10 115 
VhlΔ/Δ 1 Ad-Cre:GFP 8.7 1.5 1.86 1.92 113 
VhlΔ/Δ 2 Ad-Cre:GFP 9.0 1.8 1.81 2.01 120 
VhlΔ/Δ 3 Ad-Cre:GFP 9.0 1.5 1.84 1.97 147 
 
 
 
 
Table 5.2: Alteration in levels of miRNAs predicted to target Pten 3’UTR in hypoxic AEC2s  
 
miRNA ID Fold-Change
mmu-miR-212-5p/3p  1.9
mmu-miR-17-5p  1.8
mmu-miR-320-3p  1.2
mmu-miR-19a-3p  1.5
mmu-miR-96-5p  2.1
mmu-miR-132-3p  1.6
mmu-miR-31-5p  1.3
mmu-miR-214-3p  1.92
mmu-miR-25-3p  -1.4
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Table 5.3: List of top 50 differentially expressed large RNAs in hypoxic AEC2s identified through 
RNA-seq 
 
Upregulated mRNA Down-regulated mRNA 
Gene Name Fold-Change   Gene Name Fold-Change 
A2m 50.37   Ranbp3l -21.53 
Vwa1 36.72   Kynu -18.82 
Rarres2 31.87   Prss35 -16.75 
Ndufa4l2 25.43   Awat1 -8.86 
Cox4i2 24.60   Tal2 -8.14 
Bend5 21.00   Krtap1-5 -8.11 
Cyp2ab1 18.81   Gata5 -8.05 
2610528A11Rik 18.55   Chodl -7.74 
Muc2_3 15.96   Ccl7 -7.43 
Rab33a 15.62   Klrb1c -7.36 
Ache 14.69   Pkd2l1 -7.18 
Nxph4 14.21   Adh7 -7.04 
Lce1h 13.85   Adh1 -6.88 
Mgarp 12.97   Pkhd1l1 -6.67 
Hsd17b2 12.44   Bcl2a1d -6.46 
Lman1l 11.82   Olfr1342 -6.27 
Dio3 11.43   Tnxb -6.07 
Tfap2c 10.94   Zfp804b -6.07 
Syt5 10.81   Wdr95 -6.05 
Galr2 10.16   Tac1 -5.78 
Selenbp1 9.39   Ptprq -5.61 
Gm2373 9.32   Dpep1 -5.61 
Glt1d1 8.93   Pcdh20 -5.45 
Krt16 8.58   Hpgd -5.43 
Cda 8.27   Pld4 -5.35 
Ppp1r3g 8.19   Klra17 -5.33 
Egln3 8.13   Nxf7 -5.31 
Lce1g 8.11   Ednrb -5.18 
1500009C09Rik 7.85   Scnn1b -5.16 
9530026P05Rik 7.68   Amph -5.16 
Bnip3 7.17   Olfml2a -5.16 
Car12 7.14   Slc24a2 -5.07 
Fgf11 7.12   Sod3 -5.06 
Gm5152 7.03   4933430I17Rik -5.01 
Tmem74b 7.00   2010002M12Rik -4.89 
Cbln3 6.99   Klf15 -4.89 
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Table 5.3 (Continued) 
 
Upregulated mRNA Down-regulated mRNA 
Gene Name Fold-Change   Gene Name Fold-Change 
Flg2 6.98   Slc14a1 -4.85 
Muc4 6.97   Fndc3c1 -4.78 
Atp7b 6.85   Acss3 -4.77 
Car9 6.78   Il1rl1 -4.73 
Dio3os 6.68   Iigp1 -4.73 
Smtnl2 6.42   Kcne2 -4.72 
3632451O06Rik 6.42   Zmat4 -4.71 
Atp10b 6.32   Chrna7 -4.58 
Apln 6.11   Gapt -4.57 
Frmd3 6.05   Figf -4.53 
Prnd 6.04   Cps1 -4.48 
Fam19a2 6.01   A330076H08Rik -4.46 
Cpa4 5.99   Pex5l -4.46 
Cdh17 5.93   Ndnf -4.45 
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CHAPTER SIX: 
SUMMARY AND DISCUSSION 
 
6.1 Summary and Discussion 
 Molecular etiology of IPF has been difficult to decipher due to its late diagnosis and lack of ideal 
preclinical models that fail to recapitulate its spontaneous and progressive nature. Although the last two 
decades of research has advanced our understanding of the nature of IPF, including the use of nintedanib 
and pirfenidone as approved therapies, the prognosis for patients remain dismal with marginal improvement 
in median survival post diagnosis [1]. I believe that identification of molecular players contributing to 
pathogenesis of IPF can lead to earlier diagnosis, which can in turn open up more possibilities for 
therapeutic interventions to extend the survival post diagnosis. Therefore, combination of molecular studies 
and development of physiologically relevant preclinical models can enhance our understanding of 
molecular etiology of IPF. In this thesis, I have attempted to determine the role of hypoxia, a physiological 
characteristics of patients with various ILDs, in activation of profibrotic molecules, FAK1 and Galectin-1, 
which contribute to pathogenesis of PF. I have also established and characterized two independent mouse 
models in this study that recapitulate progressive and exacerbated nature of IPF. 
Patients with IPF often experience a slow and gradual decline of lung function, a condition 
classified as “stable IPF” [2, 3]. Likewise, many patients with IPF suffer from acute worsening of the 
disease associated with severe decline in lung function, often resulting in death. These events are classified 
as “acute exacerbation of IPF” or AE-IPF [2-4]. The causes of the exacerbation events remain unknown. 
Chronic hypoxia, as observed in patients with AE-IPF [4], leads to aberrant epithelial injury/repair 
associated with accumulation of edematous exudate in the alveolar sacs. Sustained presence of this 
interstitial fluid induces focal hypoxia in the distal lung parenchyma and alters the fibroblast phenotype [5-
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7]. Lungs of the aged, with a history of lung injuries, infections and compromised gas exchange function, 
is prone to developing focal hypoxia within the lung parenchyma. This would indeed lead to further 
epithelial injury, edema, and alveolar collapse, exacerbating hypoxemia. Particularly, when this happens in 
an IPF patient, it will likely trigger AE-IPF [8-11]. Therefore, it is important to determine the molecular 
determinants of hypoxia signaling in the lung to understand the initial injury and subsequent impaired 
wound healing potential of the lung. 
One of the reasons for limited success of preclinical candidates in clinical trials is the cellular 
response that circumvents inhibition of a single molecule. Therefore, understanding of the preexisting 
signaling network hierarchy and identifying central hubs of the signaling networks is critical to anticipation 
of cellular response to a single molecule inhibition. My studies in chapter 1 identified hubs of kinase 
signaling network using a novel structural and bioinformatics approach. Identification of hypoxia 
responsive FAK1 as a central hub of kinase signaling network built the rationale for further characterization 
of FAK1 during hypoxia response in the lung epithelium. I discovered that FAK1 and Galectin-1 were 
activated by hypoxia and played important role in controlling a profibrotic response to hypoxia in vitro and 
in vivo. Further, I also established a novel mouse model that leveraged hypoxia signaling to exacerbate an 
initial subclinical injury, causing fibrosis. Galectin-1, which interacted with and activated FAK1, has 
potential to reduce hypoxia-mediated exacerbations of initial injuries that can result in PF. I discovered that 
pFAK1 (Y397) and Galectin-1 were induced in a novel model of progressive PF, which is induced by 
epithelial loss of Vhl, an inhibitor of hypoxia signaling. RNA-Seq of primary AEC2s from Vhlflox/flox mice 
identified hypoxia-induced miR-96 as a possible regulator of Pten expression, which gives insight into 
mechanisms underlying PTEN expression loss in the lungs of IPF patients. In summary, I have established 
initial evidence of the molecular role of epithelial hypoxia in the pathogenesis of PF (Figure 6.1).  
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Figure 6.1: Epithelial hypoxia contributes to PF via FAK1 and Galectin-1 
Hypoxia induces FAK1, Galectin-1, and miR-96 and inhibits PTEN to aberrantly activate AEC2s and 
contribute to ECM remodeling. Hypoxia also contributes to increased Activin signaling, which may explain 
hyperplastic AEC2s lining fibroblastic foci. Future studies implicating FAK1 and Galectin signaling in 
conversion of activated AEC2s to hyperplastic AEC2s and honeycomb-like structures can enhance our 
understanding of pathophysiology of IPF. Blue lines depict activation and red line depict inhibition. 
 
 
Previous studies have suggested that hypoxia can simultaneously contribute to AEC2 proliferation 
via Deoxycytidine kinase (DCK) [12] and AEC2 apoptosis via Bnip3L, a Bcl2 family protein [13]. Further, 
epithelial cytoskeletal remodeling, a process that can be regulated by hypoxia following an injury [14], is a 
major characteristic of IPF [15]. It has been widely acknowledged that injured epithelial cells harbor 
regenerative potential that often goes unchecked in IPF lungs [16, 17]. I believe that delineating the role of 
hypoxia in aberrantly sustained regeneration of the epithelium, which often results in presence of 
hyperplastic AECs surrounding fibroblastic foci [18], can delineate the molecular events in profibrotic 
activation of the epithelial cells. Both FAK1 and Galectin-1 play important roles in maintenance of cancer 
stem cells [19, 20]. Therefore, I have attempted to determine the role of molecules such as FAK1 and 
Galectin-1 that can modulate cellular processes such as migration and proliferation in hypoxic epithelium. 
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FAK1 plays a potent role in modulating a number of cellular processes such as cellular 
proliferation, resistance to apoptosis, and cytoskeletal remodeling that are important in pathogenesis of IPF 
[21]. FAK1 is critical to apoptosis resistance in fibroblasts and fibroblast-to-myofibroblast differentiation 
in response to TGF-β [22]. Likewise, inhibition of FAK1 reduces bleomycin-induced PF [23] while FAK-
related non-kinase (FRNK), which is a negative regulator of FAK1, protects against bleomycin-induced PF 
in an in vivo model of bleomycin-induced PF [24]. Likewise, FAK1 is also a known tumorigenic kinase 
that has been implicated in several cancers and Phase I and Phase II clinical trials have been initiated with 
FAK1 inhibitors [25]. I discovered that FAK1 regulated non-canonical TGF-β/SMAD signaling in hypoxia 
as FAK1 knockdown dampened SMAD3 activation and subsequent mRNA induction of SMAD-dependent 
genes. This result provides impetus for future studies deciphering the profibrotic role of FAK1 in AECs. 
My studies identified a profibrotic role of Galectin-1, which physically interacted with FAK1 and 
also induced its activation. Although little is known about Galectin-1 in the context of IPF, Galectin-3 – a 
member of Galectin family of proteins – is increased in the serum samples of patients suffering from AE-
IPF compared to stable IPF [26]. My studies also identified a trend towards increased Galectin-1 serum 
levels in IPF patients. Further, I showed that Galectin-1 also induced activation of FAK1 by interacting 
with it and increasing pFAK1 (Y397) levels. Interestingly, Galectin-1 interacts with Integrin-β1 [27] and 
Integrin-β1 interacts with FAK1, inducing its pFAK1 (Y397) levels [28].  Considering that Integrin-β1 is 
activated by hypoxia to promote wound healing [29], it is likely that hypoxia leverages Galectin-1/Integrin-
β1/FAK1 axis to drive profibrotic effects in the lung. It is possible that Galectin-1 inhibition in the presence 
of active hypoxia signaling in mice interfered with activation of the profibrotic integrin-β1/FAK1 signaling, 
leading to attenuation of fibrotic response. Therefore, future studies characterizing the role of Galecin-1 in 
my model of progressive PF and other mouse models can firmly establish Galectin-1 as a therapeutic target. 
Despite the well characterized roles of profibrotic FAK1 and tumor suppressor PTEN in the context 
of IPF, the signaling circuits connecting multiple profibrotic processes remain elusive. The approach of 
targeting a single molecule without understanding the physiological processes underlying its activation 
often fails. Therefore, it is imperative to determine the role of a physiologically relevant injury causing the 
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tissue response that results in activation of the profibrotic processes. My studies suggest that hypoxic 
environment in the lung can play the role of a primary condition that activates these profibrotic molecules 
and subsequent cellular processes. Hypoxia can partially result from alveolar collapse, compromised gas-
exchange potential of apoptotic epithelium, and presence of edematous exudate in the alveolar sacs. All of 
these processes are often observed in the lungs of patients with IPF [15, 30]. Therefore, it is possible that 
the hypoxia signaling may be partially activated during the initial stages of IPF when the alveolar gas-
exchange potential is compromised due to several micro-injuries. This effect can be exacerbated in the 
lungs of patients with IPF, which can cause often fatal episodes of acute exacerbations. Therefore, I believe 
that studies involving clinical understanding of physiologically relevant phenomena should be combined 
with studies investigating molecular determinants of these phenomena to achieve comprehensive 
knowledge that lead to greater understanding of IPF. This approach can also lead to development of better 
mouse models that are based on these physiologically relevant processes instead of single profibrotic 
molecules. 
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APPENDIX A: 
MATERIALS AND METHODS 
  
 
A.A. Methods 
I have described below all the methods used to perform experiments in Chapter 2 to Chapter 5. 
 
Derivation of PPIs and network analysis: Experimentally validated protein-protein interaction (PPI) 
data of the 36 kinases and that of FAK1 interacting proteins was assembled using manual data curation 
and various softwares as described previously[1]. PPI network was constructed and visualized using 
Cytoscape[2]. Network analysis was performed to identify topologically significant hubs from the PPI 
networks using Network Analyzer[3] and CentiScaPe plug in tools[4]. 
 
Gene Ontology analysis: Gene ontology analysis was performed with BiNGO[5]. BiNGO was used to 
create two networks of molecular functions of proteins that either interacted with ordered regions or IDRs 
of FAK1. The two networks were merged using Cytoscape option “Merge” (Tools  Merge  Networks). 
In order to identify unique molecular functions present in the two networks, “difference” operation was 
selected and a new network was created with molecular functions exclusively present in either of the 
networks. p-value was calculated using Hypergeometric test and corrected with Benjamini & Hochberg 
False Discovery Rate. Molecular function terms with p < 0.05 were considered to be significant. 
 
Rate of evolution of kinases, KDs, and IDRs: The relative rates of evolution for the proteins and their 
domains were calculated as described earlier[6]. Ortholog groups were obtain using the OMA Browser[7] 
and alignments were obtained with MAFFT[8]. The orthologs alignment for the kinases was subdivided 
into each domain or IDR using the positions in the Human as a reference. An evolutionary distance matrix 
was obtained for each of these section of alignment (using protdist from PHYLIP 3.69 (ref. [9])) and the 
distance from any ortholog to the human sequence was averaged. This number is then divided by the 
average in a matrix that considers the average distances to the orthologs for the same species of all proteins 
in the human proteome. The resulting rate ratio thus indicates the relative rate of evolution of the protein 
(or protein domain) to the average human proteins.  
 
Correlation and significance studies: Rates of evolution of multiple IDRs from a single kinase were 
averaged to avoid oversampling kinases with multiple IDRs. Rates of evolution of WPs, their KDs, and 
their IDRs were then compared with each other to determine correlation. Correlations between KD-WP, 
IDR-WP, and IDR-KD were determined by calculating Pearson correlation coefficient (r) for 414 kinases 
with IDRs using PEARSON function in MS-EXCEL. Level of significance was assumed to be at or below 
0.01 for two-tailed t-test with degree of freedom (df) = 412. The work on evolution was done in 
collaboration with Dr. Tillier’s lab at University of Toronto. 
 
 
FAK1 interactome mapping and PPI distribution calculations: Original research articles that had 
reported all of the FAK1 PPIs were identified and by manual literature search, the protein-regions 
participating in interaction with FAK1 were identified. Protein interactions involving a structured region of 
FAK1 were considered to be “Ordered-region interactions (O)”, whereas, interactions involving the IDRs 
of FAK1 were considered to be “IDR interactions (DO)”. Further, per residue intrinsic disorder prediction 
of the FAK1-interacting partners was performed to identify whether the regions of interacting partners 
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involved in interaction with FAK1 were disordered. Following calculations were used to identify per 
residue PPI distribution. 
 
RDO  ൌ ୒୭.୭୤	୔୰୭୲ୣ୧୬ୱ	୍୬୲ୣ୰ୟୡ୲୧୬୥	୧୬	୍ୈୖୱ୒୭.୭୤	୲୭୲ୟ୪	ୢ୧ୱ୭୰ୢୣ୰ୣୢ	୰ୣୱ୧ୢ୳ୣୱ   RO  ൌ
୒୭.୭୤	୔୰୭୲ୣ୧୬ୱ	୍୬୲ୣ୰ୟୡ୲୧୬୥	୧୬	୭୰ୢୣ୰ୣୢ	୰ୣ୥୧୭୬ୱ
୒୭.୭୤	୲୭୲ୟ୪	୭୰ୢୣ୰ୣୢ	୰ୣୱ୧ୢ୳ୣୱ   
Multiple sequence Alignment of FAK1: FAK1 protein sequences from different species were retrieved 
from Ensembl. Alignment feature in Macvector program (MacVector Inc., Apex, North Carolina) was used. 
We used ClustalW Alignment to perform multiple sequence alignment. Gonnet series matrix was used with 
open gap penalty of 10.0, extend gap penalty of 0.2, and delay divergent of 30%. We allowed gap separation 
distance of 4 with residue-specific penalties. 
 
Cell Culture and treatments: Majority of the experiments utilizing lung epithelial cells were performed 
in H441 cells (American Type Culture Collection (ATCC) #HTB-174). H441 cells represent morphological 
features and barrier functions of normal alveolar epithelial cells and club cells derived from bronchiolar 
epithelium [10, 11]. They are also more alveolar epithelial-like than A549 cells, which, do not express any 
of the surfactant markers and contain similar surfactant phospholipids to fibroblasts [12, 13]. H441, H292 
(ATCC #CRL-1848), and A549 (ATCC # CCL-185) were kindly provided by Dr. Eric Haura (H. Lee 
Moffitt Cancer Center and Research Institute, Tampa, FL). H441 and H292 cells were cultured in RPMI 
medium (Sigma Aldrich, #R8758); A549 cells were cultured in F12K medium (Invitrogen). All cell culture 
media were supplemented with 10% fetal bovine serum and 5% mixture of penicillin G, streptomycin, 
amphotericin B (Invitrogen), and Plasmocin (Invivogen). NuLi-1 cells were purchased from ATCC (CRL-
4011) were cultured in Bronchial Epithelial Cell Growth medium (ATCC #PCS-300-040). All cell lines 
were cultured at 37°C in an incubator that maintained 5% CO2. TGF-β1 (#240-B) and Wnt-3a (#5036-WN-
010) recombinant proteins were obtained from R&D Systems (Minneapolis, MN). Galectin-1 (#450-39) 
recombinant protein was purchased from Peprotech (Rocky Hill, NJ). 
 
Transfections and transcriptional reporter assays: Artificial SMAD reporter (SBE4-Luc), a gift from 
Bert Vogelstein (Addgene # 16527) [14] and β-Catenin reporter (TOP-FLASH) [15] were transfected using 
the polyethylenimine (PEI) method [16] with modifications as previously described [17]. PF-573,228 was 
used as a FAK-inhibitor in the transcriptional studies (Selleckchem; #S2013) [18]. Luciferase assay was 
performed according to the manufacturer’s protocol using luciferase assay system (#E1501) purchased from 
Promega (Madison, WI). The light units were assayed by luminometry (Synergy H4, BioTek, Winooski, 
VT). Transfection efficiency was normalized across wells using 100ng of pCMV β-galactosidase plasmid 
(Takara Bio USA Inc., Mountain View, CA ) as described previously [19]. 
 
Isolation and culture of Type II alveolar epithelial cells (AEC2s): AEC2s were isolated from normal 
mice using previously described method [20] with minor modifications. Briefly, lungs of 129X1/SvJ mice 
(Jackson laboratories strain number: 000691) were isolated and crude lung cell suspension was prepared 
by intratracheal Dispase and low melt agarose instillation followed by mechanical shearing of the lungs. 
Crude cell suspensions were then serially passed through 100 µm and 40 µm filters. The filtered cell 
suspension was then treated with red blood cells lysis buffer to lyse red blood cells. AEC2s were purified 
by negative selection by using a CD45 (42 µg)/CD32 (16 µg) coated plate. Suspended cells were then 
collected and cultured on fibronectin coated (10 µg/mL) plates in DMEM media (ATCC #30-2002) 
supplemented with 10% fetal bovine serum and 5% mixture of penicillin G, streptomycin, amphotericin B 
(Invitrogen) and Plasmocin (Invivogen). Purity of AEC2s was measured by considering E-Cadherin-
positive cells as epithelial cells and Vimentin-positive cells as non-epithelial cells. Reagents list for AEC2 
isolation is provided in Table A.1. Primary immortalized AEC2s used Chapter 5 were established in the 
laboratory of Dr. Kathryn Wikenheiser-Brokamp, M.D. at Cincinnati Children’s Hospital Medical Center. 
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Table A.1: List of reagents used in isolation of primary AEC2 
Reagent Company Catalog Number Experiment/Technique 
Dispase I Fisher Scientific CB-40235 Primary AEC2 isolation 
Low melt agarose Bio-Rad 161-3114 Primary AEC2 isolation 
100 µm filter BD Insyte 352360 Primary AEC2 isolation 
40 µm filter Morganville Scientific CSS0100 Primary AEC2 isolation 
RBC lysis buffer Sigma Aldrich R7757 Primary AEC2 isolation 
CD45 antibody Life Technologies MA1-10231 Primary AEC2 isolation 
CD32 antibody BD Pharmingen 553142 Primary AEC2 isolation 
Fibronectin Sigma Aldrich F2006 Primary AEC2 isolation 
 
RNA isolation and Real-Time PCR Analysis: Total RNA was isolated using Trizol (Ambion AM9738) 
according to the manufacturer’s protocol. 500 ng of purified RNA was converted into cDNA using the 
qScript cDNA SuperMix (Quanta Biosciences; #95048-100) and used for Real Time Polymerase Chain 
Reaction assays using Fast SYBR® Green Master Mix (ThermoFisher Scientific, Waltham, MA #4385612) 
in StepOne Real-Time PCR System (ThermoFisher Scientific, Waltham, MA). List of primers are provided 
in Table A.2. 
 
Stable isotope labeling by amino acids in cell culture (SILAC) Proteomics and Pathway Analysis: 
H441 cells labeled with either light lysine/arginine or heavy lysine lysine(U-13C6)/arginine(U-13C6,15N6; 
red) isotope were grown for 8 doublings. Cells grown with light isotopes were exposed to normoxia (21% 
O2; 72 hrs; n=3) and cells grown with heavy isotopes were exposed to hypoxia (1% O2; 72 hrs; n=3). Total 
proteins were collected from cell lysates and subjected to digestion with trypsin followed by LC-MS/MS 
and sequencing of proteins. Raw proteomic data were analyzed against a universal protein resource database 
using Mascot (Matrix Science, Boston, MA). Peptide and protein validations were performed using 
Scaffold (version 3.00.06; Proteome Software). A total of 1476 significantly deregulated proteins in at least 
2 replicates were identified (Mann Whitney Test; P < 0.05). 
 
Pathway Analysis and Network Analysis: Data were analyzed using QIAGEN’s Ingenuity® Pathway 
Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). Following analyses were 
performed: 
Upstream Analysis: This approach determines the cascade of upstream protein regulators that can provide 
evidence of the differential regulation of proteins observed in hypoxic proteome [21]. There was a 
significant overlap between the deregulated proteins from hypoxic proteome and known targets of TGF-β 
and Wnt3a (p < 0.05). Further, TGF-β and Wnt3a were predicted to be upregulated as inferred by the status 
of the deregulated hypoxic proteins in our analysis. Both TGF-β and Wnt3a were assigned an activation z-
score > 2.00 by IPA, which suggested activation of the upstream regulators.  
Functional enrichment: 36 Kinases with IDRs extending into their KDs (Figure 2.5), FAK1-intercating 
proteins (Figure 2.6 – IDR-interactions or ordered-interactions), significantly deregulated proteins (Figure 
2.8 – MS/MS experiment; Figure 3.2 – SILAC experiment), and significantly deregulated mRNAs (Figure 
5.4 – RNA-sequencing experiment) were analyzed by IPA for their functional enrichment, which gives 
overrepresented functions of the deregulated proteins when compared to the entire human proteome as a 
reference dataset. “Core Analysis” option was used in Ingenuity Pathway Analysis (IPA; Ingenuity® 
Systems, www.ingenuity.com). An FDR ≤ 0.05 (-log P-value = 1.33) was used to reduce false positives 
and ensure that all cellular functions are derived in an unbiased manner. 
Disease enrichment: Total human kinases (Figure 2.3 – Kinase group-wise disease enrichment), 36 kinases 
with IDRs extending into their KDs (Figure 2.5) and significantly deregulated proteins (Figure 3.2 – SILAC 
experiment) were analyzed using the “Core Analysis” option in IPA. The default Human proteome from 
IPA was used as the background dataset. Disease enrichment data was derived by selecting “Diseases and 
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Disorders” from “Customize Chart” functions. An FDR ≤ 0.05 (-log P-value = 1.33) was used to reduce 
false positives and ensure that all diseases are enriched in an unbiased manner. 
 
Immunocytochemistry, Immuno-blot Analysis: For immunocytochemistry (ICC), cells were grown on 
glass coverslips, and exposed to hypoxia for the specified durations. Cells were fixed in 4% 
paraformaldehyde, blocked and permeabilized with 0.1% Triton X100 and 2% bovine serum albumin 
(BSA). The primary antibodies were diluted in 1X antibody dilution reagent at the following dilution: 
pSMAD3 (Ser423/425) (Cell signaling, #C24A9), 1:100 dilution, incubated overnight at 4°C; α-SMA 
(abcam, #ab5694), 1:200 dilution, incubated overnight at 4°C; FAK (Santa Cruz, #sc-558) and p-FAK 
(pY397) (Santa Cruz, #sc-558), 1:100 dilution, incubated at room temperature for 1 hr; E-Cadherin (Cell 
Signaling, #3195P), 1:50 dilution, incubated overnight at 4°C; Vimentin (abcam, #ab92547), 1:200 dilution, 
incubated overnight at 4°C. Cells were then washed 3 times with 1X TBS (pH 7.6) and incubated in 
appropriate secondary antibodies mixed with Phalloidin (Invitrogen, #A12381) at 1:100 dilution for 1 hour 
at room temperature and mounted with a medium containing DAPI (Vector Laboratories, #H-1500) at 1:5 
dilution in 1X TBS (pH 7.6). Cells were visualized and imaged using an Olympus IX51 microscope and 
cellSens software (Olympus). Immunoblotting was performed as previously described [1]. Primary 
antibodies used were as follows: pFAK (Y397) (Santa Cruz, #sc-11765-R) at 1:500 dilution; β-Actin 
(Sigma Aldrich, #A0560) at 1:1000; α-SMA (abcam, #ab5694) at 1:1000 dilution; HIF-1α (Cayman 
Chemicals, #10006421) at 1:500 dilution; V5 (Sigma Aldrich, #V8317) at 1:1000 dilution; GFP (Santa 
Cruz, #sc-9996) at 1:1000; PTEN (138G6; Cell Signaling, #9559) at 1:1000. Peroxidase-conjugated 
AffiniPure Goat Anti-Rabbit IgG secondary antibody (Jackson ImmunoResearch Laboratories #111-035-
045) was used at 1:10,000 dilution with incubation at room temperature. ICC and immunoblot signals in 
each experiment were quantified using ImageJ. 
 
Co-immunoprecipitation (IP): For Co-IP, HEK293T cells were transfected with 16 µg of either V5-
tagged Galectin-1 or GFP-tagged FAK1 or both. 300 µg of total protein lysates were incubated with 5 µg 
of V5 antibody (Sigma Aldrich, #V8317) for 16 hours at 4°C followed by centrifugation at 14000 rpm for 
30 minutes at 4°C. The supernatant was removed and used as input. Pellet consisting of antibody and 
proteins was washed two times with 1X TBS buffer (pH 7.6). The pellet was then boiled at 95°C for 10 
minutes in 100µl 2X laemmli sample buffer (Bio-Rad, #1610737) with 5% β-Mercaptoethanol. Proteins 
were then separated via immunoblotting as described earlier. 
 
Hypoxia treatment of cells: Different cell types were incubated in an airtight Plexiglass chamber with a 
digital oxygen sensor (BioSpherix, NY). ProOX110 regulator (BioSpherix, NY) was used to maintain 
oxygen concentration at 1% for the indicated time periods unless otherwise noted. The chamber was kept 
in a tissue culture incubator to maintain 37°C temperature and 5% CO2. 
 
Electric Cell-Substrate Impedance Sensing (ECIS): For wound healing assay, H441 or FAK-null H441 
cells (RECs) were grown to confluence on ECIS culture ware (8W1E; Applied Biophysics). Cells were 
wounded using an elevated field pulse of 3000 mA at 80,000 Hz applied for 10 seconds, producing a 
uniform circular lesion 250 μm in size. The impedance was measured at 16,000 Hz, normalized to its value 
at the start of data acquisition and plotted as a function of time. For proliferation assay, 10,000 cells were 
seeded in each well on ECIS cultureware (8W10E+; Applied Biophysics). After allowing the cells to attach, 
cells were serum starved for 16 hours, before introducing media replenished with 10% bovine serum. The 
resistance was measured at 4000 Hz for up to 160 hours. 
  
Generation of FAK-null H441 cells: H441 cells were infected with lentiviral particles expressing shRNA 
targeting FAK1 transcript. (Sigma Aldrich, #TRCN0000121129). Viral infection was performed for 8 hours 
in RPMI-1640 media containing 10 µg/mL of polybrene. Cells were washed with phosphate buffered saline 
(PBS) and replenished with normal media. Puromycin selection (2 µg/mL) identified cells with stably 
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integrated shRNA. FAK1 targeting (FAK1-null) was confirmed by immunoblotting for FAK1 expression. 
FAK1-null H441 cells were maintained in RPMI media containing 2 µg/mL puromycin. 
 
Cell Proliferation and Migration Assays: Cell proliferation assays were performed using cell counting 
kit-8 (Fluka, Biochemika) as previously described [1] with following modifications: H441 cells were plated 
in 96-well plates at described quantities and cultured in appropriate growth medium. Cells were serum 
starved overnight and exposed to either hypoxia or normoxia for indicated time period. Cell migration was 
measured by scratch assay. H441 cells were grown on 10 cm2 cell culture dish to 100% confluence. 
Scratches were made using sterile pipettes and imaged after changing media (0 hrs). H441 cells were 
exposed to normoxia or hypoxia for the indicated time period. At least three scratches were made in each 
experimental group and 10 images at 40X were taken of each scratch to be used for quantitation. Images of 
the scratches were taken every 24 hours unless otherwise indicated. Cell migration was measured as the 
percent of wound closure compared to control cells using ImageJ. 
 
Bleomycin and hypoxia treatment of mice: 129X1/SvJ mice (#000691) were obtained from Jackson 
Laboratory (Bar Harbor, ME) and housed in humidity and temperature controlled rooms on a 12 hours 
light/dark cycle with food and water. 4-6 weeks old mice were exposed to 50 µL of 0.1U bleomycin 
(Selleckchem Chemicals; #S1214) or saline via intra-tracheal instillation on Day 0 and Day 7. Mice were 
exposed to hypoxia (13% O2, maintained in a chamber A-15274-P; BioSpherix) or Normoxia (normal room 
air) on Day 8. Lung function tests were performed on mice and lungs were harvested on Day 28 (n=4 in 
each experimental group). 
 
Immunohistological Staining of Mouse Lungs: Lungs from experimental or control mice were inflation-
fixed with 4% paraformaldehyde in 1X PBS overnight at room temperature. The tissue samples were rinsed 
in 1X PBS, dehydrated, and embedded in paraffin blocks. 5 µm thick sections were cut, mounted on 
microscope slides, deparaffinized, and hydrated. Antigens retrieval was performed by microwaving the 
slides in 0.1% Sodium Citrate Buffer (pH 6.0) for 45 seconds. Endogenous peroxide activity was blocked 
by treating sections with 3% H2O2 at 37 °C for 10 min. Hematoxylin and Eosin (5-minutes incubations 
each) or appropriate primary and secondary antibodies were used to stain tissues. Primary antibodies were 
diluted in 1X antibody dilution solution at the following dilutions: HIF-1α (Cayman Chemicals, 
#10006421) at 1:20 dilution; HIF-2α (Novus Biologicals, #NB100-122) at 1:20 dilution; α-SMA (abcam, 
#ab5694) at 1:100 dilution; pFAK1-Y397 (Santa Cruz, #sc-11765-R) at 1:50 dilution; Galectin-1 (Cell 
Signaling, #13888) at 1:50 dilution. DAB (3,3'-diaminobenzidine) was used as a substrate and Hematoxylin 
was used as a counterstain. Masson’s trichrome staining was performed as per manufacturer’s protocol 
(Sigma-Aldrich; #HT15-1KT). 
 
Lung function tests: Lung function tests were performed using flexiVent system (SCIREQ Inc, Montreal, 
Qc, Canada) as described previously [22]. The flexiVent system comprises of three independent units: (1) 
Base unit, (2) EC network controller that communicates with the computer, and (3) XC accessory controller 
that controls aeronob nebulizer for aerosol delivery into the mouse lungs. Briefly, mice were sedated using 
dexmedetomidine at 0.5mg/kg, intraperitoneal (i.p.) ten minutes before the treatment with an anesthetic 
agent ketamine at 100mg/kg, i.p. The mice were kept under isoflurane at 3% throughout the intubation and 
during lung function tests. The mice were orotracheally intubated with 18G catheters (BD Insyte, 
#8366841) and then attached with the flexiVent system. The mice were ventilated at the tidal volume of 
10ml/kg with an average breathing frequency of 150 breaths/minute. Respiratory mechanics were measured 
using Forced Oscillation Technique (FOT) that applies an oscillatory waveform to the airways of mice and 
measures pressure, flow, and volume signals. Following perturbations were performed to collect different 
parameters: Snapshot-150 perturbation that measures Resistance (R), Elastance (E), and Compliance (C). 
Quick Primer-3 perturbation that measures conducting airway resistance (Rn) and small airways resistance 
or tissue damping (G). Pressure-Volume loop (PVs-P) perturbation that measured airspace closure (area) 
that indicates airway collapse. 
93	
	
 
RNA isolation from formalin-fixed paraffin embedded (FFPE) mouse lungs: Total RNA from mouse 
lungs were isolated using the MagMAXTM FFPE Total Nucleic Acid Isolation Kit from ThermoFisher 
Scientific (#4463365) according to the manufacturer’s protocol without any modifications. Briefly, two 
10µm FFPE sections were digested with protease at 60°C for 45 minutes and then at 80°C for 30 minutes. 
Samples were incubated with nucleic acid binding bids followed by DNA digestion with DNase and 
subsequent elution of RNA at 37°C in Elution Buffer. Total RNA were converted to cDNA for use in real 
time PCR as described above. 
 
Collagen quantitation: Total collagen levels from sections of FFPE lungs were quantified using Sirius 
Red/Fast Green Collagen Quantitation Kit (#9046) from Chondrex, Inc. (Redmond, WA) according to 
manufacturer’s protocol. Briefly, one 5µm FFPE sections from at least four mice in each group were 
deparaffinized and hydrated followed by incubation with 100µl dye solution containing Sirius Red and Fast 
Green for 30 minutes at room temperature. The sections were then washed in running water for 5 minutes 
followed by eluting the bound Sirius Red and Fast Green dyes in 1ml of extraction buffer. Absorbance of 
the eluted dye was measured at 540nm and 605nm in triplicate for each sample. Total collagen was 
measured using the following formula according to manufacturer’s protocol: 
 
Total Collagen (µg/section)  ൌ ୓ୈହସ଴ିሺ୓ୈ଺ହ଴∗଴.ଶଽଵሻ଴.଴ଷ଻଼  
 
The collagen values were then normalized to the average values from four mice in control group. 
 
RNA-sequencing: RNA sequencing (RNA-Seq) of total RNA was performed at Genewiz (South 
Plainfield, NJ). Libraries for large RNA (mRNAs and lncRNAs) and small RNAs (miRNAs) were prepared 
separately. Small RNA (20-30bp with 5’-monophosphate and 3’-OH structure) were enriched by gel-size 
selection method. rRNA were removed to enrich mRNA and lncRNA. The small RNA and large RNA were 
sequenced on 2 lanes of HiSeq2500 with a 1x50bp single-read sequencing configuration. Average of 
>30,000,000 sequence reads were obtained per sample for large RNAs and >20,000,000 sequence reads 
were obtained per sample for small RNAs. The sequences were then mapped to the reference genome of 
Mus musculus followed by RPKM (Read Per Kilobase of transcript per Million mapped reads) for RNAs 
to determine their relative expression levels. The expression levels were then compared between control 
and treated samples using student’s t-test with p-value < 0.05 assumed as significant. 
 
miRNA isolation: miRNAs were isolated using Trizol method and column purified based on differential 
ethanol concentration as per the Quaigen protocol. Briefly, cells were lysed using Trizol and phase 
separation was achieved using BCP (1-bromo-3-chlorpropane). The aqueous phase was mixed with equal 
part 70% ethanol and passed through RNease Mini spin column (Qiagen, Valencia, CA). The miRNA due 
to its small size are eluted through column at 70% ethanol. The collected flow-through is considered as 
miRNA-enriched RNA, which is then further purified via column purification (with 100% ethanol), washes 
with buffer RWT (Qiagen, Valencia, CA; #1067933), and elution with RNase-free water.  
 
Polyadenylation and cDNA synthesis: Isolated miRNA were then polyadenylated and cDNA were 
synthesized using qScript miRNA cDNA synthesis kit (Quanta Biosciences, Beverly, MA; #95107-025) as 
per manufacturer’s protocol. Briefly, 100ng to 500ng of miRNA enriched RNA were used for poly(A) 
tailing reaction to add adenosine monopshospates at the 3’ end of small RNAs. Samples were incubated for 
60 minutes at 37°C followed by a 5-minutes incubation at 70°C. Polyadenylated small RNAs were then 
used for cDNA synthesis utilizing qScript reverse transcriptase enzyme. Samples were incubated for 20 
minutes at 42°C followed by a 5-minutes incubation at 85°C. 
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Proximity Ligation Assay: Proximity ligation assay (PLA) kit was purchased from Sigma-Aldrich (St. 
Louis, MO; #DUO92101). H441 cells were plated on coverslips and fixed with 4% paraformaldehyde 
followed by blocking with 30 minutes. Cells were incubated with primary antibodies against FAK1 (Santa 
Cruz, #sc-558) and Galectin-1 (ThermoFisher Scienfitic, #43-7400) for two hours at room temperature. 
Rest of the protocol was as per the manufacturer. Interactions were visualized and imaged using an Olympus 
IX51 microscope and cellSens software (Olympus Corporation, Tokyo, Japan). 
 
ELISA: Galectin-1 ELISA was performed on IPF serum samples using human Galectin-1 DuoSet ELISA 
kit purchased from R&D Systems (Minneapolis, MN; #DY1152-05). Briefly, ELISA plates were coated 
with capture antibody (800ng/mL) overnight at room temperature. Plates were then washed and blocked 
for one hour at room temperature using reagent diluent supplied with the kit. Standard curve was generated 
using known quantities of recombinant human Galectin-1 in triplicates. Recombinant Galectin-1 was 
diluted in reagent diluent via serial dilution. 100 µl of undiluted IPF serum samples (n=10) or serum samples 
from control subjects (n=7) were used in duplicate for 2 hours at room temperature. Detecting antibody 
(100ng/mL) was added in each well and plates were incubated for 2 hours at room temperature. Following 
washes, Streptavidin-HRP was added to each well. Plates were incubated for 20 minutes at room 
temperature in dark. Levels of Galectin-1 were detected by adding substrate solution (Sigma Aldrich 
#T4444; 20 minutes incubation at room temperature) and stop solution (see materials) followed by 
determination of optical density of each well at 450nm with wavelength correction of 540nm. 
 
 
Table A.2 List of primers used for real time PCR 
 
Gene Name 5' to 3' Sequence 
Human Primers 
TGFβ1-F GGCCAGATCCTGTCCAAGC 
TGFβ1-R GTGGGTTTCCACCATTAGCAC  
PDGFA-F GCAAGACCAGGACGGTCATTT  
PDGFA-R GGCACTTGACACTGCTCGT  
PDGFB-F CTCGATCCGCTCCTTTGATGA  
PDGFB-R CGTTGGTGCGGTCTATGAG  
PDGFRβ-F AGCACCTTCGTTCTGACCTG 
PDGFRβ-R TATTCTCCCGTGTCTAGCCCA 
TNFα-F CCTCTCTCTAATCAGCCCTCTG 
TNFα-R GAGGACCTGGGAGTAGATGAG 
PAI1-F ACCGCAACGTGGTTTTCTCA  
PAI1-R TTGAATCCCATAGCTGCTTGAAT  
EDN1-F AAGGCAACAGACCGTGAAAAT  
EDN1-R CGACCTGGTTTGTCTTAGGTG  
EPO-F GGAGGCCGAGAATATCACGAC 
EPO-R CCCTGCCAGACTTCTACGG 
MMP9-F GGGACGCAGACATCGTCATC 
MMP9-R TCGTCATCGTCGAAATGGGC 
CTGF-F ACCAATGACAACGCCTCC 
CTGF-R TTGGAGATTTTGGGAGTACGG 
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Table A.2 (Continued) 
 
Gene Name 5' to 3' Sequence 
Human Primers 
TGFβ1-F GGCCAGATCCTGTCCAAGC 
TGFβ1-R GTGGGTTTCCACCATTAGCAC  
PDGFA-F GCAAGACCAGGACGGTCATTT  
PDGFA-R GGCACTTGACACTGCTCGT  
PDGFB-F CTCGATCCGCTCCTTTGATGA  
PDGFB-R CGTTGGTGCGGTCTATGAG  
PDGFRβ-F AGCACCTTCGTTCTGACCTG 
PDGFRβ-R TATTCTCCCGTGTCTAGCCCA 
TNFα-F CCTCTCTCTAATCAGCCCTCTG 
TNFα-R GAGGACCTGGGAGTAGATGAG 
PAI1-F ACCGCAACGTGGTTTTCTCA  
PAI1-R TTGAATCCCATAGCTGCTTGAAT  
EDN1-F AAGGCAACAGACCGTGAAAAT  
EDN1-R CGACCTGGTTTGTCTTAGGTG  
EPO-F GGAGGCCGAGAATATCACGAC 
EPO-R CCCTGCCAGACTTCTACGG 
MMP9-F GGGACGCAGACATCGTCATC 
MMP9-R TCGTCATCGTCGAAATGGGC 
CTGF-F ACCAATGACAACGCCTCC 
CTGF-R TTGGAGATTTTGGGAGTACGG 
ACTA2-F AATGCAGAAGGAGATCACGG 
ACTA2-R TCCTGTTTGCTGATCCACATC 
COL3A1-F AAGTCAAGGAGAAAGTGGTCG 
COL3A1-R CTCGTTCTCCATTCTTACCAGG 
MMP10-F GACTCCACTCACATTCTCCAG 
MMP10-R CCATAAAGCCCAGGTCCAG 
CTNNB1-F GTTCAGTTGCTTGTTCGTGC 
CTNNB1-R GTTGTGAACATCCCGAGCTAG 
TGFβRI-F GCCAAATATCCCAAACAGATGG 
TGFβRI-R ATGCCTTCCTGTTGACTGAG 
18S-F AACCCGTTGAACCCCATT 
18S-R CCATCCAATCGGTAGTAGCG 
Mouse Primers 
Pai1-F TCTGGGAAAGGGTTCACTTTACC 
Pai1-R GACACGCCATAGGGAGAGAAG 
Tgfβ1-F CAGAGAAGAACTGCTGTGTGCG 
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Table A.2 (Continued) 
 
Gene Name 5' to 3' Sequence
Mouse Primers 
Tgfβ1-R CGGGTTGTGTTGGTTGTAGAGG 
Edn1-F GCACCGGAGCTGAGAATGG 
Edn1-R GTGGCAGAAGTAGACACACTC 
N-Cadh-F GGATGAAACGGCGGGATAAAG 
N-Cadh-R TGGTCTTCTTCTCCTCCACCTTC 
Col1a1-F CTGGCGGTTCAGGTCCAAT 
Col1a1-R TTCCAGGCAATCCACGAGC 
Col5a1-F CTTCGCCGCTACTCCTGTTC 
Col5a1-R CCCTGAGGGCAAATTGTGAAAA 
Fibronectin-F CTCAGACAACCATCTCTTGGACG 
Fibronectin-R GAACTTGGAACTGTAAGGGCTCTTC 
Mmp2-F CCAACACTGGGACCTGTCACTC 
Mmp2-R GCGTCAATCTTTTCTGGGAGC 
Mmp12-F CAGTGAAACCCCCATCCTTGA 
Mmp12-R AGTAATGTTGGTGGCTGGACTCC 
Pten-F TGTAAAGCTGGAAAGGGACG 
Pten-R CCTCTGACTGGGAATTGTGAC 
18S F GTAACCCGTTGAACCCCATT 
18S R CCATCCAATCGGTAGTAGCG 
Primers used for miRNA studies (mouse) 
mmu-miR-96-5p-F CAGTTTGGCACTAGCACA 
mmu-Universal-R CCAGTGCAGGGTCCGAGGTA 
m-U6-F ATTCGTGAAGCGTTCCATAT 
m-U6-R TGGCCCCTGCGCAAGGATG 
 
 
A.B. Materials: 
I will describe some of the reagents that are not part of any kit. 
 
1. Mayer’s Hematoxylin 
Mayer’s Hematoxylin was prepared according to the following recipe: 
 
Reagent Amount Function 
Aluminum Potassium Sulfate 50 grams Mordant 
Deionized water 1000 mL Solvent 
Hematoxylin 1 gram Dye 
Sodium Iodate 0.2 gram Oxidizing agent 
Glacial acetic acid 20 mL pH control 
97	
	
  
Contents were dissolved in water by mixing. Solution was boiled for 30 minutes and cooled down at 
4°C. Mayer’s Hematoxylin was stored at 4°C for long term. 
 
2. β-galactosidase reagent (2X) 
 
2X β-galactosidase reagent was prepared according to the following recipe: 
 
Reagent Amount
0.5M Phosphatase Buffer 16 ml 
1M MgCl2 80 µl 
ONPG 53.2 mg 
 
0.5M Phosphatase buffer: 
Solution A: 138 grams of NaH2PO4:H2O in 1 liter deionized H2O. 
Solution B: 142 grams of NaH2PO4 in 1 liter deionized H2O. 
Mix 423 ml of Solution A and 577 ml of Solution B. Autoclave and store at room temperature 
 
3. Antibody diluting solution 
 
1X Antibody dilution solution was prepared by mixing the following contents in 100 ml PBS (1X): 
 
100 µl Triton-X-100 
2 grams Bovine Serum Albumin 
0.05 gram NaN3 
Store at 4°C 
 
4. 4% Paraformaldehyde 
 Add 40 grams of paraformaldehyde powder (Sigma Aldrich, #158127) in 800 ml PBS (1X) 
warmed to approximately 56°C 
 Slowly raise pH by adding 1N NaOH until solution becomes clear 
 Cool the solution and adjust pH with 1N HCl to pH 6.9 
 Aliquot and store at -80°C for up to 6 months 
 
5. Reagent Diluent (ELISA) 
 
Dissolve 1 gram BSA in 100 ml PBS (1X; pH 7.2-7.4). Filter sterilize and store at 4°C 
 
6. Stop Solution (ELISA) 
 
2N H2SO4. Store at room temperature 
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APPENDIX B: 
RAW DATA OF BIOINFORMATICS ANALYSES 
 
Table B.1: 25% of the amino acid residues of the kinome are intrinsically disordered 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
AAK1 Q2M2I8 55%   M3K9 P80192 60% 
AAPK1 Q13131 18%   M3KL4 Q5TCX8 53% 
AAPK2 P54646 20%   M4K1 Q92918 31% 
ABL1 P00519 49%   M4K2 Q12851 23% 
ABL2 P42684 45%   M4K3 Q8IVH8 27% 
ABRK1 P25098 9%   M4K4 O95819 51% 
ABRK2 P35626 9%   M4K5 Q9Y4K4 23% 
ACK1 Q07912 43%   MAK P20794 32% 
ACVL1 P37023 13%   MAP3K1 Q13233 48% 
ACVR1 Q04771 10%   MAPK2 P49137 14% 
ACVR1D P36896 7%   MAPK3 Q16644 18% 
ACVTC Q8NER5 8%   MAPK5 Q8IW41 9% 
ADCK1 Q86TW2 3%   MARK1 Q9P0L2 52% 
ADCK2 Q7Z695 5%   MARK2 Q7KZI7 52% 
ADCK3 Q8NI60 21%   MARK3 P27448 49% 
ADCK4 Q96D53 21%   MARK4 Q96L34 43% 
ADCK5 Q3MIX3 4%   MAST1 Q9Y2H9 65% 
AKT1 P31749 18%   MAST2 Q6P0Q8 67% 
AKT2 P31751 11%   MAST3 O60307 58% 
AKT3 Q9Y243 17%   MAST4 O15021 75% 
ALK Q9UM73 23%   MASTL Q96GX5 28% 
ALPK1 Q96QP1 36%   MATK P42679 12% 
ALPK2 Q86TB3 54%   MELK Q14680 12% 
ALPK3 Q96L96 68%   MERTK Q12866 6% 
AMHR2 Q16671 19%   MET P08581 4% 
ANKK1 Q8NFD2 6%   MINK1 Q8N4C8 52% 
ANPRA P16066 6%   MK01 P28482 8% 
ANPRB P20594 5%   MK03 P27361 12% 
ARAF P10398 29%   MK04 P31152 25% 
ATM Q13315 6%   MK06 Q16659 15% 
ATR Q13535 4%   MK07 Q13164 52% 
AURKA O14965 32%   MK08 P45983 15% 
AURKB Q96GD4 22%   MK09 P45984 18% 
AURKC Q9UQB9 17%   MK10 P53779 16% 
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Table B.1 (Continued) 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
AVR2A P27037 10%   MK11 Q15759 15% 
AVR2B Q13705 14%   MK12 P53778 7% 
BCKDK O14874 12%   MK13 O15264 17% 
BCR P11274 36%   MK14 Q16539 11% 
BLK P51451 10%   MK15 Q8TD08 38% 
BMP2K Q9NSY1 60%   MKNK1 Q9BUB5 27% 
BMPR2 Q13873 40%   MKNK2 Q9HBH9 26% 
BMR1A P36894 12%   MLKL Q8NB16 20% 
BMR1B O00238 12%   MLTK Q9NYL2 31% 
BMX P51813 22%   MOK Q9UQ07 33% 
BRAF P15056 34%   MOS P00540 19% 
BRSK1 Q8TDC3 51%   MP2K1 Q02750 25% 
BRSK2 Q8IWQ3 35%   MP2K2 P36507 23% 
BTK Q06187 14%   MP2K3 P46734 17% 
BUB1 O43683 25%   MP2K4 P45985 23% 
BUB1B O60566 37%   MP2K5 Q13163 13% 
CaMKK2 Q96RR4 41%   MP2K6 P52564 13% 
CAMKV Q8NCB2 42%   MP2K7 O14733 32% 
CD11A Q9UQ88 58%   MRCKa Q5VT25 32% 
CDC7 O00311 17%   MRCKb Q9Y5S2 37% 
CDK1 P06493 8%   MRCKG Q6DT37 40% 
CDK10 Q15131 11%   MST4 Q9P289 22% 
CDK11 Q9BWU1 35%   MTOR P42345 9% 
CDK12 Q9NYV4 73%   MUSK O15146 10% 
CDK13 Q14004 69%   MYLK Q15746 35% 
CDK14 O94921 19%   MYLK2 Q9H1R3 43% 
CDK15 Q96Q40 17%   MYLK3 Q32MK0 49% 
CDK16 Q00536 29%   MYLK4 Q86YV6 16% 
CDK17 Q00537 29%   MYO3A Q8NEV4 25% 
CDK18 Q07002 32%   MYO3B Q8WXR4 20% 
CDK2 P24941 7%   NEK1 Q96PY6 51% 
CDK20 Q8IZL9 6%   NEK10 Q6ZWH5 21% 
CDK3 Q00526 8%   NEK11 Q8NG66 35% 
CDK4 P11802 14%   NEK2 P51955 36% 
CDK5 Q00535 5%   NEK3 P51956 32% 
CDK6 Q00534 9%   NEK4 P51957 36% 
CDK7 P50613 11%   NEK5 Q6P3R8 25% 
CDK8 P49336 29%   NEK6 Q9HC98 12% 
CDK9 P50750 11%   NEK7 Q8TDX7 12% 
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Table B.1 (Continued) 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
CDKL1 Q00532 8%   NEK8 Q86SG6 12% 
CDKL2 Q92772 26%   NEK9 Q8TD19 31% 
CDKL3 Q8IVW4 49%   NIM1 Q8IY84 22% 
CDKL4 Q5MAI5 13%   NLK Q9UBE8 30% 
CDKL5 O76039 65%   NRBP Q9UHY1 26% 
CHK1 O14757 12%   NRBP2 Q9NSY0 16% 
CHK2 O96017 26%   NRK Q7Z2Y5 45% 
CK1g1 Q9HCP0 25%   NTKL Q96KG9 35% 
CK2a2 P19784 7%   NTRK1 P04629 9% 
CLK1 P49759 34%   NTRK2 Q16620 11% 
CLK2 P49760 33%   NTRK3 Q16288 6% 
CLK3 P49761 46%   NuaK1 O60285 48% 
CLK4 Q9HAZ1 31%   NuaK2 Q9H093 50% 
CSK P41240 5%   OBSCN Q5VST9 6% 
CSK21 P68400 20%   OXSR1 O95747 32% 
CSKP O14936 13%   PAK1 Q13153 40% 
CTRO O14578 43%   PAK2 Q13177 34% 
DAPK1 P53355 10%   PAK3 O75914 34% 
DAPK2 Q9UIK4 18%   PAK4 O96013 42% 
DAPK3 O43293 33%   PAK6 Q9NQU5 44% 
DCLK1 O15075 29%   PAK7 Q9P286 39% 
DCLK2 Q8N568 29%   PASK Q96RG2 25% 
DCLK3 Q9C098 54%   PDGFRb P09619 13% 
DDR1 Q08345 24%   PDK1 Q15118 19% 
DDR2 Q16832 14%   PDK1L Q8N165 11% 
DMPK Q09013 29%   PDK2 Q15119 8% 
DUSTY Q6XUX3 13%   PDK3 Q15120 10% 
DYR1A Q13627 49%   PDK4 Q16654 7% 
DYRK1B Q9Y463 46%   PDPK1 O15530 26% 
DYRK2 Q92630 41%   PEAK1 Q9H792 54% 
DYRK3 O43781 27%   PGFRa P16234 11% 
DYRK4 Q9NR20 31%   PHKg1 Q16816 6% 
E2AK1 Q9BQI3 30%   PHKg2 P15735 5% 
E2AK2 P19525 34%   PIK3R4 Q99570 15% 
E2AK3 Q9NZJ5 31%   PIM1 P11309 25% 
E2AK4 Q9P2K8 21%   PIM2 Q9P1W9 17% 
eEF2K O00418 33%   PIM3 Q86V86 7% 
EGFR P00533 9%   PINK1 Q9BXM7 12% 
EphA1 P21709 14%   PKDCC Q504Y2 32% 
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Table B.1 (Continued) 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
EphA2 P29317 10%   PKN1 Q16512 38% 
EphA3 P29320 9%   PKN2 Q16513 29% 
EphA4 P54764 8%   PKN3 Q6P5Z2 37% 
EphA5 P54756 7%   PLK1 P53350 19% 
EphA6 Q9UF33 6%   PLK2 Q9NYY3 20% 
EphA7 Q15375 6%   PLK3 Q9H4B4 24% 
EphA8 P29322 8%   PLK4 O00444 32% 
EPHAA Q5JZY3 9%   PMYT1 Q99640 46% 
EphB1 P54762 7%   PRKDC P78527 10% 
EphB2 P29323 10%   PRKX P51817 13% 
EphB3 P54753 10%   PRP4B Q13523 60% 
EphB4 P54760 10%   PRPK Q96S44 23% 
EphB6 O15197 10%   PTK6 Q13882 6% 
ErbB2 P04626 16%   PTK7 Q13308 13% 
ErbB3 P21860 26%   PXK Q7Z7A4 29% 
ErbB4 Q15303 12%   RAF1 P04049 24% 
ERN1 O75460 15%   RET P07949 6% 
ERN2 Q76MJ5 15%   RIOK1 Q9BRS2 40% 
FAK1 Q05397 24%   RIOK2 Q9BVS4 38% 
FAK2 Q14289 14%   RIOK3 O14730 18% 
FER P16591 20%   RIPK1 Q13546 28% 
FES P07332 36%   RIPK2 O43353 14% 
FGFR1 P11362 20%   RIPK3 Q9Y572 43% 
FGFR2 P21802 14%   RIPK4 P57078 20% 
FGFR3 P22607 21%   RK Q15835 8% 
FGFR4 P22455 19%   RN5A Q05823 11% 
FGR P09769 5%   ROCK1 Q13464 53% 
FLT3 P36888 11%   ROCK2 O75116 50% 
FMS P07333 10%   RON Q04912 8% 
FRK P42685 6%   ROR1 Q01973 23% 
FYN P06241 11%   ROR2 Q01974 26% 
GAK O14976 42%   ROS P08922 4% 
GPRK4 P32298 7%   RPKL1 Q9Y6S9 27% 
GPRK5 P34947 17%   RYK P34925 20% 
GPRK6 P43250 10%   SBK Q52WX2 36% 
GPRK7 Q8WTQ7 11%   SBK2 P0C263 21% 
GSK3A P49840 32%   SCYL2 Q6P3W7 33% 
GSK3B P49841 24%   SCYL3 Q8IZE3 22% 
GUC2C P25092 5%   SG110 P0C264 31% 
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Table B.1 (Continued) 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
GUC2D Q02846 13%   SG196 Q9H5K3 10% 
GUC2F P51841 7%   SG223 Q86YV5 61% 
Haspin Q8TF76 45%   SGK1 O00141 14% 
HCK P08631 17%   SGK2 Q9HBY8 20% 
HIPK1 Q86Z02 36%   SGK3 Q96BR1 16% 
HIPK2 Q9H2X6 36%   SGK71 Q8NE28 11% 
HIPK3 Q9H422 23%   SIK1 P57059 41% 
HIPK4 Q8NE63 23%   SIK2 Q9H0K1 46% 
HUNK P57058 42%   SIK3 Q9Y2K2 56% 
ICK Q9UPZ9 44%   SLK Q9H2G2 74% 
IGF1R P08069 14%   SMG1 Q96Q15 12% 
IKKa O15111 7%   SNRK Q9NRH2 41% 
IKKb O14920 19%   SPEG Q15772 52% 
IKKe Q14164 10%   SRC P12931 16% 
ILK Q13418 9%   SRMS Q9H3Y6 10% 
INSR P06213 14%   SRPK1 Q96SB4 46% 
INSRR P14616 11%   SRPK2 P78362 47% 
IRAK1 P51617 38%   SRPK3 Q9UPE1 35% 
IRAK2 O43187 24%   ST17A Q9UEE5 25% 
IRAK3 Q9Y616 18%   ST17B O94768 24% 
IRAK4 Q9NWZ3 14%   ST32A Q8WU08 19% 
ITK Q08881 9%   ST32B Q9NY57 22% 
JAK1 P23458 6%   ST32C Q86UX6 38% 
JAK2 O60674 5%   ST38L Q9Y2H1 17% 
JAK3 P52333 4%   STK10 O94804 69% 
KALRN O60229 16%   STK16 O75716 16% 
KAPCA P17612 9%   STK24 Q9Y6E0 22% 
KAPCB P22694 9%   STK25 O00506 27% 
KAPCG P22612 8%   STK3 Q13188 38% 
KC1A P48729 16%   STK31 Q9BXU1 7% 
KC1AL Q8N752 16%   STK33 Q9BYT3 38% 
KC1D P48730 33%   STK35 Q8TDR2 41% 
KC1E P49674 33%   STK36 Q9NRP7 17% 
KC1G2 P78368 27%   STK38 Q15208 22% 
KC1G3 Q9Y6M4 34%   STK39 Q9UEW8 26% 
KCC1A Q14012 11%   STK4 Q13043 34% 
KCC1B Q6P2M8 13%   STK40 Q8N2I9 17% 
KCC1D Q8IU85 19%   STRAA Q7RTN6 24% 
KCC1G Q96NX5 19%   STRAB Q9C0K7 21% 
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Table B.1 (Continued) 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
KCC2A Q9UQM7 14%   STYK1 Q6J9G0 13% 
KCC2B Q13554 40%   SYK P43405 8% 
KCC2D Q13557 14%   TAF1 P21675 41% 
KCC2G Q13555 29%   TAOK1 Q7L7X3 62% 
KCC4 Q16566 25%   TAOK2 Q9UL54 59% 
KGP1 Q13976 13%   TAOK3 Q9H2K8 58% 
KGP2 Q13237 17%   TBCK Q8TEA7 12% 
KIS Q8TAS1 3%   TBK1 Q9UHD2 3% 
KIT P10721 6%   TEC P42680 10% 
KKCC1 Q8N5S9 35%   TESK1 Q15569 52% 
KPCA P17252 15%   TESK2 Q96S53 31% 
KPCB P05771 20%   TEX14 Q8IWB6 50% 
KPCD Q05655 6%   TGFR1 P36897 8% 
KPCD1 Q15139 25%   TGFR2 P37173 6% 
KPCD2 Q9BZL6 25%   TIE1 P35590 5% 
KPCD3 O94806 24%   TIE2 Q02763 1% 
KPCE Q02156 21%   TITIN Q8WZ42 2% 
KPCG P05129 10%   TLK1 Q9UKI8 45% 
KPCi P41743 20%   TLK2 Q86UE8 49% 
KPCL P24723 11%   TNI3K Q59H18 11% 
KPCT Q04759 9%   TNIK Q9UKE5 57% 
KPCZ Q05513 18%   TNK1 Q13470 27% 
KPSH1 P11801 26%   TOPK Q96KB5 17% 
KPSH2 Q96QS6 28%   TRIB1 Q96RU8 23% 
KS6A1 Q15418 13%   TRIB2 Q92519 19% 
KS6A2 Q15349 10%   TRIB3 Q96RU7 23% 
KS6A3 P51812 9%   TRIO O75962 25% 
KS6A4 O75676 18%   TRPM6 Q9BX84 14% 
KS6A5 O75582 16%   TRPM7 Q96QT4 15% 
KS6A6 Q9UK32 11%   TRRAP Q9Y4A5 7% 
KS6B1 P23443 36%   TSSK1 Q9BXA7 27% 
KS6B2 Q9UBS0 31%   TSSK2 Q96PF2 23% 
KS6C1 Q96S38 35%   TSSK3 Q96PN8 6% 
KSR1 Q8IVT5 37%   TSSK4 Q6SA08 7% 
KSR2 Q6VAB6 29%   TSSK6 Q9BXA6 11% 
LATS1 O95835 65%   TTBK1 Q5TCY1 72% 
LATS2 Q9NRM7 42%   TTBK2 Q6IQ55 46% 
LCK P06239 5%   TTK P33981 29% 
LIMK1 P53667 20%   TXK P42681 13% 
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Table B.1 (Continued) 
 
 Name Uniprot ID % DO   Name Uniprot ID % DO 
LIMK2 P53671 17%   TYK2 P29597 11% 
LKB1 Q15831 25%   TYRO3 Q06418 16% 
LMTK1 Q6ZMQ8 62%   UFO P30530 16% 
LMTK2 Q8IWU2 56%   ULK1 O75385 55% 
LMTK3 Q96Q04 74%   ULK2 Q8IYT8 45% 
LRRK1 Q38SD2 11%   ULK3 Q6PHR2 13% 
LRRK2 Q5S007 6%   ULK4 Q96C45 18% 
LTK P29376 30%   VGFR1 P17948 8% 
LYN P07948 14%   VGFR2 P35968 10% 
M3K10 Q02779 57%   VGFR3 P35916 18% 
M3K11 Q80XI6 53%   VRK1 Q99986 16% 
M3K12 Q12852 59%   VRK2 Q86Y07 17% 
M3K13 O43283 56%   VRK3 Q8IV63 28% 
M3K14 Q99558 32%   Wee1 P30291 50% 
M3K15 Q6ZN16 19%   Wnk1 Q9H4A3 75% 
M3K19 Q56UN5 39%   Wnk2 Q9Y3S1 72% 
M3K2 Q9Y2U5 39%   Wnk3 Q9BYP7 45% 
M3K3 Q99759 42%   Wnk4 Q96J92 67% 
M3K4 Q9Y6R4 26%   YES P07947 17% 
M3K5 Q99683 18%   ZAP70 P43403 20% 
M3K6 O95382 23%   Wee1b P0C1S8 47% 
M3K7 O43318 45%   STK19 P49842 27% 
M3K8 P41279 24%   FASTK Q14296 28% 
 
Table B.2: List of protein kinases that have IDRs flanking their KDs 
 
Name Group Uniprot ID 
SGK1 AGC O00141 
CDC7 Other O00311 
eEF2K Atypical O00418 
PLK4 Other O00444 
STK25 STE O00506 
CTRO AGC O14578 
MP2K7 STE O14733 
CHK1 CAMK O14757 
AURKA Other O14965 
GAK Other O14976 
MAST4 AGC O15021 
DCLK1 CAMK O15075 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
MK13 CMGC O15264 
PDPK1 AGC O15530 
IRAK2 TKL O43187 
M3K13 TKL O43283 
DAPK3 CAMK O43293 
M3K7 TKL O43318 
RIPK2 TKL O43353 
DYRK3 CMGC O43781 
NuaK1 CAMK O60285 
MAST3 AGC O60307 
ROCK2 AGC O75116 
ULK1 Other O75385 
ERN1 Other O75460 
KS6A5 AGC O75582 
KS6A4 AGC O75676 
STK16 Other O75716 
PAK3 STE O75914 
CDKL5 CMGC O76039 
ST17B CAMK O94768 
STK10 STE O94804 
CDK14 CMGC O94921 
M3K6 STE O95382 
OXSR1 STE O95747 
M4K4 STE O95819 
LATS1 AGC O95835 
PAK4 STE O96013 
CHK2 CAMK O96017 
ABL1 TK P00519 
MOS Other P00540 
RAF1 TKL P04049 
ErbB2 TK P04626 
KPCB AGC P05771 
INSR TK P06213 
FMS TK P07333 
IGF1R TK P08069 
PDGFRb TK P09619 
SBK2 Other P0C263 
SG110 Other P0C264 
ARAF TKL P10398 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
BCR Atypical P11274 
PIM1 CAMK P11309 
FGFR1 TK P11362 
KPSH1 CAMK P11801 
INSRR TK P14616 
BRAF TKL P15056 
PGFRa TK P16234 
VGFR1 TK P17948 
E2AK2 Other P19525 
MAK CMGC P20794 
TAF1 Atypical P21675 
TAF1 Atypical P21675b 
EphA1 TK P21709 
FGFR2 TK P21802 
ErbB3 TK P21860 
FGFR4 TK P22455 
FGFR3 TK P22607 
KS6B1 AGC P23443 
KPCL AGC P24723 
MK03 CMGC P27361 
MARK3 CAMK P27448 
LTK TK P29376 
TYK2 TK P29597 
Wee1 Other P30291 
UFO TK P30530 
MK04 CMGC P31152 
AKT1 AGC P31749 
AKT2 AGC P31751 
RYK TK P34925 
VGFR3 TK P35916 
MP2K2 STE P36507 
M3K8 STE P41279 
KPCi AGC P41743 
MATK TK P42679 
ABL2 TK P42684 
ZAP70 TK P43403 
SYK TK P43405 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
MK08 CMGC P45983 
MK09 CMGC P45984 
MP2K4 STE P45985 
MP2K3 STE P46734 
KC1A CK1 P48729 
KC1D CK1 P48730 
MAPK2 CAMK P49137 
CDK8 CMGC P49336 
KC1E CK1 P49674 
CLK1 CMGC P49759 
CLK2 CMGC P49760 
CLK3 CMGC P49761 
GSK3A CMGC P49840 
GSK3B CMGC P49841 
CDK9 CMGC P50750 
IRAK1 TKL P51617 
KS6A3 AGC P51812 
PRKX AGC P51817 
NEK2 Other P51955 
NEK3 Other P51956 
MP2K6 STE P52564 
PLK1 Other P53350 
LIMK1 TKL P53667 
LIMK2 TKL P53671 
MK10 CMGC P53779 
HUNK CAMK P57058 
RIPK4 TKL P57078 
CSK21 CMGC P68400 
SRPK2 CMGC P78362 
KC1G2 CK1 P78368 
M3K9 TKL P80192 
CDK16 CMGC Q00536 
CDK17 CMGC Q00537 
ROR1 TK Q01973 
ROR2 TK Q01974 
KPCE AGC Q02156 
MP2K1 STE Q02750 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
M3K10 TKL Q02779 
GUC2D RGC Q02846 
KPCT AGC Q04759 
RON TK Q04912 
FAK1 TK Q05397 
KPCZ AGC Q05513 
TYRO3 TK Q06418 
CDK18 CMGC Q07002 
ACK1 TK Q07912 
DDR1 TK Q08345 
DMPK AGC Q09013 
M3K12 TKL Q12852 
STK4 STE Q13043 
PAK1 STE Q13153 
MK07 CMGC Q13164 
PAK2 STE Q13177 
STK3 STE Q13188 
MAP3K1 STE Q13233 
PTK7 TK Q13308 
ROCK1 AGC Q13464 
TNK1 TK Q13470 
RIPK1 TKL Q13546 
KCC2B CAMK Q13554 
KCC2G CAMK Q13555 
KCC2D CAMK Q13557 
DYR1A CMGC Q13627 
BMPR2 TKL Q13873 
KGP1 AGC Q13976 
CDK13 CMGC Q14004 
FAK2 TK Q14289 
CDK10 CMGC Q15131 
KPCD1 CAMK Q15139 
STK38 AGC Q15208 
KS6A2 AGC Q15349 
KS6A1 AGC Q15418 
TESK1 TKL Q15569 
MYLK CAMK Q15746 
MK11 CMGC Q15759 
SPEG CAMK Q15772 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
LKB1 CAMK Q15831 
PKN1 AGC Q16512 
PKN2 AGC Q16513 
KCC4 CAMK Q16566 
NTRK2 TK Q16620 
MAPK3 CAMK Q16644 
AMHR2 TKL Q16671 
AAK1 Other Q2M2I8 
MYLK3 CAMK Q32MK0 
PKDCC Other Q504Y2 
SBK Other Q52WX2 
TNI3K TKL Q59H18 
CDKL4 CMGC Q5MAI5 
M3KL4 TKL Q5TCX8 
TTBK1 CK1 Q5TCY1 
OBSCN CAMK Q5VST9 
TTBK2 CK1 Q6IQ55 
MAST2 AGC Q6P0Q8 
KCC1B CAMK Q6P2M8 
PKN3 AGC Q6P5Z2 
KSR2 TKL Q6VAB6 
M3K15 STE Q6ZN16 
ERN2 Other Q76MJ5 
MARK2 CAMK Q7KZI7 
TAOK1 STE Q7L7X3 
STRAA STE Q7RTN6 
PXK Other Q7Z7A4 
M3K11 TKL Q80XI6 
NEK8 Other Q86SG6 
ALPK2 Atypical Q86TB3 
TLK2 Other Q86UE8 
ST32C AGC Q86UX6 
VRK2 CK1 Q86Y07 
SG223 Other Q86YV5 
MYLK4 CAMK Q86YV6 
HIPK1 CMGC Q86Z02 
KCC1D CAMK Q8IU85 
VRK3 CK1 Q8IV63 
M4K3 STE Q8IVH8 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
KSR1 TKL Q8IVT5 
CDKL3 CMGC Q8IVW4 
TEX14 Other Q8IWB6 
BRSK2 CAMK Q8IWQ3 
NIM1 CAMK Q8IY84 
ULK2 Other Q8IYT8 
STK40 CAMK Q8N2I9 
MINK1 STE Q8N4C8 
DCLK2 CAMK Q8N568 
KKCC1 Other Q8N5S9 
KC1AL CK1 Q8N752 
MLKL TKL Q8NB16 
CAMKV CAMK Q8NCB2 
SGK71 Other Q8NE28 
NEK11 Other Q8NG66 
MK15 CMGC Q8TD08 
NEK9 Other Q8TD19 
BRSK1 CAMK Q8TDC3 
STK35 Other Q8TDR2 
NEK7 Other Q8TDX7 
Haspin Other Q8TF76 
TITIN CAMK Q8WZ42 
TRIB2 CAMK Q92519 
DYRK2 CMGC Q92630 
CDKL2 CMGC Q92772 
M4K1 STE Q92918 
SGK3 AGC Q96BR1 
ULK4 Other Q96C45 
ADCK4 Atypical Q96D53 
AURKB Other Q96GD4 
MASTL AGC Q96GX5 
Wnk4 Other Q96J92 
MARK4 CAMK Q96L34 
ALPK3 Atypical Q96L96 
KCC1G CAMK Q96NX5 
TSSK2 CAMK Q96PF2 
NEK1 Other Q96PY6 
LMTK3 TK Q96Q04 
CDK15 CMGC Q96Q40 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
ALPK1 Atypical Q96QP1 
KPSH2 CAMK Q96QS6 
TRPM7 Atypical Q96QT4 
CaMKK2 Other Q96RR4 
TRIB3 CAMK Q96RU7 
TRIB1 CAMK Q96RU8 
KS6C1 AGC Q96S38 
PRPK Other Q96S44 
TESK2 TKL Q96S53 
SRPK1 CMGC Q96SB4 
M3K14 STE Q99558 
PMYT1 Other Q99640 
VRK1 CK1 Q99986 
E2AK1 Other Q9BQI3 
RIOK1 Atypical Q9BRS2 
MKNK1 CAMK Q9BUB5 
RIOK2 Atypical Q9BVS4 
CDK11 CMGC Q9BWU1 
TRPM6 Atypical Q9BX84 
TSSK1 CAMK Q9BXA7 
PINK1 Other Q9BXM7 
Wnk3 Other Q9BYP7 
STK33 CAMK Q9BYT3 
KPCD2 CAMK Q9BZL6 
DCLK3 CAMK Q9C098 
STRAB STE Q9C0K7 
NuaK2 CAMK Q9H093 
MYLK2 CAMK Q9H1R3 
SLK STE Q9H2G2 
TAOK3 STE Q9H2K8 
HIPK2 CMGC Q9H2X6 
Wnk1 Other Q9H4A3 
PLK3 Other Q9H4B4 
PEAK1 Other Q9H792 
CLK4 CMGC Q9HAZ1 
MKNK2 CAMK Q9HBH9 
SGK2 AGC Q9HBY8 
NEK6 Other Q9HC98 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
CK1g1 CK1 Q9HCP0 
PAK6 STE Q9NQU5 
DYRK4 CMGC Q9NR20 
LATS2 AGC Q9NRM7 
STK36 Other Q9NRP7 
NRBP2 Other Q9NSY0 
BMP2K Other Q9NSY1 
IRAK4 TKL Q9NWZ3 
ST32B AGC Q9NY57 
CDK12 CMGC Q9NYV4 
PLK2 Other Q9NYY3 
E2AK3 Other Q9NZJ5 
MARK1 CAMK Q9P0L2 
PIM2 CAMK Q9P1W9 
PAK7 STE Q9P286 
MST4 STE Q9P289 
E2AK4 Other Q9P2K8 
E2AK4 Other Q9P2K8b 
NLK CMGC Q9UBE8 
KS6B2 AGC Q9UBS0 
ST17A CAMK Q9UEE5 
STK39 STE Q9UEW8 
NRBP Other Q9UHY1 
KS6A6 AGC Q9UK32 
TNIK STE Q9UKE5 
TLK1 Other Q9UKI8 
TAOK2 STE Q9UL54 
ALK TK Q9UM73 
SRPK3 CMGC Q9UPE1 
ICK CMGC Q9UPZ9 
MOK CMGC Q9UQ07 
CD11A CMGC Q9UQ88 
AURKC Other Q9UQB9 
KCC2A CAMK Q9UQM7 
AKT3 AGC Q9Y243 
ST38L AGC Q9Y2H1 
MAST1 AGC Q9Y2H9 
M3K2 STE Q9Y2U5 
Wnk2 Other Q9Y3S1 
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Table B.2 (Continued) 
 
Name Group Uniprot ID 
DYRK1B CMGC Q9Y463 
M4K5 STE Q9Y4K4 
RIPK3 TKL Q9Y572 
IRAK3 TKL Q9Y616 
STK24 STE Q9Y6E0 
KC1G3 CK1 Q9Y6M4 
M3K4 STE Q9Y6R4 
RPKL1 AGC Q9Y6S9 
 
 
 
Table B.3: 36 Kinases have IDRs extending into their kinase domains 
 
Name Group Uniprot ID 
BCR Atypical P11274 
TAF1 Atypical P21675 
TAF1 Atypical P21675 
VGFR3 TK P35916 
SRPK2 CMGC P78362 
SG223 Other Q86YV5 
SRPK1 CMGC Q96SB4 
RIOK2 Atypical Q9BVS4 
PEAK1 Other Q9H792 
E2AK3 Other Q9NZJ5 
E2AK4 Other Q9P2K8 
SRPK3 CMGC Q9UPE1 
CDC7 Other O00311 
STK16 Other O75716 
M3K6 STE O95382 
FMS TK P07333 
VGFR1 TK P17948 
MP2K2 STE P36507 
M3K8 STE P41279 
MATK TK P42679 
MP2K1 STE Q02750 
FAK1 TK Q05397 
SBK1 Other Q52WX2 
STRAA STE Q7RTN6 
PXK Other Q7Z7A4 
ALPK2 Atypical Q86TB3 
115 
 
Table B.3 (Continued) 
 
Name Group Uniprot ID 
NEK9 Other Q8TD19 
E2AK1 Other Q9BQI3 
STRAB STE Q9C0K7 
DYRK1B CMGC Q9Y463 
RPKL1 AGC Q9Y6S9 
E2AK2 Other P19525 
TYK2 TK P29597 
STK35 Other Q8TDR2 
TRIB1 CAMK Q96RU8 
PMYT1 Other Q99640 
PINK1 Other Q9BXM7 
 
Table B.4: Mapping of FAK1-interacting proteins onto ordered or disordered domains of FAK1 
 
Protein A Protein B DO? Region A RegionA_ID Region B RegionB_ID
FAK1 A4 Y -- --     
FAK1 AMPH Y IDR 2 Y SH3 N 
FAK1 ASAP1 Y IDR 2 Y SH3 N 
FAK1 ATG12 Y -- --     
FAK1 BBS10 N -- --     
FAK1 BCAR1 Y IDR Y SH3 N 
FAK1 BIN1 Y IDR 2 Y SH3 N 
FAK1 BMX Y FERM N PH N 
FAK1 CASL Y IDR 2 Y SH3 N 
FAK1 CASS4 Y IDR Y     
FAK1 CBL Y -- --     
FAK1 CCR5 N -- --     
FAK1 CHIP Y -- --     
FAK1 CIB1 N -- --     
FAK1 CIN85 Y IDR Y SH3 N 
FAK1 CRK Y -- --     
FAK1 CSK N -- -- SH2 N 
FAK1 CXCR4 Y -- --     
FAK1 DAG1 Y -- --     
FAK1 DCC Y FAT N P3 Y 
FAK1 DOCK1 Y -- --     
FAK1 DX39A Y -- --     
FAK1 EF1G Y -- --     
FAK1 EGFR Y FERM N     
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Table B.4 (Continued) 
 
Protein A Protein B DO? Region A RegionA_ID Region B RegionB_ID
FAK1 ELAV1 N -- --     
FAK1 EPHA2 N 875-881 Y SH3 N 
FAK1 ES8L2 Y -- --     
FAK1 EZRI Y FERM N --   
FAK1 F13A Y -- --     
FAK1 F16P1 N -- --     
FAK1 FAK1 Y FERM N FAT N 
FAK1 FGR N -- --     
FAK1 FYN N -- --     
FAK1 G3P Y -- --     
FAK1 GATA4 Y FERM N     
FAK1 GELS Y -- --     
FAK1 GIT1 Y -- --     
FAK1 GRAF2 Y IDR Y     
FAK1 GRB2 N IDR2 Y     
FAK1 GRB7 Y Linker Y SH2 N 
FAK1 GSK3B Y FRNK ?     
FAK1 HEF1 Y IDR Y SH3   
FAK1 HES1 Y -- --     
FAK1 HS90A Y -- --     
FAK1 IGF1R Y FERM N 
Intracellular 
Domain N 
FAK1 IQGA1 Y -- --     
FAK1 IRS1 Y FAT N --   
FAK1 ITA4 N Indirect --     
FAK1 ITB3 N FERM N 
Cytoplasmic 
Chain N 
FAK1 ITB5 N -- --     
FAK1 JAK2 Y -- --     
FAK1 JIP3 Y Linker Y 1-343 Y 
FAK1 KCNJ3 Y -- --     
FAK1 KSYK Y -- --     
FAK1 LPXN Y -- --     
FAK1 LYAM2 N -- --     
FAK1 LYN Y C-term Y     
FAK1 MBD2 Y FAT N N-term Y 
FAK1 MDM2 Y FERM(F2/F3) N     
FAK1 MET N FERM N     
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Table B.4 (Continued) 
 
Protein A Protein B DO? Region A RegionA_ID Region B RegionB_ID
FAK1 NACAD Y -- --     
FAK1 Nanog Y FERM N     
FAK1 NASP Y -- --     
FAK1 NCK1 N -- --     
FAK1 NCK2 Y Linker Y SH2   
FAK1 NEC1 Y -- --     
FAK1 NEDD8 Y -- --     
FAK1 NEO1 Y FAT N LD Motif Y 
FAK1 NRF1 Y -- --     
FAK1 P53 Y FERM(F1/F2) N 65-71 Y 
FAK1 P85A Y IDR 2 Y SH3   
FAK1 PARP1 Y -- --     
FAK1 PAXI Y FAT N LD2/4 Y 
FAK1 PDC6I Y -- -- 
Proline Rich 
Region Y 
FAK1 PLCG1 Y Linker Y SH2 N 
FAK1 PP1A N FRNK ? 194-260 AA N 
FAK1 PP1B N -- --     
FAK1 PTAFR Y -- --     
FAK1 PTEN Y -- --     
FAK1 PTH2 Y -- --     
FAK1 PTN11 Y -- --     
FAK1 PTPa N FAT N 
Phosphatase 
Domain N 
FAK1 RAC1 N -- --     
FAK1 RBCC1 Y KD N     
FAK1 RBNS5 Y -- --     
FAK1 RHG26 Y IDR 2 Y     
FAK1 RL40 N -- --     
FAK1 RS27A Y -- --     
FAK1 SAE1 N -- --     
FAK1 SH3K1 Y IDR Y SH3 N 
FAK1 SHC1 Y Linker Y     
FAK1 SOCS1 Y Linker Y 
KIR and 
SH2 N 
FAK1 SOCS2 Y -- --     
FAK1 SOCS3 Y Linker Y 
KIR and 
SH2 N 
FAK1 SRC Y Linker Y SH3 N 
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Protein A Protein B DO? Region A RegionA_ID Region B RegionB_ID
FAK1 SRC8 Y IDR Y SH3 N 
FAK1 SRPK1 Y -- --     
FAK1 STAP2 Y FERM N SH2-linke N 
FAK1 STAT1 Y C-tail Y     
FAK1 STAT3 Y -- --     
FAK1 TGFI1 Y 707-1052 Y     
FAK1 TLN1 Y FAT N FERM N 
FAK1 TRI72 N FERM N B-Box N 
FAK1 TRIP6 Y -- --     
FAK1 TSC1 Y -- --     
FAK1 TSC2 Y KD N 609-1080 Unknown 
FAK1 UBB N -- --     
FAK1 UBC N -- --     
FAK1 UBE2H Y -- --     
FAK1 YES Y -- --     
FAK1 ZN331 Y -- --     
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